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ABSTRACT 
 Microtubule-actin interactions underlie a diverse number of biological processes 
including cell motility, neuronal outgrowth, cellular wound healing, cell division and 
cortical flow. CRMPs (Collapsin Response Mediator Proteins) are a family of cytosolic 
phosphoproteins that play roles in regulating both actin and microtubule dynamics. The 
roles of the CRMP family of proteins in regulating these cellular processes have only 
been partially described. Our lab has been particularly interested in the function of the 
CRMP4 isoform because of its unique ability to complex with RhoA, a master regulator 
of the actin cytoskeleton. In this thesis we explore the function of CRMP4 in two 
biological processes that are dependent on actin and microtubule dynamics: mitosis 
(Chapter 2) and axon regeneration (Chapter 3 and 4). In Chapter 2, we identify 
CRMP4 as an important regulator of mitotic chromosomal alignment. We show that 
CRMP4 localizes to spindle microtubules during mitosis and that loss of CRMP4 disrupts 
chromosomal alignment, mitotic progression and spindle morphology. Furthermore, we 
demonstrate that these processes are dependent on CRMP4 phosphorylation, which may 
be important for recruitment of additional proteins to the mitotic machinery. In Chapter 3, 
we investigate the ability of an adeno-associated virus (AAV) encoding a CRMP4 
antagonist C4RIP (CRMP4-RhoA inhibitory peptide) to enhance adult retinal ganglion 
cell (RGC) axon regeneration in an in vivo preclinical optic nerve injury model. We 
describe the inability of AAV-C4RIP to promote RGC regeneration and discuss the 
likelihood that AAV-mediated expression levels of C4RIP may be insufficient to promote 
regeneration. In Chapter 4, we describe the development and validation of cell permeable 
recombinant C4RIP (TAT-C4RIP) and discuss our data testing the effects of TAT-C4RIP 
on regeneration in vitro and in vivo. Together, these studies identify CRMP4 as an 
important regulator of mitosis, and describe our ongoing studies testing the effects of a 
CRMP4 antagonist on nerve regeneration. 
 
RÉSUMÉ 
 
 Les interactions entre l’actine et les microtubules  sont sous-jacentes à divers 
processus biologiques incluant la motilité cellulaire, le guidage neuronal, la cicatrisation 
cellulaire, la division cellulaire et la circulation corticale. Les protéines CRMPs 
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(Collapsin Response Mediator Protein) sont une famille de phosphoprotéines 
cytosoliques jouant un rôle dans la régulation de la dynamique de l'actine et des 
microtubules. Cependant, cette régulation du cytosquelette par les CRMPs  n'a été que 
partiellement décrite. Notre laboratoire s’intéresse à la fonction de l'isoforme CRMP4 en 
raison de sa capacité unique d’interagir avec RhoA, un régulateur important du 
cytosquelette d'actine. Dans cette thèse, nous explorons la fonction de CRMP4 dans 
deux processus biologiques qui dépendent de la dynamique de l'actine et des 
microtubules: la mitose (chapitre 2) et la régénération des axones (chapitre 3 et 4). 
Dans le chapitre 2 sera présentée notre identification de CRMP4 en tant que régulateur 
important de l'alignement chromosomique durant la mitose. Nous démontrons que, 
pendant la mitose, CRMP4 se situe sur les fuseaux mitotiques formés de microtubules et 
que la perte de CRMP4 perturbe l'alignement chromosomique, la progression de la 
mitose et la morphologie des fuseaux. En outre, nous démontrons que ces processus sont 
dépendants de la phosphorylation de CRMP4. Ceci pourrait être crucial pour le 
recrutement de protéines supplémentaires nécessaire pour la mitose. Dans le chapitre 3, 
nous étudions la capacité d'un virus adéno-associé (AAV) codant pour l'antagoniste de 
CRMP4, nommé C4RIP (CRMP4-RhoA inhibitory peptide), de favoriser la régénération 
de l’axone de cellules ganglionnaires de la rétine (RGC) chez l’adulte. Pour cela, nous 
utilisons un modèle in vivo de traumatismes du nerf optique chez le rat adulte. Nous 
décrivons l'incapacité des virus AAV-C4RIP de favoriser la régénération des RGCs et 
discutons de la probabilité que les niveaux de AAV-C4RIP exprimés puissent être 
insuffisants afin de favoriser la régénération. Le chapitre 4, quant à lui, est consacré à la 
description du développement et de la validation de la protéine recombinante TAT-
C4RIP qui a le potentiel de traverser la membrane cellulaire. Nous y discutons les 
données concernant les effets de TAT-C4RIP sur la régénération in vitro et in vivo. Dans 
l’ensemble, ces études caractérisent CRMP4 comme important régulateur de la mitose et 
décrivent une nouvelle méthode de purification pour des protéines perméables à la 
membrane cellulaire. 
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1.1 INTRODUCTION 
 Cells are dynamic structures that must be mechanically strong and resilient, while 
still labile enough to organize themselves correctly and adapt to their changing 
environment. They must be able to rearrange their internal compartment in response to 
internal and external signals, which results in complex and specialized functions. For 
example, during cell division the cell positions chromosomes, pulls them apart and 
separates into two daughter cells. During infections, white blood cells crawl and migrate 
along the endothelial lining of blood vessels patrolling for foreign bodies. Following an 
injury, fibroblasts and macrophages proliferate and invade into the injury site, 
respectively. During the formation of our nervous system, neurons extend processes from 
their cells bodies that grow long distances yet accurately innervate their designated 
targets. The ability of a cell to participate in these highly dynamic and regulated 
processes is dependent on a system of filaments called the cytoskeleton.  
 The cytoskeleton is composed of an interconnected network of actin and tubulin 
monomers that can assemble into microfilaments and microtubules, respectively, and 
associate with intermediate filaments. Regulation of the assembly and disassembly of 
these structures, as well as the interactions between them, are important determinants of 
how a single cell or a network of cells can perform a specific biological function. In this 
thesis, we attempt to elucidate the role of Collapsin Response Mediator Protein 4 
(CRMP4), a cytosolic phosphoprotein that has been shown to regulate the cytoskeleton, 
in the biological processes of mitosis and nerve regeneration. 
1.1.1 COLLAPSIN RESPONSE MEDIATOR PROTEINS (CRMPs) 
 CRMPs are cytosolic phosphoproteins that are highly expressed in the nervous 
system during development (Goshima, Nakamura et al. 1995; Wang and Strittmatter 
1996; Gaetano, Matsuo et al. 1997; Byk, Ozon et al. 1998; Quinn, Gray et al. 1999; 
Quach, Duchemin et al. 2004). The CRMPs are homologs of UNC-33, a protein 
originally identified in Caenorhabditis elegans to be important for axon extension and 
guidance (Hedgecock, Culotti et al. 1985; Siddiqui and Culotti 1991). The CRMP family 
members have been previously identified as TOAD-64 (turned on after division, 64 kDa), 
Ulip (UNC-33 like protein), DRP (dihydropyrimidinase related protein) and TUC 
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(TOAD-64/Ulip/CRMP) (Goshima, Nakamura et al. 1995; Minturn, Fryer et al. 1995; 
Byk, Dobransky et al. 1996; Gaetano, Matsuo et al. 1997; Inatome, Tsujimura et al. 2000; 
Quinn, Chen et al. 2003). Although the CRMP sequences are similar to those of 
dihydropyrimidinase (DHPase), a liver enzyme involved with pyrimidine catabolism, 
they do not share any related enzymatic activity (Wang and Strittmatter 1997). The 
CRMP family is composed of five family members (CRMP1-5) in vertebrates, where 
CRMP1-4 share 70-80% amino acid homology while CRMP5 shares only 50-51% 
(Goshima, Nakamura et al. 1995; Minturn, Fryer et al. 1995; Byk, Dobransky et al. 1996; 
Gaetano, Matsuo et al. 1997; Wang and Strittmatter 1997; Inatome, Tsujimura et al. 
2000; Quinn, Chen et al. 2003). Each CRMP allele produces two transcripts that differ in 
their amino terminal domains producing long (L-CRMP) and short (S-CRMP) isoforms 
that have been alternatively referred to as ‘a’ and ‘b’ isoforms (Fig. 1) (Quinn, Chen et al. 
2003; Yuasa-Kawada, Suzuki et al. 2003; Alabed, Pool et al. 2007; Pan, Chao et al. 2009; 
Alabed, Pool et al. 2010). Although the CRMPs share a high degree of homology, their 
physiological roles in different biological processes are diverse and in certain cases have 
been shown to be antagonistic (Brot, Rogemond et al. 2010). Additionally, CRMPs can 
form multimers and hetero-oligomers with other CRMPs (Wang and Strittmatter 1997; 
Fukada, Watakabe et al. 2000; Inatome, Tsujimura et al. 2000; Yuasa-Kawada, Suzuki et 
al. 2003; Brot, Rogemond et al. 2010). However, the functional relevance of these CRMP 
multimers and hetero-oligomers has not been fully elucidated. 
1.1.1.1 Expression pattern 
1.1.1.1.1 Embryonic Central Nervous System  
 The CRMPs are highly expressed throughout the developing embryonic nervous 
system, with levels peaking in the first postnatal week and decreasing into adulthood 
(Wang and Strittmatter 1996; Fukada, Watakabe et al. 2000). While CRMP1, CRMP2, 
CRMP4 and CRMP5 are ubiquitously expressed throughout the embryonic day 15 rat 
brain, CRMP3 expression is restricted to the brain stem and spinal cord (Wang and 
Strittmatter 1996; Quinn, Gray et al. 1999; Fukada, Watakabe et al. 2000). CRMP4 is 
highly expressed during corticogenesis in postmitotic neurons as they migrate out of the 
ventricular zone into the developing cortical plate (Minturn, Geschwind et al. 1995). 
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Chapter 1 - Figure 1. Schematic representation of the short and long CRMP family 
members. 
CRMP1-4 family members contain 2 isoforms: long (L) and short (S). While CRMP1-4 
contain a dihydropyrimidinase-like (DHP) domain, they do not have its enzymatic 
activity. CRMP4 consists of a C-terminus common domain and a unique N-terminus 
domain of 126 amino acids for the long isoform and 13 amino acids for the short isoform.    
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The expression of CRMP4 in early postmitotic neurons but not in mitotic cells of the 
ventricular zone has resulted in its use as a neuronal marker for cells that have committed 
to a neuronal fate (Minturn, Fryer et al. 1995). The CRMP5 expression pattern in the 
brain is very similar to CRMP4 (Fukada, Watakabe et al. 2000). In contrast to CRMP4, 
CRMP2 is expressed in both neurons and their progenitors in the developing cortical 
plate and the ventricular zone (Wang and Strittmatter 1996). All the CRMPs are 
expressed in the embryonic and post-natal retina, with strongest expression in the 
postmitotic retinal ganglion cells (Wang and Strittmatter 1996; Fukada, Watakabe et al. 
2000). Additionally, CRMP1, CRMP2, CRMP3 and CRMP4 are also expressed in 
oligodendrocytes, but not astrocytes, during all stages from progenitor to the 
differentiated cell (Ricard, Stankoff et al. 2000). The expression profiles of the CRMPs in 
the developing brain indicate that CRMP1, CRMP4 and CRMP5 are similarly regulated, 
while CRMP2 and CRMP3 are not (Fukada, Watakabe et al. 2000).  
1.1.1.1.2 Spinal Cord 
 The CRMPs are also expressed in the embryonic rat spinal cord with highest 
levels in the marginal zone during embryonic day 16 and day 20, a period a rapid axonal 
outgrowth (Geschwind, Kelly et al. 1996; Wang and Strittmatter 1996). At earlier 
embryonic day 13, CRMP1 and CRMP4 are expressed in the ventral horn while CRMP2 
and CRMP3 are expressed throughout the spinal cord. However, by embryonic day 15 
CRMP1, CRMP2 and CRMP4 are expressed through out the entire spinal cord, while 
CRMP3 is limited to the dorsal germinal matrix layer (Wang and Strittmatter 1996; 
Quinn, Gray et al. 1999). CRMP5 has a similar expression profile to CRMP1, CRMP2 
and CRMP4 in the mouse embryonic day 17 spinal cord (Fukada, Watakabe et al. 2000). 
1.1.1.1.3 Peripheral Nervous System 
 CRMP expression is not restricted to the CNS as DRG neurons show strong 
expression (Minturn, Fryer et al. 1995; Wang and Strittmatter 1996; Fukada, Watakabe et 
al. 2000; Quinn, Chen et al. 2003). CRMP4 is also regulated in neuronal cell lines in 
response to nerve growth factor (NGF) or retinoic acid, and in dorsal root ganglion 
(DRG) neurons by ciliary neurotrophic factor (CNTF) (Byk, Dobransky et al. 1996; 
Gaetano, Matsuo et al. 1997; Jang, Shin et al. 2010). 
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1.1.1.1.4 Adult Nervous System  
 Compared to the developing brain, CRMP expression levels are much lower in 
the adult brain, except for CRMP2 and CRMP3 levels (Wang and Strittmatter 1996; 
Charrier, Reibel et al. 2003; Cnops, Van de Plas et al. 2004; Bretin, Reibel et al. 2005). 
CRMP3 expression is primarily restricted to the hippocampus, pontine nuclei and olivary 
complex and granule cells of the cerebellum (Wang and Strittmatter 1996; Quach, 
Mosinger et al. 2000; Quach, Massicotte et al. 2008). CRMP4 expression in adult 
nervous tissue is highest in areas where ongoing neurogenesis occurs: the subventricular 
zone, the dentate granular layer of the hippocampus, the olfactory bulbs and the rostral 
migratory stream (Nacher, Rosell et al. 2000; Liu, Yang et al. 2003; Liu and Martin 
2003). However, CRMP4 expression is also observed in other regions of the brain that 
are not associated with ongoing neurogenesis such as the cerebral cortex, hypothalamus, 
interpeduncular nucleus, median raphe, superior colliculus, granule cerebellar neurons 
and the visual cortex (Nacher, Rosell et al. 2000; Cnops, Van de Plas et al. 2004). 
Intriguingly, many of these regions have been shown to exhibit synaptic rearrangement 
and axonal outgrowth into adulthood (Nacher, Rosell et al. 2000). 
 CRMP1, CRMP2, CRMP3 and CRMP4 are all expressed in adult rat 
oligodendrocytes. While CRMP2 mRNA is detected in the majority of oligodendrocytes, 
CRMP2 protein is observed only in a subpopulation of oligodendrocytes increasing in a 
rostro-caudal gradient, where strongest expression is seen in the cerebellum, brainstem 
and spinal cord (Ricard, Stankoff et al. 2000).    
1.1.1.1.5 Outside the Nervous System 
 CRMP expression levels outside the nervous system are relatively low, although 
expression is detected in the developing heart and muscles (Goshima, Nakamura et al. 
1995; Byk, Dobransky et al. 1996). However, this expression pattern could be attributed 
to the neural constituents of these organs (Quinn, Gray et al. 1999). More recently, 
CRMPs expression has been associated with prostate, lung and glial cancer (Shih, Yang 
et al. 2001; Shih, Lee et al. 2003; Gao, Pang et al. 2010).  
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1.1.1.2 Diverse Roles of the CRMPs 
1.1.1.2.1 Neural Development  
 The CRMPs were originally characterized as intracellular proteins that mediate 
collapsin/semaphorin signal transduction based on the finding that an antibody to 
CRMP2 inhibited growth cone collapse in chick DRG neurons in response to collapsin-
1/sema D (Goshima, Nakamura et al. 1995). CRMP2 is also necessary for 
lysophosphatidic acid (LPA)-induced growth cone collapse (Arimura, Inagaki et al. 
2000). Furthermore, CRMP1 can form a complex with the neuronal receptor PlexinA1 
(PlexA1) to mediate Sema3A–induced axonal repulsion (Deo, Schmidt et al. 2004). 
However, the expression of CRMPs in neurons that do not respond to semaphorins, such 
as retinal ganglion cells, suggests that CRMPs participate in other semaphorin-
independent processes (Takahashi, Nakamura et al. 1998). The expression pattern of 
CRMPs through out the nervous system suggests that CRMPs could play roles in 
neurogenesis, neuronal migration and axonal growth.  
 In addition to its role in growth cone collapse, CRMP2 also plays a role in 
axon/dendrite fate and neuronal polarity. Overexpression of CRMP2 in hippocampal 
neurons induces supernumerary axons while the expression of truncated CRMP2 mutants 
suppressed the formation of primary axon (Inagaki, Chihara et al. 2001; Yoshimura, 
Kawano et al. 2005; Yoshimura, Arimura et al. 2006). CRMP2 overexpression can also 
promote neurite outgrowth and branching (Hall, Brown et al. 2001; Fukata, Itoh et al. 
2002). Similarly, L-CRMP4 overexpression, but not S-CRMP4, results in an increase in 
neurite length and branching in embryonic cortical neurons (Quinn, Chen et al. 2003). 
However, S-CRMP4 overexpression in neonatal hippocampal neurons does promote axon 
elongation (Cole, Causeret et al. 2006), while CRMP4 depletion in DRGs does not affect 
neurite outgrowth (Alabed, Pool et al. 2007). In mature cerebellar granule neurons 
overexpression of CRMP3 inhibits neurite outgrowth, whereas CRMP3 depletion 
promotes neurite outgrowth (Aylsworth, Jiang et al. 2009). Similarly, in N1E-115 cells, 
overexpression of CRMP5 inhibit neurite outgrowth, while CRMP5 depletion promotes 
outgrowth (Brot, Rogemond et al. 2010). In hippocampal neurons, CRMP5 regulates 
neuronal polarity through its ability to inhibit dendrite initiation but not axon initiation 
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(Brot, Rogemond et al. 2010). These observations indicate that the CRMP family 
participates in neurite outgrowth where CRMP2 and CRMP4 can promote neurite 
outgrowth while CRMP3 and CRMP5 inhibit neurite outgrowth.   
 The expression of CRMPs in oligodendrocytes suggests that they may play a role 
in oligodendrocyte function. The application of Sema3A conditioned medium to a 
purified mature oligodendrocyte culture results in oligodendrocytes that remain rounded 
and fail to extend processes (Ricard, Stankoff et al. 2000). These findings indicate that in 
addition to its role in regulating neurite outgrowth, CRMP may also participate in 
oligodendrocyte process outgrowth during myelination and remyelination.  
 The genetic deletion of CRMP1 and CRMP3 has provided significant insight into 
CRMP function. CRMP1 gene disruption in mice leads to an alteration of granule cell 
precursor proliferation, apoptosis and migration during postnatal cerebellar development, 
and a delay in Reelin-mediated neuronal migration in the cerebral cortex (Charrier, 
Mosinger et al. 2006; Yamashita, Uchida et al. 2006). CRMP1 gene disruption also 
results in an impairment in long-term potentiation (LTP) and spatial learning and 
memory, which has been attributed to improper neurite outgrowth (Su, Chien et al. 2007). 
CRMP3 gene disruption leads to abnormal dendrite and spine morphogenesis in the 
hippocampus but not the cerebral cortex (Quach, Massicotte et al. 2008). Further, no 
axonal abnormalities are observed in these mice suggesting that CRMP3 specifically 
regulates dendrite arborization and patterning in the hippocampus. These morphological 
abnormalities also result in a functional impairment in LTP (Quach, Massicotte et al. 
2008). 
1.1.1.2.2 Cellular Proliferation 
 CRMP2 has also been implicated in pathways that regulate the proliferation of 
non-neuronal cells (Tahimic, Tomimatsu et al. 2006). CRMP2 can be dephosphorylated 
in response to contact inhibition-induced quiescence and is hyperphosphorylated in 
tumor-derived cell lines and the tumor tissue (Tahimic, Tomimatsu et al. 2006). Although 
the CRMPs localize to the mitotic spindle and midbody in various cell lines, a functional 
role for CRMP in mitosis and cytokinesis has not been identified (Gu and Ihara 2000; 
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Fukata, Itoh et al. 2002; Yoshimura, Kawano et al. 2005; Tahimic, Tomimatsu et al. 
2006).  
1.1.1.2.3 Pathological Conditions 
 High CRMP expression levels have been implicated in neurological pathological 
conditions such as Alzheimer’s disease and epilepsy (Czech, Yang et al. 2004; Good, 
Alapat et al. 2004; Uchida, Ohshima et al. 2005; Cole, Noble et al. 2007). The presence 
of CRMP5 autoantibodies in patient serum has also been associated with a variety of 
paraneoplastic neurological disorders, however it is not clear if these autoantibodies are 
merely a marker of a host immune response or are involved with the manifestation 
specific neurological symptoms (Antoine, Honnorat et al. 1993; Camdessanché, 
Lassablière et al. 2006; Honnorat, Cartalat-Carel et al. 2009). High titers of CRMP5 
autoantibodies are associated with paraneoplastic optic neuropathy and vitritis in patients 
with small cell lung carcinoma (Thambisetty, Scherzer et al. 2001; Cross, Salomao et al. 
2003; Czech, Yang et al. 2004; Margolin, Flint et al. 2008). CRMP3 and CRMP4 
autoantibodies in patient serum have also been associated with limbic encephalitis and 
thymoma, when classical onconeural antibodies such as CRMP5 are not found (Knudsen, 
Bredholt et al. 2007).  
 More recently, CRMPs have been identified as metastatic and invasion 
suppressors in prostate, lung and glial cancer (Shih, Yang et al. 2001; Shih, Lee et al. 
2003; Gao, Pang et al. 2010). These studies demonstrate that CRMP1 expression is 
inversely associated with the invasive potential of human lung adenocarcinoma cell lines 
and advanced disease stage in patients, and CRMP4 expression is inversely associated 
with lymph node metastasis of prostate cancer (Shih, Yang et al. 2001; Shih, Lee et al. 
2003; Gao, Pang et al. 2010). Similarly, loss of CRMP1 promotes invasion of human 
glioblastoma multiform (GBM) cells expressing oncogenic mutations of EGFR 
(Mukherjee, DeSouza et al. 2009). Additionally, CRMP2 has also been identified as 
potential marker of colorectal carcinoma through a comparative analysis of cancer cell 
secretomes (Wu, Chen et al. 2008). 
 CRMP2 is expressed in T lymphocytes and is involved with both spontaneous and 
chemokine-induced T lymphocyte migration. The increased expression of CRMP2 in T 
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lymphocytes from patients suffering for neuroinflammatory disease suggests that a 
pathological role for CRMP2 in T lymphocytes may exist (Vincent, Collette et al. 2005; 
Vuaillat, Varrin-Doyer et al. 2007). The implication of CRMPs in pathological conditions 
that do not involve the nervous system provides evidence for a broader role for CRMPs 
in diverse physiological processes. 
1.1.1.3 Mechanism of action 
1.1.1.3.1 Microtubule Polymerization and Depolymerization 
 While all the CRMPs bind tubulin, they vary in their ability to promote 
microtubule polymerization (Fukata, Itoh et al. 2002). CRMP2 has the ability to bind 
tubulin heterodimers and promote microtubule assembly (Fukata, Itoh et al. 2002). It has 
been proposed that CRMP2 carries tubulin heterodimers to the assembly plus end of 
nucleation sites or growing microtubules and can then co-polymerize with tubulin 
heterodimers into microtubules (Fukata, Itoh et al. 2002). The expression of a CRMP2 
mutant lacking its microtubule assembly domain inhibits axonal growth and branching in 
a dominant-negative manner (Fukata, Itoh et al. 2002). CRMP2 can also regulate tubulin 
transport in the growing axon of hippocampal neurons by linking tubulin and Kinesin-1. 
CRMP2 binds directly to kinesin light chain 1 and tubulin where it regulates soluble 
tubulin transport to the growth tip of the axon (Kimura, Watanabe et al. 2005). In contrast 
to CRMP2, both CRMP3 and CRMP5 have been shown to inhibit microtubule 
polymerization (Aylsworth, Jiang et al. 2009; Brot, Rogemond et al. 2010). CRMP5 
forms a ternary complex with tubulin and MAP2, which can inhibit tubulin 
polymerization and neurite elongation (Brot, Rogemond et al. 2010). Interestingly, the 
co-expression of CRMP5 with CRMP2 antagonizes the ability of CRMP2 to promote 
neurite outgrowth (Brot, Rogemond et al. 2010). CRMP5 can bind microtubules and 
impair the ability of CRMP2 to transport tubulin and promote microtubule assembly. 
Therefore, CRMP5 plays a role in regulating neuronal polarity during brain development 
(Brot, Rogemond et al. 2010). While CRMP4 does bind directly to tubulin, how CRMP4 
modulates tubulin and tubulin-based structures remains unknown (Fukata, Itoh et al. 
2002; Rembutsu, Soutar et al. 2008). 
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1.1.1.3.2  F-actin Bundling 
 The CRMPs have the ability to bind actin. CRMP2 has been localized to actin 
within the growth cone but its role in regulating actin dynamics remains unknown 
(Arimura, Ménager et al. 2005). CRMP2 does not bind actin monomers directly and it 
has been proposed that CRMP2 interacts with Specifically Rac1-Associated protein (Sra-
1), which directly interacts with filamentous-actin (F-actin) in growth cones (Arimura, 
Ménager et al. 2005). CRMP4 can bind directly to F-actin and organize F-actin into 
bundles (Rosslenbroich, Dai et al. 2005). CRMP4 localizes to F-actin within the 
lamellipodia of B35 neuroblastoma cells and DRG growth cones. CRMP4 can regulate 
the actin cytoskeleton, where overexpression of CRMP4 inhibits migration of B35 
neuroblastoma cells, while CRMP4 depletion promotes migration (Rosslenbroich, Dai et 
al. 2005). Recently, CRMP4 has been identified as a metastasis-suppressor in prostate 
cancer through expression profiling of metastasis-associated proteins (Gao, Pang et al. 
2010). CRMP4 expression is inversely associated with lymph node metastasis of prostate 
cancer. Overexpression of CRMP4 suppresses the invasive ability of prostate cancer cells 
and strongly inhibits tumor metastasis in an animal model (Gao, Pang et al. 2010). The 
overexpression of CRMP4 in these tumor cells results in a rounded cellular morphology 
that is deficient in filopodial protrusions (Gao, Pang et al. 2010). In contrast, in neuronal 
growth cones, L-CRMP4 overexpression promotes an actin-based phenotype where both 
filopodial length and branch numbers are increased (Alabed, Pool et al. 2007). Similarly, 
CRMP5 also localizes to the filopodia of growth cones, where CRMP5 overexpression 
promotes filopodia and growth cone formation, while CRMP5 knockdown blocks 
filopodia formation and leads to aberrant growth cone morphology (Hotta, Inatome et al. 
2005). These findings demonstrate that CRMPs can regulate the actin cytoskeleton in 
non-neuronal and neuronal cells, and provide additional evidence for a broader role for 
CRMPs in cytoskeletal regulation. 
1.1.1.3.3 Rho GTPase Modulator 
 The Rho family of small guanosine triphosphatases (GTPases) are molecular 
switches that regulate many cellular processes including adhesion, cell cycle progression, 
gene transcription and actin dynamics (Bishop and Hall 2000). The best-characterized 
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mammalian Rho GTPases, Rho, Rac and Cdc42 (cell division cycle 42), have all been 
shown to be important intracellular regulators of the cytoskeleton (Ridley and Hall 1992; 
Ridley, Paterson et al. 1992; Bishop and Hall 2000). Previous studies have linked 
extracellular ligands to signaling cascades that activate Rho, Rac or Cdc42 to promote the 
formation of actin stress fibers, lamellipodia or filopodia, respectively, in non-neuronal 
cells (Bishop and Hall 2000). Subsequent studies have demonstrated that the Rho 
GTPases also play key roles in regulating diverse biological processes that are dependent 
on the actin cytoskeleton such as cell migration, mitosis, cytokinesis, wound healing, 
nerve regeneration and axon extension (Luo, Jan et al. 1996; Drechsel, Hyman et al. 
1997; Luo, Jan et al. 1997; Nobes and Hall 1999; Prokopenko, Saint et al. 2000; Ellezam, 
Dubreuil et al. 2002; Winton, Dubreuil et al. 2002; Dubreuil, Winton et al. 2003; Benink 
and Bement 2005; Dubreuil, Marklund et al. 2006; Narumiya and Yasuda 2006). We 
have previously demonstrated that L-CRMP4 can physically and functionally interact 
with RhoA to mediate neurite outgrowth inhibition in response to inhibitory CNS myelin 
(Alabed, Pool et al. 2007; Alabed, Pool et al. 2010). L-CRMP1 is also a negative 
regulator of Rho signaling since L-CRMP1 can interact with the kinase domain of Rho 
Kinase (ROCKII), a Rho effector, and inhibit its catalytic activity towards other 
substrates (Leung, Ng et al. 2002). Further, CRMP1 has been identified as a metastatic 
and invasion suppressor, where CRMP1 overexpression results in a decrease in Rac 
activity and increase in Rho activity. Consistent with these findings, CRMP1 knockdown 
results in an increase in Rac activity and a decrease in Rho activity. As a consequence of 
this shift in Rho GTPase activity, CRMP1 can promote actin contractility, focal adhesion 
formation and decrease invasive potential (Mukherjee, DeSouza et al. 2009) 
 The expression of CRMP2 in N1E-115 neuroblastoma cells can alter cellular 
morphology in response to active Rho GTPases. Normally, active RhoA signaling results 
in growth cone collapse and neurite retraction, while active Rac1 signaling leads to cell 
spreading, membrane ruffling and formation of neurites (Hall, Brown et al. 2001). The 
overexpression of CRMP2 switches RhoA and Rac1 morphology, where dominant active 
RhoA promotes neurite outgrowth and dominant active Rac1 induces collapse, in a 
ROCKII-dependent manner (Hall, Brown et al. 2001). The ability of CRMP2 to switch 
these responses indicates that CRMP2 is an important regulator of Rho GTPase signaling.  
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1.1.1.4  Post-translational regulation of CRMPs 
1.1.1.4.1  Phosphorylation and Dephosphorylation 
 Numerous consensus phosphorylation sites, such as casein kinase II (CKII), 
protein kinase A (PKA), cyclin-dependent kinase (cdk) and MAP kinase (MAPK), were 
found in the CRMP sequences when they were first identified (Byk, Dobransky et al. 
1996; Byk, Ozon et al. 1998). The regulation of CRMP phosphorylation was first 
demonstrated through NGF differentiation of PC12 cells where NGF treatment resulted 
in a decrease in the phosphorylated forms of the CRMPs (Byk, Dobransky et al. 1996; 
Byk, Ozon et al. 1998). Subsequent studies began to identify the kinases and 
phosphatases responsible for regulating CRMP phosphorylation levels. ROCKII can 
phosphorylate CRMP2 at Thr-555 in response to LPA-induced growth cone collapse in 
chick DRGs, and following myelin associated glycoprotein (MAG) or Nogo-66 treatment 
of rat cerebellar neurons (Arimura, Inagaki et al. 2000; Mimura, Yamagishi et al. 2006). 
Ca2+/calmodulin–dependent protein kinase II (CaMKII) can also phosphorylate CRMP2 
at Thr-555 in response to ischemic neuronal damage (Hou, Jiang et al. 2009). CRMP2 is 
also phosphorylated at residues Thr-509, Ser-518 and Ser-522, and this phosphorylated 
form of CRMP2 has been localized to neurofibrillary tangles and plaque neurites in 
Alzheimer’s disease brains (Gu, Hamajima et al. 2000; Cole, Astell et al. 2007). These 
residues were identified as a consensus site for glycogen synthase kinase-3β (GSK3β) 
(Yoshimura, Kawano et al. 2005).  
 GSK3 is a serine/threonine kinase originally identified as a kinase that 
phosphorylates glycogen synthase during glycogen metabolism. There are two isoforms 
of GSK3, GSK3α and GSK3β, which are ubiquitously expressed and constitutively 
active in cells. GSK3 is inactivated by phosphorylation at its amino-terminus serine 
(serine 21 for α or serine 9 for β) by several protein kinases such as protein kinase B 
(PKB, also called Akt), MAPK-activated protein kinase-1 (MAPKAP-K1, also called 
RSK) and p70 ribosomal S6 kinase-1 (Frame and Cohen 2001). Following an initial 
priming event on Ser-522 that is mediated by cyclin dependent kinase 5 (Cdk5), CRMP2 
is sequentially phosphorylated by GSK3β on residues Ser-518, Thr-514, and Thr-509 
(Cole, Knebel et al. 2004). These residues are conserved among CRMP1 and CRMP4, 
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but not CRMP3 (Cole, Causeret et al. 2006). Additionally, CRMP4, but not CRMP1 or 
CRMP2, can be primed by dual specificity tyrosine phosphorylation regulated kinase 2 
(DYRK2) (Cole, Causeret et al. 2006). In GSK3β and GSK3α/β knockout mice, CRMP2 
and CRMP4 phospho-Thr-509 levels are almost undetectable in cortex tissues, thus 
confirming that GSK3β phosphorylates CRMP2 and CRMP4 in vivo (Soutar, Kim et al. 
2010). GSK3β phosphorylates CRMP2 at Thr-514 and decreases the ability of CRMP2 to 
interact with tubulin and promote axon elongation and branching (Yoshimura, Kawano et 
al. 2005). Intriguingly, overexpression of CRMP2 mutated at its cdk-5 priming site Ser-
522 abrogates its ability to promote neurite formation and elongation in the human 
neuroblastoma cell line SH-SY5Y and in primary hippocampal neurons (Cole, Knebel et 
al. 2004). Further, the upregulation of protein phosphatase 2A (PP2A) can 
dephosphorylate CRMP2 to promote axon formation and elongation (Zhu, Zheng et al. 
2010). These findings demonstrate that phosphorylation of the CRMPs regulates 
important physiological functions such as axon outgrowth.  
 Phosphorylation of CRMP2 inhibits its ability to bind tubulin heterodimers and 
promote microtubule assembly (Mimura, Yamagishi et al. 2006). Similarly, the ability of 
CRMP2 to bind tubulin heterodimers, microtubules and Numb is disrupted by 
phosphorylation by ROCKII (Arimura, Ménager et al. 2005). However, the ability of 
CRMP2 to bind actin is unaltered by ROCKII phosphorylation (Arimura, Ménager et al. 
2005). Stimulation of cerebellar neurons with myelin associated inhibitors lead to the 
inactivation of GSK3β and the subsequent dephosphorylation of CRMP4 (Alabed, Pool 
et al. 2010). The decrease in CRMP4 phosphorylation status increases the ability of 
CRMP4 to complex with RhoA (Alabed, Pool et al. 2010). In one study to identify 
proteins that bind to CRMP2 and CRMP4 in a phosphorylation-dependent manner, 
different interacting proteins were identified (Rembutsu, Soutar et al. 2008). CRMP1, 
CRMP4 and adenine nucleotide translocator-1 (ANT-1) bound to dephosphorylated 
CRMP2 but not to phosphorylated CRMP2 (Rembutsu, Soutar et al. 2008). CRMP1, 
CRMP2, ANT-1, -2, and DYRK bound to dephosphorylated CRMP4 but not to 
phosphorylated CRMP4, while the peptidyl prolyl isomerase Pin1 bound only to 
phosphorylated CRMP4 (Rembutsu, Soutar et al. 2008). These results show that the 
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phosphorylation status of the CRMPs modulates their ability to bind to each other and to 
other interacting proteins. 
1.1.1.4.2 Calpain-mediated Cleavage 
 All of the CRMPs are targeted for cleavage by ischemia-activated calpain 
following cerebral ischemia by middle cerebral artery occlusion in mice (Jiang, Kappler 
et al. 2007). Similarly, in an in vivo model of traumatic brain injury, CRMP1, CRMP2 
and CRMP4 are found cleaved in the rat cortex and hippocampus following cortical 
impact injury (Zhang, Ottens et al. 2007). The application of NMDA or H2O2 to primary 
cortical neurons in vitro also results in calpain-mediated cleavage of all the CRMPs 
(Kowara, Chen et al. 2005; Bretin, Rogemond et al. 2006; Kowara, Moraleja et al. 2006; 
Kowara, Moraleja et al. 2008; Liu, Zhou et al. 2009). These studies demonstrate that 
CRMPs are important targets of activated calpain and that they may play a role in 
modulating ischemic neuronal death.  
 Despite the similarities in amino acid identity, it is surprising that calpain 
cleavage of the CRMPs does not occur at the same location within the protein sequence. 
CRMP1, CRMP2 and CRMP4 are cleaved by calpain near the carboxy terminus while 
CRMP3 is cleaved near the amino terminus (Liu, Zhou et al. 2009). The site of cleavage 
does not, however, determine the physiological consequence of cleavage as over-
expression of the cleaved forms of CRMP3 and CRMP4, but not CRMP1 or CRMP2, 
induces neuronal apoptosis (Liu, Zhou et al. 2009). In particular, the calpain cleavage 
product of CRMP3 translocates to the nucleus and mediates axonal retraction and 
neuronal death following glutamate excitotoxicity in vitro and cerebral ischemia in vivo 
(Hou, Jiang et al. 2006). After nuclear translocation, the calpain cleavage CRMP3 
product can associate with vimentin and cause nuclear condensation. However, this 
interaction with vimentin is not required for the calpain cleaved CRMP3 to inhibit neurite 
outgrowth or to promote neuronal death (Aylsworth, Jiang et al. 2009). In contrast, other 
calpain cleavage products of CRMPs, specifically CRMP2, may be responsible for the 
increased tolerance to ischemic injury that neurons acquire following an initial insult 
(Bretin, Rogemond et al. 2006). The calpain cleavage product of CRMP2 can reduce the 
amount of NR2B NMDA receptor subunit surface expression on neurons following 
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excitotoxic injury (Bretin, Rogemond et al. 2006). Interestingly, a similar C-terminal 
processed CRMP2 isoform is also observed during brain development and localizes to the 
nucleus through a nuclear localization signal (NLS) (Rogemond, Auger et al. 2008). This 
short CRMP2 isoform inhibits neurite outgrowth in neuroblastoma cells and cortical 
neurons, whereas full length CRMP2 promotes neurite outgrowth (Rogemond, Auger et 
al. 2008). This data supports CRMP2 cleavage in neurons as a part of normal brain 
development, in addition to its role in pathological processes. Together, these findings 
demonstrate that calpain cleavage of the CRMPs is a regulated process that can lead to 
different effects depending on the CRMP that is targeted.  
1.2 CRMP4 as a Cytoskeletal Regulator during Mitosis and Nerve Regeneration 
1.2.1 ROLE OF CRMPs IN MITOSIS  
 The CRMPs have been implicated in cellular proliferation in non-neuronal cells 
and have also been identified as metastatic and invasion suppressors in prostate, lung and 
glial cancer. These observations prompted us to investigate the role of CRMP4 in mitosis.  
1.2.1.1 Introduction 
 The ability of a cell to accurately replicate its DNA (S phase), segregate its 
chromosomes and divide into two daughters cells (M phase) is a fundamental property 
that mitotic cells must possess. Failure to do so results in chromosome non-disjunction 
and aneuploidy (Decordier, Cundari et al. 2008). Therefore, chromosomal alignment and 
segregation are important well-controlled steps in mitosis.  
 Mitosis is divided into five main stages: prophase, prometaphase, metaphase, 
anaphase and telophase (Fig. 2). During prophase, the nuclear envelope breaks down, 
chromatin condenses into chromosomes, and centrosomes composed of two centrioles 
form two microtubule organizing centers (MTOC) at the spindle poles. Sister chromatids 
are attached at the centromere, where two kinetochores form and await for microtubules 
to bind to them. Microtubules emanating from the MTOC search for and bind 
kinetochores, where they position chromosomes at the equatorial plane located 
equidistant from the two centrosomes. Metaphase occurs when all the chromosomes align 
at the equatorial plane, also known as the metaphase plate. Importantly, for proper 
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chromosome segregation to occur all chromosomes must be aligned at the metaphase 
plate. To prevent premature progression to anaphase, a mitotic spindle checkpoint called 
the spindle assembly checkpoint (SAC) exists to ensure that every kinetochore is bound 
to a microtubule and that all chromosomes are aligned at the metaphase plate. Once this 
checkpoint is reached, the cell progress to anaphase, which is further divided into 
anaphase A and anaphase B. In Anaphase A chromosomes move towards the spindle 
poles, while during anaphase B the poles separate farther from each other. In telophase, 
the chromosomes decondense into chromatin, the nuclear envelope reforms and 
microtubules continue to lengthen and elongate the cell. At the end of telophase, 
cytokinesis occurs which divides the cell into two daughter cells.  
1.2.1.2 The Mitotic Spindle Apparatus 
 The mitotic spindle machinery is composed of microtubules, MAPs and other 
regulatory proteins that are responsible for accurate chromosome alignment and 
segregation. During mitosis, there are two MTOC that form and organize microtubules 
into two asters that interact in an antiparallel array at the spindle midzone. The 
microtubule minus end is embedded in the spindle pole while the plus end is directed 
outwards. These spindle microtubules can either capture sister chromatids by their 
kinetochores and direct them to the metaphase plate (kinetochore microtubules), interact 
with microtubules from the other spindle pole (interpolar microtubules), or interact with 
the cortex (astral microtubules) to help position the spindle poles and the cleavage furrow 
(Lutz, Hamaguchi et al. 1988; Gundersen 2002; Rodriguez, Schaefer et al. 2003). These 
microtubule interactions are largely mediated through motor proteins such as kinesin and 
dynein and other regulatory proteins. Although the majority of actin is associated with the 
cortex during mitosis, there is some actin that localizes to mitotic spindle microtubules 
(Silverman-Gavrila and Forer 2000). It has been proposed that the role of this spindle 
actin, in association with myosin, is to induce tubulin flux from the kinetochore to the 
spindle pole (Silverman-Gavrila and Forer 2000). Disruption of mitotic spindle 
machinery results in a dysregulated mitotic spindle that yields misaligned chromosomes. 
Perturbation of mitotic microtubule dynamics with the microtubule-stabilizing drug taxol 
results in long astral tubules in cells, along with misaligned chromosomes located at the 
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ends of these astral tubules (Ault, DeMarco et al. 1991; Jordan, Wendell et al. 1996; 
Wakefield, Stephens et al. 2003). Depolymerizing microtubules with nocodazole results 
in a reversible prometaphase arrest (Centonze and Borisy 1991). Together, these findings 
highlight the importance of dynamic microtubules during mitosis since global 
stabilization or depolymerization of microtubules leads to defects in chromosomal 
alignment or mitotic arrest, respectively. Furthermore, the application of actin 
depolymerization drugs such as latrunculin B and cytochalasin D disrupts spindle actin 
and reduces tubulin flux from the kinetochore to the spindle pole, while the F-actin 
stabilization drug jasplakinolide has no effect (Silverman-Gavrila and Forer 2000). The 
application of a myosin ATPase inhibitor 2,3-butanedione 2-monoxime also results in a 
similar phenotype. Therefore, spindle actin is composed of stable F-actin and is necessary 
for the generation of actomyosin forces that induce tubulin flux from the kinetochore to 
the spindle pole (Silverman-Gavrila and Forer 2000).  
1.2.1.3 Regulators of Chromosome Alignment and mitotic progression 
1.2.1.3.1 Chromosome Alignment 
 Proper chromosomal segregation during mitosis requires the coordination of 
various processes such as accurate chromosome alignment to the metaphase plate, 
maturation of correct microtubule-kinetochore attachments, correction of erroneous 
attachments and the silencing of the SAC (Manning, Bakhoum et al. 2010). Microtubules 
originating from centrosomes undergo a process known as search and capture, where the 
plus ends of microtubules are highly dynamic and exploratory until they bind to a 
kinetochore. Once a kinetochore is bound to a microtubule, an increasing number of 
microtubules also bind to form a kinetochore fiber (McEwen, Heagle et al. 1997; Kapoor 
and Compton 2002). For normal segregation to occur, a chromosome must bi-orient 
through the attachment of sister kinetochores with microtubules originating from opposite 
spindle poles. Incorrect microtubule-kinetochore attachments do occur, such as 
monotelic, merotelic or syntelic attachments, but correction mechanisms exist to ensure 
that proper amphitelic attachments (bi-orientation) form. Monotelic attachments, where 
only one sister kinetochore is attached to microtubules from one spindle pole, are part of 
the normal progression to bi-orientation. The presence of an unattached kinetochore is a 
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potent checkpoint signal where levels of mitotic-arrest deficient homologue-2 (MAD2) 
and BubR1 remain high and maintain the SAC (Cimini and Degrassi 2005; Musacchio 
and Salmon 2007). The presence of merotelic attachments, where a kinetochore is bound 
by microtubules from both spindle poles, activates a correction mechanism that is based 
on Aurora B kinase (Cimini and Degrassi 2005; Musacchio and Salmon 2007). Syntelic 
attachments, where both kinetochores are bound to microtubules originating from the 
same spindle pole, are also corrected by an Aurora B kinase mechanism (Tanaka, Rachidi 
et al. 2002; Cimini and Degrassi 2005; Musacchio and Salmon 2007). Therefore, the 
progression from metaphase to anaphase in the presence of misaligned or mal-attached 
chromosomes indicates that a component of correction mechanism is compromised.  
 The regulation of mitotic spindle dynamics and chromosomal alignment has been 
shown to be partly regulated by GSK3 (Frame and Cohen 2001; Wakefield, Stephens et 
al. 2003; Cohen and Goedert 2004; Tighe, Ray-Sinha et al. 2007). Reports that GSK3β 
plays a role in regulating microtubule dynamics during interphase provide evidence that 
GSK3 may also regulate spindle microtubules (Ciani, Krylova et al. 2004). GSK3β can 
decrease microtubule stability through phosphorylation of MAPs such as Tau, MAP1B 
and MAP2C (Wang, Wu et al. 1998; Goold, Owen et al. 1999; Ciani, Krylova et al. 
2004). During mitosis, GSK3 localizes along spindle microtubules and at the 
centrosomes (Wakefield, Stephens et al. 2003). Repressing GSK3 function with GSK3 
inhibitors (lithium chloride, SB-216763, SB-415286, AR-A014418, I-Azakenpaullone or 
CHIR99021) or GSK3β RNA interference alters spindle morphology through an increase 
in spindle length and a weakening of the spindle midzone (Wakefield, Stephens et al. 
2003; Tighe, Ray-Sinha et al. 2007). GSK3 inhibition also results in defects in 
chromosomal alignment, where syntelic and monotelic attachments predominate (Tighe, 
Ray-Sinha et al. 2007). Although GSK3 inhibition delays mitotic progression, anaphase 
onset eventually occurs in the presence of misaligned chromosomes resulting in 
chromosome non-disjunction (Tighe, Ray-Sinha et al. 2007). In mouse preimplantation 
embryos, GSK3 inhibition delays mitotic cell cycle progression and results in defects in 
chromosome alignment and cytokinesis (Acevedo, Wang et al. 2007). While the 
importance of GSK3 as a mitotic kinase has been recognized, the physiological substrates 
that mediate these GSK3-dependent effects during mitosis have yet to be fully identified. 
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Aurora-A-interacting protein (AIP), a negative regulator of Aurora-A, is a mitotic target 
of GSK3 (Fumoto, Lee et al. 2008). GSK3 interacts with AIP to regulate the degradation 
of Aurora A in early mitotic phase. In Chapter 2, we demonstrate that GSK3 regulates 
mitotic chromosomal alignment through CRMP4.  
1.2.1.3.2 Spindle Assembly Checkpoint 
   Another regulatory mechanism that exists to ensure that proper chromosomal 
alignment occurs before mitotic progression can continue is the presence of the spindle 
assembly checkpoint (SAC). The SAC inhibits metaphase progression to anaphase by 
negatively regulating the anaphase-promoting complex (APC, also known as the 
cyclosome) through CDC20 inhibition (Musacchio and Salmon 2007). APC is an 
ubiquitin ligase that targets cyclin B and securin to the proteasome through 
ubiquitination. The proteolysis of cyclin B inactivates the mitotic kinase CDK1 and 
activates mitotic progression. Securin is an inhibitor of the protease separase, which 
cleaves the cohesin complex that binds sister chromatids together (Musacchio and 
Salmon 2007). The presence of unattached kinetochores during prophase and 
prometaphase results in high SAC levels that prevent anaphase onset. As chromosomes 
align at the metaphase plate, the levels of SAC decrease until all of chromosomes are bi-
oriented with proper kinetochore microtubule attachments, which result in the 
inactivation of the checkpoint and the onset of anaphase.  
 In addition to proper kinetochore microtubule attachments, the SAC also monitors 
tension between sister kinetochores (Nicklas, Ward et al. 1995; Musacchio and Salmon 
2007). Bi-orientation of sister kinetochores results in an increase in kinetochore tension 
that leads to an increase in kinetochore-to-kinetochore distance and stretching of 
centromeric chromatin (Nicklas, Ward et al. 1995; Nicklas 1997). However, tension 
monitoring alone is not sufficient to detect all incorrect attachments since merotelic 
attachments are attached to opposite spindle poles. Monotelic and syntelic attachments 
are still detected since they are attached to only one spindle pole and fail to generate 
enough tension.  
1.2.1.3.3  Rho GTPases as Mitotic Regulators 
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 Although the importance of Rho GTPases during the process of cytokinesis has 
been well recognized for some time, it was believed that they did not participate in 
mitosis because a Rho inhibitor, C3 exoenzyme, did not inhibit mitosis (Narumiya and 
Yasuda 2006). Furthermore, it was commonly believed that microtubules and actin 
participated in separate stages of cell division, mitosis and cytokinesis, respectively 
(Narumiya and Yasuda 2006). However, several studies now demonstrate that the Rho 
GTPases do participate in mitosis and that actin-microtubule interactions are important 
for both mitosis and cytokinesis. The inactivation of all members of the Rho subfamily of 
GTPases, but not other GTPases, with toxin B from Clostridium difficile arrests cells in 
prometaphase with disrupted microtubule-kinetochore attachments and also leads to an 
increase in chromosome misalignment (Yasuda, Oceguera-Yanez et al. 2004). The 
expression of a dominant negative mutant of Cdc42 (N17-Cdc42) or the depletion of its 
effector mDia3 phenocopies toxin B treatment. Therefore, it has been proposed that a 
Cdc42-mDia3 pathway regulates spindle microtubule-kinetochore attachments and 
mitotic progression (Tatsumoto, Sakata et al. 2003; Narumiya, Oceguera-Yanez et al. 
2004; Yasuda, Oceguera-Yanez et al. 2004; Oceguera-Yanez, Kimura et al. 2005; 
Narumiya and Yasuda 2006). While these studies demonstrate a role for Cdc42 during 
mitosis, other studies have demonstrated a role for RhoA in regulating microtubule 
dynamics during mitosis (Narumiya and Yasuda 2006). Lfc, a Rho GEF, associates with 
microtubules during interphase and on spindle microtubules during mitosis (Benais-Pont, 
Punn et al. 2003; Bakal, Finan et al. 2005). Neutralization of Lfc with a function-blocking 
antibody or Lfc depletion with RNA interference results in a decrease in spindle length, 
increase in chromosome missegregation and an increase in the cells arrested in 
prophase/prometaphase (Benais-Pont, Punn et al. 2003; Bakal, Finan et al. 2005). 
Further, neutralization of mDia1 with a function-blocking antibody phenocopies Lfc 
neutralization/depletion. This supports a model where active RhoA and mDia1 can 
regulate microtubule attachment to kinetochores and to the cortex, and in turn influence 
mitotic progression (Kodama, Karakesisoglou et al. 2003; Wen, Eng et al. 2004; Bakal, 
Finan et al. 2005; Narumiya and Yasuda 2006). Further, it has also been shown that the 
actomyosin contractility can regulate centrosome separation and positioning after nuclear 
envelope breakdown and that these events involve ROCK activity (Rosenblatt, Cramer et 
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al. 2004). Application of latrunculin A, blebbistatin or the ROCK inhibitor Y-27632 
alters spindle morphology and increases chromosome misalignment (Rosenblatt, Cramer 
et al. 2004).  
1.2.1.4 Why CRMPs are ideally positioned to regulate mitosis 
 The assembly and regulation of the mitotic spindle is a critical aspect of mitosis. 
In Chapter 2, we investigate the role of CRMP4 during mitosis based on previous studies 
that have demonstrated that (1) CRMPs can interact directly with tubulin and localize to 
the mitotic spindle  (2) CRMP4 can interact directly with actin and promote actin-based 
phenotypes, (3) CRMP4 can physically and functionally interact with RhoA and (4) 
CRMP4 is a physiological target of the mitotic kinase GSK3β (Fukata, Itoh et al. 2002; 
Rosslenbroich, Dai et al. 2005; Cole, Causeret et al. 2006; Alabed, Pool et al. 2007; 
Rembutsu, Soutar et al. 2008; Alabed, Pool et al. 2010; Soutar, Kim et al. 2010).  
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Chapter 1 - Figure 2. Schematic representation of cell division. 
Mitosis is divided into five main stages: prophase, prometaphase, metaphase, anaphase 
and telophase. During mitotic progression, decondensed DNA condense into 
chromosomes and are positioned to the equatorial by microtubules. This process is also 
dependent on F-actin since the disruption of spindle actin reduces tubulin flux from the 
kinetochore to the spindle pole (Silverman-Gavrila and Forer 2000). During prophase and 
prometaphase, the activation of Rho through the Rho GEF, Lfc, regulates microtubule 
dynamics (Benais-Pont, Punn et al. 2003; Bakal, Finan et al. 2005). Disruption of Lfc 
function leads to a decrease in spindle length, an increase in chromosome missegregation 
and an increase in the cells arrested in prophase/prometaphase (Benais-Pont, Punn et al. 
2003; Bakal, Finan et al. 2005). 
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1.2.2 ROLE OF CRMPs IN NERVE REGENERATION 
 The CRMPs have been largely characterized in the context of neural 
development. However, despite their strong expression pattern in the nervous system, not 
many studies have investigated the roles of CRMPs during nerve regeneration. We have 
previously identified CRMP4 as key intracellular neuronal protein that mediates neurite 
outgrowth inhibition in response to myelin and aggrecan (Alabed, Pool et al. 2007). 
These in vitro findings prompted us to further investigate the role of CRMP4 in nerve 
regeneration.   
1.2.2.1 Introduction 
 The inability of the adult central nervous system (CNS) to regenerate following 
traumatic injuries, such as spinal cord injury (SCI), stroke and neurodegenerative 
diseases, results in devastating clinical consequences. Over the past 30 years, much 
progress has been made in the identification of the molecular components and signaling 
cascades involved with nerve injury and regeneration. Damage to neurons located in the 
adult CNS often leads to persistent deficits due to the inability of axons to regenerate and 
reform functional connections following injury. In contrast to the CNS, neurons located 
in the PNS can regrow their transected axons over long distances and reform functional 
synapses. Ramόn y Cajal observed that following injury, the terminal ends of axons 
swelled up and would not regenerate. He proposed that these “dystrophic endballs” no 
longer had the capacity to regenerate and that the CNS environment was limiting their 
regenerative potential. Further evidence to support Ramόn y Cajal’s hypothesis was 
provided by studies by Aguayo and colleagues, in which they demonstrated that the CNS 
and PNS environments were quite different in their ability to promote nerve regeneration. 
They showed that neurons located in the CNS, which normally do not regenerate 
following injury, have the ability to regenerate their damaged axons into a sciatic nerve 
graft (Richardson, McGuinness et al. 1980). When a sciatic nerve was grafted to the brain 
or spinal cord, long distance regeneration was observed into the graft, with the 
regenerating axons stopping abruptly when they re-encountered the CNS environment 
(David and Aguayo 1981). Subsequent studies began identifying the molecular 
components of inhibitory CNS myelin such as Nogo, MAG (Myelin-assciated 
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glycoprotein), and OMgp (Oligodendrocyte myelin glycoprotein). In addition, the glial 
scar composed of reactive astrocytes and inhibitory chondroitin sulfate proteogylcans 
(CSPGs) can form a physical and chemical barrier to regeneration. More recently, 
embryonic chemorepulsive guidance molecules such as ephrin B3, Sema4D and Netrin-1 
are thought to contribute to the inhibition of regeneration (Yiu and He 2006).  
 Both CSPGs and MAIs contribute to the heterogeneous inhibitory environment 
found in CNS myelin that limits nerve regeneration. These inhibitory molecules signal 
through receptor complexes located on the neuronal membrane to mediate myelin 
inhibition (Yiu and He 2006). Despite the diversity of ligands and receptor complexes, 
intracellular signaling converges to activate the RhoA pathway to mediate neurite 
outgrowth inhibition via its effects on the cytoskeleton. One approach to promote nerve 
regeneration following injury has been to target and neutralize inhibitory molecules in 
extracellular environment or on the neuronal plasma membrane. An alternative approach 
has been to inactivate the intracellular molecule RhoA and its downstream effector Rho 
kinase (Lehmann, Fournier et al. 1999; Winton, Dubreuil et al. 2002; Dubreuil, Winton et 
al. 2003; Fournier, Takizawa et al. 2003; McKerracher and Higuchi 2006; Lord-Fontaine, 
Yang et al. 2008). Currently, clinical trials investigating the neuroprotective and 
neuroregenerative properties of the Rho antagonist, Cethrin®, in patients with thoracic 
and cervical SCI are underway. However, the ubiquitous expression of RhoA and its 
involvement in multiple physiological processes in many cells may limit its role as a 
therapeutic agent due to deleterious side effects. Therefore, to develop a more specific 
therapeutic agent to promote functional recovery following CNS injury, a greater 
understanding of the basic mechanisms underlying neuronal injury is needed. 
1.2.2.2 Receptor Mechanisms  
 MAIs are extracellular ligands for receptors located at the neuronal membrane. 
The MAIs Nogo, MAG and OMgp signal through a tri-partite receptor complex 
composed of NgR1 (Nogo-66 receptor) (Fournier, GrandPre et al. 2001) or PirB (Paired 
immunoglobulin-like receptor B) (Atwal, Pinkston-Gosse et al. 2008), LINGO1 (LRR 
and Ig containing Nogo Receptor interacting protein) (Mi, Lee et al. 2004) and either p75 
neurotrophin receptor (p75NTR) (Wang, Kim et al. 2002; Wong, Henley et al. 2002; 
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Yamashita, Higuchi et al. 2002) or TROY (p75 low affinity neurotrophin receptor or 
Tumor necrosis factor superfamily member 19 or Taj) (Park, Yiu et al. 2005; Shao, 
Browning et al. 2005). Other inhibitory molecules such as ephrin-B3, netrin-1 and 
Sema4D signal through their respective receptors, ephA4, DCC/UNC5 and CD72 
(Moreau-Fauvarque, Kumanogoh et al. 2003; Benson, Romero et al. 2005; Löw, 
Culbertson et al. 2008). CSPGs signal through the neural receptor PTPσ to mediate their 
inhibitory effects on nerve regeneration (Shen, Tenney et al. 2009).  
1.2.2.3 The Growth Cone 
 During development, neurons project their axons to innervate specific targets. 
This is a finely tuned process that relies on the ability of the growth cone to integrate 
information from multiple environmental guidance cues to produce one functional output. 
The growth cone, a highly motile fan-shaped structure located at the tip of a growing 
axon, is continually sampling its extracellular environment by extending and retracting its 
plasma membrane through filopodia and lamellipodia formation and extension. The 
highly dynamic nature of the growth cone results from specific cytoskeletal changes in 
actin and microtubules at discrete locations within the growth cone. The peripheral 
domain of the growth cone is composed primarily of actin-based filopodia and 
lamellipodia, while the central domain is composed primarily of microtubules. 
Microtubules originating from the central domain can extend into the peripheral domain, 
where they play an important role in growth cone steering (Dent, Gupton et al. 2010). 
The transition domain, located between the peripheral and central domain, is composed 
of an actin network associated with myosin-2 that generates retrograde actin flow. 
Receptors located at the growth cone plasma membrane are responsible for generating 
intracellular signaling cascades activated by extracellular ligand binding. Therefore, 
extracellular molecules bind to neuronal receptors located at the growth cone to activate 
intracellular signaling cascades that converge onto proteins that regulate the cytoskeleton 
and ultimately direct the growth cone to its proper target.  
 For the regeneration of transected axons to occur following axotomy, the 
proximal end of the axon must transform into a competent growth cone (Spira, Oren et al. 
2003; Sahly, Khoutorsky et al. 2006; Erez, Malkinson et al. 2007; Erez and Spira 2008). 
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This process requires appropriately controlled microtubule restructuring, vesicle 
accumulation and actin polymerization (Sahly, Khoutorsky et al. 2006). Perturbation of 
microtubules with nocodozale inhibits the formation of the microtubule compartment but 
does not affect actin-based lamellipodia formation. Similarly, inhibition of actin 
polymerization with cytochalasin D or jasplakinolide disrupts lamellipodia formation but 
not the microtubule compartment and vesicle accumulation. Thus, while it appears that 
these processes can occur independently of each other, a competent growth cone does not 
form and the axon does not regenerate if one of these processes is disrupted (Sahly, 
Khoutorsky et al. 2006). In the CNS, transected axons form swellings at their axon tips 
known as retraction bulbs, which are the nongrowing equivalents of growth cones 
(Ertürk, Hellal et al. 2007). In contrast, in the PNS transected axons readily form growth 
cones and maintain the capacity to regenerate. These differences in morphology and 
regenerative capacity have been largely attributed to the underlying microtubule network, 
where competent growth cones have tightly bundled microtubules and retraction bulbs 
have a disorganized microtubule network (Ertürk, Hellal et al. 2007). The in vitro and in 
vivo administration of pharmacological agents that disrupt microtubules, such as 
nocodazole, transforms growth cones into retraction bulbs in the PNS following injury. 
Consistent with these findings, pharmacological agents that stabilize microtubules, such 
as taxol, prevent transected axon in the CNS from forming retraction bulbs, decrease 
axonal degeneration and promote neurite outgrowth following injury (Ertürk, Hellal et al. 
2007). Therefore, strategies aimed at microtubule stabilization may promote competent 
growth cone formation and subsequently increase the regenerative capacity of transected 
axons in the CNS following injury (Hellal, Hurtado et al. 2011).          
1.2.2.4 RhoA GTPase and its downstream effectors in nerve regeneration 
 Following CNS injury, damaged axons are exposed to an unfavorable 
heterogeneous environment composed of multiple MAIs and inhibitory components of 
the glial scar. Neutralizing only one of these specific inhibitory components may be 
limited as a strategy to promote nerve regeneration since multiple layers of inhibition 
exists. Therefore, targeting an intracellular pathway common to these multiple sources of 
inhibition could be an effective approach to circumvent the heterogeneous inhibitory 
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environment at the CNS lesion site. So far, the best-characterized intracellular pathway 
involves the activation of RhoA and its downstream effector Rho-associated kinase 
(ROCK) (Jin and Strittmatter 1997; Lehmann, Fournier et al. 1999; Borisoff, Chan et al. 
2003; Fournier, Takizawa et al. 2003). 
  RhoA activation in non-neuronal cells results in the formation of contractile 
actin-myosin filaments (stress fibers) and associated focal adhesion complexes (Ridley 
and Hall 1992). In neuronal growth cones, RhoA has been implicated in the 
rearrangement of the cytoskeleton in response to guidance cues such as Sema4D 
(Aurandt, Vikis et al. 2002; Perrot, Vazquez-Prado et al. 2002; Swiercz, Kuner et al. 
2002). Further, RhoA activation in neuronal cells has been associated with neurite 
retraction and cell rounding. An increase in RhoA activation is observed in neurons that 
are plated on an inhibitory myelin substrate (Niederöst, Oertle et al. 2002; Winton, 
Dubreuil et al. 2002; Fournier, Takizawa et al. 2003). The inactivation of Rho using C3 
transferase toxin from Clostridium botulinum, which ADP ribosylates and inactivates 
RhoA, RhoB and RhoC isoforms, is sufficient to overcome growth inhibition on an 
inhibitory myelin substrate (Lehmann, Fournier et al. 1999). Since Rho activation in 
neuronal cell is observed following exposure to most of the inhibitory components of the 
CNS, it was expected that Rho activation also occurred in neurons following SCI 
(McKerracher and Higuchi 2006). In vivo Rho activation occurs in both white matter and 
grey matter, where Rho activation is localized to both cell bodies and axons (Madura, 
Yamashita et al. 2004). Further, in vivo Rho activation is also seen through a pull-down 
assay using the Rho binding domain of Rhotekin in neurons following SCI in both rats 
and mice (Dubreuil, Winton et al. 2003). In addition to neurons, increased Rho activation 
following SCI has also been detected in glial cells such as astrocytes and 
oligodendrocytes (Dubreuil, Winton et al. 2003).  
 Intriguingly, inhibitory molecules such as CSPGs that do not signal through the 
NgR1 receptor complex also lead to the intracellular activation of RhoA (Schweigreiter, 
Walmsley et al. 2004). Further, the application of the RhoA inhibitor C3 transferase or 
ROCK inhibitors Y-27632 and HA1077 (Fasudil hydrochloride) increase neurite 
outgrowth on CSPG substrates (Borisoff, Chan et al. 2003; Monnier, Sierra et al. 2003; 
Lingor, Teusch et al. 2007). Recent evidence supports PKC as a convergent mediator of 
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RhoA activation following stimulation with either MAIs or CSPGs (Sivasankaran, Pei et 
al. 2004). EphrinB3 and netrin-1 can also activate RhoA through their receptors, ephA4 
and DCC, respectively (Sahin, Greer et al. 2005; Moore, Correia et al. 2008). The 
convergence of signaling pathways from diverse inhibitory molecules that prevent nerve 
regeneration supports the strategy to target RhoA activation as a therapeutic treatment for 
SCI.  
1.2.2.4.1 RhoA effectors and Cytoskeleton Remodeling 
 RhoA activation signals through downstream effectors, such as ROCK, to 
modulate the cytoskeleton and influence neurite outgrowth. Antagonizing ROCK 
signaling with the pharmacological inhibitors Y-27632 and HA1077, or with a dominant-
negative form of ROCK, attenuates myelin-induced growth cone collapse and neurite 
outgrowth inhibition (Hara, Takayasu et al. 2000; Dergham, Ellezam et al. 2002; 
Borisoff, Chan et al. 2003; Fournier, Takizawa et al. 2003; Alabed, Grados-Munro et al. 
2006). ROCKII is activated in response to the Nogo and enhances phosphorylation of 
MLCII, an important signaling component for growth cone collapse and neurite 
outgrowth inhibition (Alabed, Grados-Munro et al. 2006; Kubo, Endo et al. 2008). 
Further, following spinal cord injury MLCII is phosphorylated in a ROCK-dependent 
manner in damaged axons (Kubo, Endo et al. 2008). These findings support an inhibitory 
signaling cascade whereby RhoA activation promotes ROCK-mediated phosphorylation 
of MLCII to cause cytoskeletal rearrangements in response to inhibitory molecules.   
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Chapter 1 - Figure 3. Schematic representation of the ligands and receptors that 
participate in CNS growth inhibition. 
Myelin associated inhibitors (MAG, Nogo-66 and OMgp), CSPGs, and other inhibitory 
molecules (Netrin-1, Sema4D, Sema3A, Sema5A and EphrinB3) signal through receptor 
complexes at the neuronal plasma membrane to stimulate growth inhibition. Inside 
neurons, the growth inhibitory signals converge to RhoA, a master switch that regulates 
the growth cone cytoskeleton in motility. RhoA effectors such as Rho Kinase and 
CRMP4 are important in mediating these effects. Adapted from Essentials of Spinal Cord 
Injury: Targeting Rho inactivation to promote regeneration and treat spinal cord injury: 
Bench to bedside translational medicine (In press) by L. McKerracher, M. Fehlings, A.E. 
Fournier and S. Ong Tone, 2010, NY: Thieme Medical Publishers.  
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1.2.2.5 The Role of CRMPs in nerve regeneration 
 Although the role of CRMPs in embryonic development of the nervous system 
and neuronal polarity has been studied, the role of CRMPs in nerve regeneration is still 
unknown. In a rat hypoglossal nerve injury model CRMP2a mRNA levels were 
increased, while CRMP3a and CRMP4a mRNA levels were unchanged following 
axotomy (Suzuki, Nakagomi et al. 2003). Overexpression of CRMP2 through an 
adenoviral vector accelerates hypoglossal nerve regeneration following injury. This study 
demonstrates that CRMP2 has potent neurite elongation activity in an in vivo model of 
PNS injury. The role of CRMP3 in nerve regeneration has not been extensively studied, 
although the ability of CRMP3 to inhibit microtubule polymerization and neurite 
outgrowth in vitro suggest that CRMP3 is most likely a negative regulator of nerve 
regeneration. In another PNS injury model, CRMP4 mRNA and protein expression were 
increased in both adult sciatic motor neurons and DRG neurons that were regenerating 
following a sciatic nerve lesion (Minturn, Fryer et al. 1995; Jang, Shin et al. 2010). 
Furthermore, an increase in CRMP4 protein expression is observed in the peripheral axon 
following the injury (Jang, Shin et al. 2010).  
 With respect to CNS injury, the CRMP family has also been implicated in the 
signaling cascade activated in response to MAIs and CSPGs (Mimura, Yamagishi et al. 
2006; Alabed, Pool et al. 2007; Alabed, Pool et al. 2010). It has been shown that both in 
vitro treatment of postnatal cerebellar neurons with two components of CNS myelin, 
MAG and Nogo-66, and in vivo spinal cord injury in the adult rat, result in ROCK-
dependent phosphorylation of CRMP2 (Mimura, Yamagishi et al. 2006). Further, siRNA- 
mediated CRMP-2 protein knockdown mimics the inhibitory effect of MAG on neurite 
outgrowth. Following SCI, microtubule density decreases in a ROCK-dependent manner, 
which is consistent with CRMP-2 function in promoting microtubule assembly (Mimura, 
Yamagishi et al. 2006). Consistent with its role in PNS regeneration, overexpression of 
CRMP2 or a nonphosphorylatable form of CRMP2 in these neurons attenuates their 
response to these inhibitors in vitro (Mimura, Yamagishi et al. 2006). However, whether 
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overexpression of CRMP2 can promote nerve regeneration in an in vivo CNS injury 
model remains to be investigated.  
 We have previously demonstrated that L-CRMP4 can physically and functionally 
interact with RhoA to mediate neurite outgrowth inhibition in vitro (Alabed, Pool et al. 
2007; Alabed, Pool et al. 2010). Although CRMP4 depletion in DRGs does not affect 
neurite outgrowth on a permissive laminin coated substrate, CRMP4 depletion does 
attenuate neurite outgrowth inhibition on CNS myelin (Alabed, Pool et al. 2007). This 
data demonstrates that RhoA signals through L-CRMP4 to inhibit neurite outgrowth. 
Further, Nogo66 stimulation increases the RhoA-L-CRMP4 interaction, which is also 
independent of the nucleotide binding state of RhoA. This suggests that additional 
upstream signaling pathways other than those leading to RhoA activation may be 
involved. Blockade of the RhoA-L-CRMP4 interaction with a competitive peptide, 
C4RIP (CRMP4b-RhoA Inhibitory Peptide), attenuates neurite outgrowth inhibition on 
both CNS myelin and aggrecan (Alabed, Pool et al. 2007). These findings identify 
CRMP4 as a convergent regulator of axon outgrowth inhibition, where RhoA-L-CRMP4 
pathway activation leads to cytoskeletal rearrangements.   
1.2.2.6 Why CRMPs are ideally positioned to regulate nerve regeneration 
 Following CNS injury, inhibitory extracellular molecules signal through receptor 
complexes on the injured axon to activate intracellular pathways that inhibit regeneration. 
These inhibitory pathways largely converge onto the cytoskeleton to prevent growth cone 
formation and subsequent regenerative axonal outgrowth. While the biological function 
of CRMPs in an in vivo model of regeneration has not been extensively studied, we 
investigate the role of CRMP4 in nerve regeneration based on (1) the localization of 
CRMP4 to growth cones, (2) CRMP4 binds directly to tubulin, (3) CRMP4 binds directly 
to actin and promotes actin-based phenotypes such as filopodial elongation, (4) CRMP4 
depletion attenuates neurite outgrowth on myelin, (5) the specific ability of L-CRMP4 to 
physically and functionally interact with RhoA to mediate neurite outgrowth inhibition in 
vitro, and (6) the disruption of the L-CRMP4-RhoA interaction with the competitive 
peptide C4RIP attenuates neurite outgrowth inhibition in response to myelin and 
aggrecan (Fukata, Itoh et al. 2002; Rosslenbroich, Dai et al. 2005; Cole, Causeret et al. 
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2006; Alabed, Pool et al. 2007; Rembutsu, Soutar et al. 2008; Alabed, Pool et al. 2010; 
Soutar, Kim et al. 2010). In Chapters 3 and 4, we investigate CRMP4 function in an in 
vivo preclinical model of CNS nerve regeneration through the development of two 
versions of C4RIP: (1) an adeno-associated virus encoding C4RIP and (2) a recombinant 
cell permeable TAT C4RIP protein, respectively. 
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1.3 THESIS RATIONALE 
 CRMPs are cytosolic phosphoproteins that have been implicated in various 
biological processes that include neurite outgrowth, cellular proliferation, cell migration, 
cell invasion and metastasis. The ability of the CRMPs to participate in these processes 
has largely been attributed to its role as a cytoskeleton regulator. While all the CRMPs 
can bind directly to tubulin, and either directly or indirectly to actin, only CRMP4 has 
been shown to physically and functional bind to RhoA, a key signaling molecule in CNS 
regeneration and mitosis. Further, this interaction between CRMP4 and RhoA can be 
regulated by GSK3, a kinase implicated in both mitosis and regeneration. This thesis 
investigates the role of CRMP4 during mitosis and CNS regeneration. In Chapter 2, we 
identify CRMP4 as an important regulator of mitotic chromosomal alignment in HeLa 
cells. We also identify CRMP4 as a physiological substrate of GSK3 and demonstrate the 
importance of GSK3-dependent phosphorylation of CRMP4 in regulating spindle 
morphology and mitotic chromosomal alignment. In Chapters 3 and 4, we investigate the 
role of CRMP4 in CNS regeneration through the administration of a L-CRMP4-RhoA 
competitive antagonist C4RIP in an in vivo preclinical optic nerve injury model in the 
adult rat. In Chapter 3, we investigate the ability of an adeno-associated virus encoding 
C4RIP to enhance adult retinal ganglion cell axon regeneration following optic nerve 
injury. In Chapter 4, we develop a novel method to generate cytosolic recombinant cell 
permeable TAT fusion proteins and investigate the ability of TAT C4RIP to enhance 
adult retinal ganglion cell axon regeneration following optic nerve injury.  
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2.1 PREFACE 
In Chapter 1, we discuss the importance of the cytoskeleton and cytoskeleton regulators 
during mitosis. We also identify some key properties about CRMPs, specifically CRMP4, 
that support a model in which they play a broader role in biological processes that rely on 
cytoskeleton rearrangements. CRMPs can interact directly with tubulin and localize to the 
mitotic spindle, and CRMP4 can interact directly with actin and promote actin-based 
phenotypes. We have also previously shown that CRMP4 can physically and functionally 
interact with RhoA, an important mitotic regulator. Additionally, CRMP4 is a 
physiological target of the mitotic kinase GSK3β. Based on this published data, we 
investigated the role of CRMP4 during mitosis. 
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2.2 ABSTRACT 
2.2.1 Background 
Glycogen Synthase Kinase 3 (GSK3) has been implicated in regulating 
chromosomal alignment and mitotic progression but the physiological substrates 
mediating these GSK3-dependent effects have not been identified. Collapsin Response 
Mediator Protein 4 (CRMP4) is a cytosolic phosphoprotein known to regulate 
cytoskeletal dynamics and is a known physiological substrate of GSK3. In this study, we 
investigate the role of CRMP4 during mitosis.  
2.2.2 Methodology and Principal Findings 
Here we demonstrate that during mitosis CRMP4 phosphorylation is regulated in 
a GSK3-dependent manner. We show that CRMP4 localizes to spindle microtubules 
during mitosis and loss of CRMP4 disrupts chromosomal alignment and mitotic 
progression. The effect of CRMP4 on chromosomal alignment is dependent on 
phosphorylation by GSK3 identifying CRMP4 as a critical GSK3 substrate during mitotic 
progression. We also provide mechanistic data demonstrating that CRMP4 regulates 
spindle microtubules consistent with its known role in the regulation of the microtubule 
cytoskeleton.   
2.2.3 Conclusion and Significance 
Our findings identify CRMP4 as a key physiological substrate of GSK3 in 
regulating chromosomal alignment and mitotic progression through its effect on spindle 
microtubules.  
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2.3 INTRODUCTION 
Chromosomal alignment and segregation are important well-controlled steps in 
mitosis. This process is largely regulated by the mitotic spindle where microtubules and 
microtubule binding proteins capture condensed chromosomes by their kinetochores and 
direct them to the metaphase plate. Understanding the molecular mechanisms responsible 
for regulating the process of chromosomal alignment is important because failure to 
accurately segregate chromosomes results in chromosome non-disjunction and 
aneuploidy (Decordier, Cundari et al. 2008).         
Glycogen Synthase Kinase 3 (GSK3) is a serine/threonine kinase originally 
identified as a kinase that phosphorylates glycogen synthase during glycogen 
metabolism. There are two isoforms of GSK3, GSK3α and GSK3β, which are 
ubiquitously expressed and constitutively active in cells. GSK3 is inactivated by 
phosphorylation at its amino-terminus serine (serine 21 for α or serine 9 for β) by several 
protein kinases such as protein kinase B (PKB, also called Akt), MAPK-activated protein 
kinase-1 (MAPKAP-K1, also called RSK) and p70 ribosomal S6 kinase-1 (Frame and 
Cohen 2001). GSK3 has been implicated in a diverse range of cellular functions 
including the regulation of mitotic spindle dynamics and chromosomal alignment (Frame 
and Cohen 2001; Wakefield, Stephens et al. 2003; Cohen and Goedert 2004; Tighe, Ray-
Sinha et al. 2007).  
 Reports that GSK3β plays a role in regulating microtubule dynamics during 
interphase provide evidence that GSK3 may regulate spindle microtubules (Ciani, 
Krylova et al. 2004). GSK3β can phosphorylate microtubule-associated proteins (MAPs) 
such as Tau, MAP1B and MAP2C resulting in decreased microtubule stability (Wang, 
Wu et al. 1998; Goold, Owen et al. 1999; Ciani, Krylova et al. 2004). Repressing GSK3 
function with GSK3 inhibitors or GSK3β RNAi alters spindle morphology, increases 
defects in chromosomal alignment, and subsequently delays mitotic progression 
(Wakefield, Stephens et al. 2003; Tighe, Ray-Sinha et al. 2007). Although the importance 
of GSK3 as a mitotic kinase has been recognized, the physiological substrates that 
mediate the GSK3-dependent effects during mitosis have yet to be identified.  
Collapsin Response Mediator Proteins (CRMPs) are cytosolic phosphoproteins 
that are highly expressed in the nervous system during development (Goshima, 
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Nakamura et al. 1995; Wang and Strittmatter 1996; Gaetano, Matsuo et al. 1997; Byk, 
Ozon et al. 1998; Quinn, Gray et al. 1999; Quach, Duchemin et al. 2004). The CRMP 
family is composed of five family members (CRMP1-5) in vertebrates (Goshima, 
Nakamura et al. 1995; Minturn, Fryer et al. 1995; Byk, Dobransky et al. 1996; Gaetano, 
Matsuo et al. 1997; Inatome, Tsujimura et al. 2000). Each CRMP allele produces two 
transcripts that differ in their amino terminal domains producing a long (L-CRMP) and 
short (S-CRMP) isoforms that have been alternatively referred to as ‘a’ and ‘b’ isoforms 
(Quinn, Chen et al. 2003; Yuasa-Kawada, Suzuki et al. 2003; Alabed, Pool et al. 2007; 
Pan, Chao et al. 2009). The CRMPs have been implicated in regulating axon path finding 
and neurite outgrowth (Hedgecock, Culotti et al. 1985; Goshima, Nakamura et al. 1995; 
Minturn, Fryer et al. 1995; Quinn, Gray et al. 1999; Quinn, Chen et al. 2003; Yoshimura, 
Arimura et al. 2005; Alabed, Pool et al. 2007). Although the CRMPs have not been 
directly implicated in mitosis, previous studies have shown that CRMP1 and CRMP2 
localize to the mitotic spindle (Gu and Ihara 2000; Shih, Yang et al. 2001; Arimura, 
Ménager et al. 2005). CRMP1-4 bind to tubulin heterodimers and microtubules, while 
CRMP4 has been shown to promote F-actin bundling (Fukata, Itoh et al. 2002; 
Rosslenbroich, Dai et al. 2005; Alabed, Pool et al. 2007). Further, CRMP4, but not other 
CRMP family members, binds to RhoA, an important regulator of cell cycle progression 
and cytokinesis (Glotzer 2001; Narumiya and Yasuda 2006; Alabed, Pool et al. 2007). 
These observations suggest that CRMPs, particularly CRMP4, may play a role in 
regulating microtubule dynamics during mitosis.  
In this study, we investigate the role of CRMP4, a known physiological substrate 
of GSK3, during mitosis (Cole, Knebel et al. 2004; Cole, Causeret et al. 2006). We 
identify CRMP4 as a GSK3 substrate that regulates chromosomal alignment during 
mitosis.  
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2.4 MATERIALS AND METHODS 
2.4.1 Cell Culture 
 HeLa cells (ATCC; catalogue number CCL-2) were grown in DMEM (Invitrogen, 
Burlington, Ontario) supplemented with 10% FBS (HyClone, Logan, UT) and were 
maintained in 5% CO2 at 37 °C. Cells were synchronized using a double thymidine block 
as previously described (Yüce, Piekny et al. 2005). In brief, HeLa cells (∼45% 
confluency) were grown in 2.5 mM thymidine for 18-24 hours, released for 12-13 hours, 
and grown in 2.5 mM thymidine for 12-13 hours. The cells were released from the 
second block and fixed 9 hours later for immunofluorescence microscopy when most of 
the cells were in metaphase. For immunoblotting, HeLa cells were collected at different 
time intervals following release from the second block. In some experiments, HeLa cells 
were blocked with 1 uM nocodazole for 16 hours.  
2.4.2 Plasmids and antibodies 
 The L-CRMP4-WT-V5 construct was described previously (Alabed, Pool et al. 
2007). L-CRMP4-AAA-V5 was generated using site-directed mutagenesis (Thr622, 
Thr627, Ser631) (Stratagene, La Jolla, CA). CRMP4 antibody to the antigen 
YDGPVFDLTTTPK (as per (Minturn, Geschwind et al. 1995)) and phosphospecific 
CRMP4 antibody to the antigen FDLTT(pT)PKGGTPAGC (where pT is 
phosphothreonine) were generously provided by Biogen Idec (Cambridge, MA). 
Antiserum was affinity purified on an antigen-Sepharose column or was affinity purified 
by depleting antibodies that recognize unphosphorylated CRMP4 on a non-
phosphorylated peptide column followed by selecting phospho-specific antibodies on a 
phosphopeptide antigen column. Other antibodies that were used: mouse α-tubulin 
(Sigma-Aldrich, Oakville, ON), sheep anti-tubulin (Cytoskeleton, Denver, CO), mouse 
BubR1 (BD Bioscience, MD), mouse and rabbit V5 (Sigma-Aldrich), mouse GAPDH 
(ABCAM, Cambridge, MA), rabbit phospho-Threonine (Sigma-Aldrich), and sheep 
phospho-CRMP2 (pT509/514) (generously provided by Dr. Calum Sutherland, 
Neurosciences Institute, University of Dundee). The sheep phospho-CRMP2 (pT509/514) 
antibody recognizes CRMP2 phosphorylated at its Thr509 and Thr514, which are known 
GSK3 sites (Cole, Knebel et al. 2004). The following secondary antibodies were used: 
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goat anti-rabbit Alexa Fluor 488, goat anti-rabbit Alexa Fluor 568, goat anti-sheep Alexa 
Fluor 546, goat anti-human Alexa Fluor 647, goat anti-mouse Alexa Fluor 647 
(Invitrogen); goat anti-rabbit-HRP, goat anti-mouse-HRP and goat anti-sheep-HRP 
(Sigma-Aldrich); goat anti-rabbit IRDye 800CW and goat anti-mouse IRDye 800CW 
(LI-COR Biosciences). 
2.4.3 Pharmacological inhibitors 
 GSK3 inhibitors were used at the following concentrations: 10 uM SB-216763 
(Sigma-Aldrich) and 2 uM CT-99021 (generously provided by Dr. Rodolfo Marquez, 
School of Life Sciences, University of Dundee). For inhibitor experiments, the drugs 
were added for 90 minutes 7.5 hours after release from the second thymidine block. 
Control treatments with solvent (DMSO) were performed in parallel. 
2.4.4 RNAi 
 Fluorescently tagged siRNA duplexes were designed to knockdown human 
CRMP4 (both long “L” and short “S” isoforms) protein expression: sense 5’ Alexa 488 
GUG UUG AUG ACG UAC GUU ATT 3’, antisense 5’ UAA CGU ACG UCA UCA 
ACA CTT 3’ (Invitrogen). CRMP4 siRNA was transfected into HeLa cells using 
LipofectAMINE 2000 according to the manufacturer’s instructions (Invitrogen). Control 
cells were transfected with non-targeting control siRNA (Dharmacon, Colorado, USA). 
HeLa cells were incubated with the transfection mixture for 5 hours after which the 
media was replaced with fresh growth medium.  
2.4.5 Flow Cytometry 
 HeLa cells were transfected with CRMP4 siRNA and synchronized by double 
thymidine block. HeLa cells were collected at different time intervals after the second 
thymidine block by trypsinizing the cells off the culture dish and fixing them in ice-cold 
ethanol. HeLa cells were resuspended in propidium iodide and analyzed using a 
FACScan at the McGill Flow Cytometry Facility.  
2.4.6 Immunoblot 
 HeLa cells were washed twice with ice cold PBS and lysed in complete HEPES 
RIPA buffer (20 mM HEPES, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% 
Triton X-100, 1 mM Na3VO4, 5 mM NaF, 1X protease inhibitors (Roche Diagnostics, 
 70 
Laval, Quebec), 100 nM Calyculin A (Cell Signaling Technology, Danvers, MA)). For 
experiments requiring plasmid transfection, HeLa cell were grown to subconfluence and 
transfected with Effectene according to manufacturer’s instructions (Qiagen, 
Mississauga, ON). Lysates were separated by SDS-PAGE and immunoblotted with 
phospho-CRMP4, CRMP4 and GAPDH antibodies. 
2.4.7 Immunoprecipitation 
 Transfected lysates were precleared with protein A/G-agarose (Santa Cruz 
Biotechnology, Santa Cruz, CA) and subjected to immunoprecipitation with V5-agarose 
(Sigma-Aldrich). After washing three times with ice-cold lysis buffer, bound protein was 
eluted with SDS and immunoblotted with anti-V5, phospho-CRMP4, phospho-CRMP2 
(pT509/514) or phospho-Threonine antibodies. Briefly, either L-CRMP1-V5 or S-
CRMP2-V5 was immunoprecipitated with V5-agarose and immunoblotted with a 
phospho-Threonine antibody or phospho-CRMP2 (pT509/514), respectively. In another 
experiment, either L-CRMP4-WT-V5 or L-CRMP4-AAA-V5 was immunoprecipitated 
with V5-agarose and immunoblotted with phospho-CRMP4 antibody.  
2.4.8 Immunofluorescence 
 HeLa cells were briefly washed in extraction buffer (Microtubule Stabilization 
Buffer (MTSB): 100 mM PIPES pH 6.8, 1 mM EGTA, 5 mM MgCl2), incubated with 
MTSB / 0.05% Triton X-100 for 2 minutes at room temperature, and fixed with 2% 
paraformaldehyde (PFA) / 0.02% Triton X-100 / 0.05 mM Taxol in MTSB for 1 hour at 
room temperature. HeLa cells were incubated with Image-iT FX signal enhancer 
(Invitrogen) for 30 minutes at room temperature and blocked in 5% BSA / 0.2% Triton 
X-100 in PBS for 30 minutes at room temperature. Primary antibodies were diluted in 
0.5% BSA in PBS for 3 hours at room temperature. Secondary antibodies were diluted in 
0.5% BSA in PBS for 1 hour at room temperature. Actin was visualized with an Alexa 
Fluor 568 phalloidin (Invitrogen) and DNA was stained using DAPI (Invitrogen) or 
Hoechst 33342 (Invitrogen). Cover slips were mounted using PermaFluor (Thermo 
Scientific, Rockford, IL) and images were acquired with a Zeiss Axiovert 200 using a 
63X or 100X oil objective. 
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2.4.9 Chromosome Alignment Scoring 
 HeLa cells were transfected with CRMP4 siRNA or control siRNA, synchronized 
by double thymidine block and fixed 9 hours following the second block in 4% PFA / 
20% sucrose in PBS for 30 minutes at room temperature. In rescue experiments, L-
CRMP4-WT-V5 or L-CRMP4-AAA-V5 was co-transfected with the siRNA duplexes. In 
some experiments, the GSK3 inhibitor SB-216763 was added to the cells 7.5 hours 
following the second thymidine block for 90 minutes. HeLa cells were permeabilized 
with 0.2% Triton X-100 in PBS for 4 minutes and blocked with 5% BSA in PBS for 30 
minutes. HeLa cells were incubated with a rabbit anti-V5 antibody followed by a goat 
anti-rabbit AlexaFluor 568. DNA was visualized with Hoechst 33342. Coverslips were 
mounted using Fluoromount-G (SouthernBiotech, Birmingham, AL). CRMP4 siRNA-
transfected cells were identified by virtue of the fluorescent tag and only cells in 
metaphase were scored. HeLa cells with at least one misaligned chromosome were scored 
as abnormal metaphase. At least 100 cells were scored per experiment. 
2.4.10 Live Time-Lapse Microscopy 
 For time-lapse analysis, HeLa cells were cultured on 35 mm glass bottom dishes 
(MatTek Co., Ashland, MA) and transfected with an mcherry Histone H3 construct 
(generously provided by Dr. Paul Maddox, Université de Montreal) and either control or 
CRMP4 siRNA. Microscopy was performed on Zeiss Axiovert 200 using a 20X objective 
equipped with an automated stage and an environmental control chamber, which 
maintained the cells at 37˚C and 5% CO2. Nuclear envelope breakdown (NEB) was 
defined as the point when prophase chromatin lost a smooth, linear periphery, and the 
time of anaphase onset was defined to be the first frame where coordinated pole wards 
movement was observed (Tighe, Ray-Sinha et al. 2007).  
2.4.11 Morphometric analysis of mitotic spindles 
 For pole to pole distance measurements, tubulin fluorescence intensities were 
measured from one end of the cell to the other end along the spindle axis using ImageJ, 
and when plotted as a function of spindle position, the tubulin intensity gave two peaks 
corresponding to the spindle poles (Fig. S3) (Tighe, Ray-Sinha et al. 2007). For spindle 
width measurements, the two lateral edges of the mitotic spindle were identified by 
tubulin fluorescence and the distance between them was measured using ImageJ. For pole 
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to pole distance and spindle width measurements, at least 3 independent experiments 
were performed with at least 20 cells per condition measured in each experiment.   
 
2.4.12 Cold Stability Assay 
 Cold stability assay was performed as previously described (Jeffery, Urquhart et 
al. 2010). Briefly, HeLa cells were incubated with ice cold media for 10 minutes before 
fixation and immunostaining for α-tubulin. For quantification of average tubulin intensity 
at the mitotic spindle, images were acquired at the same exposure and mitotic spindles 
were traced using ImageJ. For average tubulin intensity measurements at the mitotic 
spindle, at least 3 independent experiments were performed with at least 19 cells per 
condition measured in each experiment. 
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2.5 RESULTS 
2.5.1 CRMP4 localizes to spindle microtubules during mitosis 
Previous studies have shown that CRMP1 and CRMP2 localize to the mitotic 
spindle (Gu and Ihara 2000; Shih, Yang et al. 2001; Arimura, Ménager et al. 2005). 
Although CRMP4 has been shown to bind to tubulin and F-actin, CRMP4 localization 
throughout the mitotic cycle has not been investigated (Fukata, Itoh et al. 2002; 
Rosslenbroich, Dai et al. 2005). To investigate CRMP4 localization during mitosis we 
double stained HeLa cells with CRMP4 and α-tubulin antibodies. We established the 
specificity of the CRMP4 antibody by immunostaining HeLa cells that were depleted of 
CRMP4 and observed a reduction in the immunoreactivity at the mitotic spindle (Fig. 1). 
Throughout the different stages of mitosis we observed CRMP4 co-localizing with 
microtubules (Fig. 1). During interphase, CRMP4 was primarily associated with 
microtubules located in the perinuclear region of the cell but was also associated along 
actin stress fibers. Further, we observed CRMP4 localization to actin structures such as 
the cleavage furrow and the cortex. As the cells entered mitosis and progressed from 
prometaphase to metaphase, CRMP4 localized along spindle microtubules. CRMP4 
remained localized with microtubules throughout anaphase and telophase, and strongly 
co-localized with microtubules associated with the mid-body.  
2.5.2 CRMP4 influences chromosomal alignment and mitotic progression 
The presence of CRMP4 along the mitotic spindle raises the possibility that 
CRMP4 regulates mitotic microtubules. To investigate the role of CRMP4 during mitosis 
we used RNA interference to knockdown CRMP4 protein expression in HeLa cells and 
followed the mitotic progression of these cells following synchronization with a double 
thymidine block. Introduction of CRMP4 siRNA robustly inhibited CRMP4 protein 
expression while a control siRNA had no effect (Fig. 2A). To examine chromosomal 
alignment, we fixed and stained the cells with Hoechst 33342 to visualize DNA 9 hours 
following the second thymidine block when the majority of cells were in metaphase. We 
frequently observed CRMP4 siRNA-transfected mitotic cells with abnormal metaphase 
plates that were characterized by at least one misaligned chromosome (Fig. 2B). CRMP4 
knockdown resulted in a significant increase in the percentage of cells with abnormal 
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metaphase (Fig. 2C). We confirmed that the increase in abnormal metaphase could be 
attributed to the targeted repression of CRMP4 by rescuing the phenotype with an 
siRNA-resistant wild type rat CRMP4 construct (L-CRMP4-WT-V5) (Fig. 2C). These 
results demonstrate that CRMP4 plays an important role in the proper alignment of 
chromosomes during mitosis. 
A similar abnormal metaphase phenotype has been reported as a result of GSK3 
inhibition (Wakefield, Stephens et al. 2003; Tighe, Ray-Sinha et al. 2007). Consistent 
with previous reports, we find that approximately 40% of cells treated with the GSK3 
inhibitor SB-216763 exhibited misaligned chromosomes (Wakefield, Stephens et al. 
2003; Tighe, Ray-Sinha et al. 2007), very similar to the severity of effects observed with 
CRMP4 loss of function (Fig. 2C). In addition, a delay in mitotic entry and exit has also 
been described with GSK inhibition and has been attributed to an increase in time taken 
for cells to align their chromosomes and progress from prophase to metaphase (Tighe, 
Ray-Sinha et al. 2007), thus we investigated if CRMP4 knockdown would affect the rate 
of mitotic progression. We transfected HeLa cells with a fluorescently tagged mcherry 
Histone H3 and either control (Fig. 3A and Video S1) or CRMP4 siRNA (Fig. 3B and 
Video S2) and visualized mitotic progression by time-lapse microscopy. 48 hours 
following transfection, we measured the time from nuclear envelope breakdown (NEB) to 
anaphase onset. The average time taken for control siRNA treated cells to progress 
through NEB to anaphase was 38 minutes, while CRMP4 siRNA treated cells took an 
average of 47 minutes (Fig. 3C) indicating that CRMP4 regulates the rate of mitotic 
progression. Although the phenotype we observed with CRMP4 protein knockdown was 
equal in severity to that seen with GSK3 inhibition (Fig. 2C), cells depleted of CRMP4 
protein eventually aligned all their chromosomes and progressed through mitosis. This 
finding suggests that CRMP4 regulates accurate chromosomal alignment, but in its 
absence, compensatory mechanisms are activated to ensure that the cell does not initiate 
anaphase with misaligned chromosomes. 
Consistent with previous reports we found that the release of synchronized HeLa 
cells into SB-216763 resulted in an observable delay in mitotic progression by flow 
cytometry (Fig. S1) (Tighe, Ray-Sinha et al. 2007). We did not detect a similar delay in 
mitotic progression in CRMP4 siRNA treated cells by flow cytometry, likely because 
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hourly collection of cells fails to detect short mitotic delays (Fig. 3C). The severe effect 
of GSK3 inhibition on mitotic progression compared to CRMP4 knockdown suggests 
that additional GSK3 substrates affect mitotic progression. 
2.5.3 CRMP4 depletion yields monopolar syntelic attachments and reduces cold 
stable microtubules 
 It has been previously demonstrated that GSK3 inhibitor-treated cells delay 
chromosomal alignment largely due to their inability to perfectly bi-orient all their 
chromosomes (Tighe, Ray-Sinha et al. 2007). More specifically, monopolar syntelic 
attachments predominate in GSK3 inhibitor-treated cells (Tighe, Ray-Sinha et al. 2007). 
To determine if a similar phenotype was observed following CRMP4 depletion, we 
transfected HeLa cells with CRMP4 siRNA and immunostained for α-tubulin and the 
kinetochore protein BubR1. Both GSK3 inhibition and CRMP4 depletion resulted in the 
presence of monopolar syntelic attachments in HeLa cells, where both sister kinetochores 
were attached to the same spindle pole (Fig. 4). Thus, both GSK3 inhibition and CRMP4 
depletion affected the ability of a cell to perfectly bi-orient all of its chromosomes.   
The presence of monopolar syntelic attachments, and the increase in 
chromosomal misalignment following CRMP4 depletion suggest that spindle microtubule 
stability is affected. To assess spindle microtubule stability in CRMP4 depleted cells, we 
performed a cold stability assay, which disintegrates mitotic spindle structures over time 
except for spindle microtubules that are stably attached to kinetochores (Lampson and 
Kapoor 2005; Jeffery, Urquhart et al. 2010). While CRMP4 depletion or GSK3 inhibition 
had no effect on the average tubulin intensity at the mitotic spindle at 0 minutes exposure 
(Fig. 5A), we observed a significant reduction in cold stable microtubules following a 10 
minute exposure to ice cold media (Fig. 5B). These findings indicate that both GSK3 and 
CRMP4 regulate spindle microtubule attachment to kinetochores. 
2.5.4 CRMP4 is phosphorylated in a GSK3-dependent manner during mitosis 
Previous studies have identified CRMP4 as a physiological substrate of GSK3 
(Cole, Knebel et al. 2004; Cole, Causeret et al. 2006). Following an initial priming event 
that may be mediated by either cyclin dependent kinase 5 (Cdk5) or dual specificity 
tyrosine phosphorylation regulated kinase 2 (DYRK2), L-CRMP4 is sequentially 
phosphorylated by GSK3β on residues Ser631, Thr627 and Thr622 (Cole, Knebel et al. 
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2004). We generated a phospho-specific antibody recognizing pThr622 of L-CRMP4 
(pThr509 of S-CRMP4) (Cole, Knebel et al. 2004) to detect CRMP4 that has been primed 
and fully phosphorylated by GSK3. To investigate CRMP4 phosphorylation throughout 
mitosis we synchronized HeLa cells using a double thymidine block, collected the cells at 
different time intervals, and immunoblotted with phospho-CRMP4 antibody. Lysates 
from synchronized cells showed an increase in CRMP4 phosphorylation from 7 hours to 
11 hours following release from the second block (Fig. 6A). This time interval 
corresponds to when the majority of synchronized HeLa cells are undergoing mitosis 
(Fig. S1).  Furthermore, as the synchronized cells progressed through mitosis and 
returned to interphase, the levels of phosphorylated CRMP4 decreased to similar levels 
seen in unsynchronized cells. The phospho-CRMP4 doublet that appears corresponds to 
distinct phospho-species of the long isoform of CRMP4 (Fig. S2A and S2B). The 
increase in phosphorylated CRMP4 was also observed in HeLa cells blocked with 
nocodazole for 16 hours (Fig. 6C and Fig. S2A). A rat CRMP4 triple alanine substitution 
mutant (L-CRMP4-AAA-V5) for the three carboxy terminal phospho-residues targeted 
by GSK3β (Thr622, Thr627, Ser631) fails to undergo phosphorylation in response to 
nocodazole establishing the specificity of the antibody for phospho-CRMP4 (Fig. S2C).    
To investigate if GSK3 is the kinase responsible for CRMP4 phosphorylation 
during mitosis, we synchronized HeLa cells with a double thymidine block and released 
them into thymidine-free media for 7.5 hours followed by a 90-minute incubation with a 
GSK3 inhibitor. Two GSK3 inhibitors were used at concentrations previously shown to 
inhibit GSK3 activity: SB-216763 (10 uM) or CT-99021 (2 uM) (Wakefield, Stephens et 
al. 2003; Bain, Plater et al. 2007; Tighe, Ray-Sinha et al. 2007). SB-216763 and CT-
99021 both attenuated CRMP4 phosphorylation following cellular synchronization and 
release with a double thymidine block or with nocodazole (Fig. 6B and 6C). Although 
CRMP4 phosphorylation was reduced in the presence of GSK3 inhibitors, the phospho-
signal was not completely abrogated raising the possibility that additional kinases 
contribute to CRMP4 phosphorylation during mitosis.  
To determine if other CRMP family members may be similarly regulated, we 
examined the phosphorylation profile of CRMP1 and CRMP2, known GSK3 substrates, 
during mitosis (Cole, Causeret et al. 2006). Following cellular synchronization and 
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release, we did not observe any changes in threonine phosphorylation levels of CRMP1 
(Fig. 6D) or CRMP2 phosphorylation at their GSK3 sites (Fig. 6E and 6F). This suggests 
that although several CRMPs localize to the mitotic spindle, CRMP4 may be specifically 
regulated by GSK3 during mitosis. 
2.5.5 Chromosomal alignment during mitosis is phospho-CRMP4-dependent 
To localize phosphorylated CRMP4 in mitotic HeLa cells, we immunostained 
dividing cells with phospho-CRMP4 antibody. We established the specificity of the 
phospho-CRMP4 antibody by immunostaining HeLa cells that were depleted of CRMP4 
or exposed to the GSK3 inhibitor SB-216763 and observed a reduction in the pCRMP4 
signal compared to control cells (Fig. 7).  Phosphorylated CRMP4 localized to both the 
cortex adjacent to the spindle poles and to the spindle microtubules in metaphase (Fig. 7). 
During anaphase and telophase, phosphorylated CRMP4 also localized to microtubules 
and to the cortex and cleavage furrow located between the two dividing cells (Fig. 7). 
The phospho-CRMP4 localization pattern is consistent with previous reports that have 
shown GSK3 localization to the spindle microtubules of mitotic HeLa cells (Wakefield, 
Stephens et al. 2003). Additionally, inactivated phosphorylated GSK3 was concentrated 
at the centrosomes and not along the spindle microtubules (Wakefield, Stephens et al. 
2003). This localization pattern provides indirect evidence that GSK3 associated with the 
spindle microtubules is active.  
To determine the importance of CRMP4 phosphorylation in chromosomal 
alignment, we depleted endogenous CRMP4 protein using CRMP4 siRNA, and assessed 
whether a CRMP4 mutant that is not phosphorylated by GSK3β, L-CRMP4-AAA-V5, 
could rescue the chromosomal misalignment phenotype. As shown previously (Fig. 2C) 
rat L-CRMP4-WT-V5 rescues the chromosomal misalignment phenotype in CRMP4-
depleted cells; however rat L-CRMP4-AAA-V5 fails to mediate rescue (Fig. 8). This 
result demonstrates that CRMP4 phosphorylation is necessary for proper chromosomal 
alignment during mitosis.  
2.5.6 CRMP4 regulates spindle morphology 
CRMP proteins are known to affect microtubule polymerization raising the 
possibility that the role of phospho-CRMP4 may be to regulate spindle microtubules. To 
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investigate if phosphorylation altered the ability of CRMP4 to associate with spindle 
microtubules, we transfected HeLa cells with either L-CRMP4-WT-V5 or L-CRMP4-
AAA-V5 and immunostained for V5, α-tubulin and DNA. Only wild type CRMP4 
localized to the spindle microtubules during metaphase, while the CRMP4 phospho-
mutant was observed throughout the cytoplasm (Fig. 9A) indicating that an important 
role for CRMP4 phosphorylation is to localize CRMP4 to the spindle microtubules. To 
further investigate the role of GSK3-dependent phosphorylation of CRMP4 during 
mitosis, we treated HeLa cells with SB-216763 for 90 minutes and immunostained for 
CRMP4. We observed a significant reduction of CRMP4 signal at the spindle 
microtubules in SB-216763 treated HeLa cells compared to DMSO treated cells (Fig. 9B 
and 9C). This finding is consistent with our data showing that CRMP4 phosphorylation 
was reduced in the presence of GSK3 inhibitors (Fig. 6B and 6C) but was not completely 
abrogated.  
We investigated the role of CRMP4 in regulating spindle morphology by 
transfecting HeLa cells with control or CRMP4 siRNA, fixing and immunostaining for α-
tubulin. We performed a morphometric analysis of the mitotic spindle by measuring 
spindle length (pole to pole distance) and spindle width 9 hours following release from a 
double thymidine block (Fig. 10A -10C), as described previously with GSK3 inhibitors 
(Tighe, Ray-Sinha et al. 2007). While siRNA-mediated CRMP4 knockdown had no 
effect on spindle width (Fig. 10C), we did observe a significant decrease in the pole to 
pole distance compared to control treated cells (Fig. 10A and 10B). In CRMP4 siRNA-
treated cells, L-CRMP4-WT-V5 but not L-CRMP4-AAA-V5 rescued the spindle 
morphology phenotype (Fig. 10A and 10B). This finding and the inability of L-CRMP4-
AAA-V5 to localize to spindle microtubules (Fig. 9A) indicate that phosphorylated 
CRMP4 regulates spindle morphology.  
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2.6 DISCUSSION 
2.6.1 Identification of CRMP4 as a regulator of mitotic chromosomal alignment 
Herein, we identify CRMP4 as a regulator of chromosomal alignment during 
mitosis. We show that CRMP4 localizes to spindle microtubules and demonstrate that 
CRMP4 loss of function leads to defects in chromosomal alignment during mitosis and 
delays in mitotic progression. We provide evidence that CRMP4 is phosphorylated 
during mitosis in a GSK3-dependent manner and demonstrate that CRMP4 
phosphorylation by GSK3 regulates chromosomal alignment. Further, we show that 
CRMP4 loss of function yields monopolar syntelic attachments, reduces cold stable 
microtubules, and alters spindle morphology. These findings identify CRMP4 as a 
downstream regulator of GSK3-dependent chromosomal alignment during mitosis. 
2.6.2 CRMP4 mechanism of action in regulating chromosomal alignment 
 The proteins that regulate microtubules during mitosis have not been fully 
elucidated and our findings indicate that CRMP4 plays such a role. CRMP1-4 bind to 
tubulin and CRMP1, 2 and 4 localize to the mitotic spindle (Shih, Yang et al. 2001; 
Fukata, Itoh et al. 2002); however our data demonstrating that the phosphorylation status 
of CRMP4 at its GSK3 sites, but not CRMP1 or CRMP2, is regulated through the mitotic 
cycle suggests that CRMP4 plays a unique role downstream of GSK3 during mitosis. 
These observations raise the possibility that CRMP1 and CRMP2 recruitment to the 
mitotic spindle is regulated through a GSK3-independent mechanism.  
We demonstrate that CRMP4 localizes along spindle microtubules in HeLa cells, 
and that CRMP4 depletion results in chromosomal misalignment, mitotic delay, 
monopolar syntelic attachments, a reduction in cold stable microtubules and a decrease in 
spindle length. These findings provide evidence for an important role for CRMP4 in 
organizing microtubules during mitosis. Moreover, since microtubule dynamics are the 
major determinants of metaphase spindle length, CRMP4 may have a role in regulating 
microtubule dynamics (Goshima, Wollman et al. 2005). Specifically, the decrease in 
spindle length observed with CRMP4 depletion suggests that CRMP4 may be involved 
with microtubule stabilization since RNAi-depletion of proteins that promote microtubule 
stabilization such EB1, Minispindles [Dis1/XMAP215/TOG], and Mast/Orbit [CLASP] 
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result in a shorten metaphasic spindle (Goshima, Wollman et al. 2005). In contrast, 
RNAi-depletion of proteins that promote microtubule depolymerization such as Kinesin-
8 and Kinesin-13 result in a longer metaphasic spindle (Goshima, Wollman et al. 2005).  
L-CRMP4-WT-V5, but not L-CRMP4-AAA-V5, localizes to microtubules at the 
mitotic spindle, rescues chromosomal misalignment and the altered spindle morphology 
phenotype seen in CRMP4-depleted cells. We generated a rat CRMP4 triple glutamic 
acid substitution mutant (L-CRMP4-EEE-V5) for the three carboxy terminal phospho-
residues targeted by GSK3β (Thr622, Thr627, Ser631) and find that it does not rescue the 
misalignment phenotype observed with GSK3 inhibition (data not shown); however, we 
believe that the L-CRMP4-EEE-V5 mutant does not function as a phospho-mimetic 
based on published results demonstrating that an S-D mutation on a CRMP2 and CRMP4 
priming residue (S522) does not mimic phosphorylation (Cole, Knebel et al. 2004). These 
findings support a model in which CRMP4 phosphorylation at its GSK3 sites plays an 
important role in regulating spindle microtubules during mitosis.  
 Our findings that CRMP4 depletion reduces cold stable microtubules and yields 
monopolar syntelic attachments suggest that CRMP4 is involved in the regulation of 
stable microtubule-kinetochore attachments. However, the observation that CRMP4 
depleted cells have an organized metaphasic plate and eventually progress through 
mitosis with all their chromosomes aligned indicates that stable microtubule-kinetochore 
attachments do occur. Therefore the unstable microtubule-kinetochore attachment 
phenotype we observed is most likely a transient one, whereby compensatory 
mechanisms, such as Aurora B kinase activation, can eliminate microtubule-kinetochore 
attachments that do not generate tension and thereby ensure that the cell does not 
progress through mitosis with misaligned chromosomes (Tanaka, Rachidi et al. 2002; 
Dewar, Tanaka et al. 2004; Lampson, Renduchitala et al. 2004; Maure, Kitamura et al. 
2007).  
CRMP4 can also promote an actin-based phenotype. Overexpression of CRMP4 
results in the extension of filopodia and neurite branches in neurons (Alabed, Pool et al. 
2007). Similarly, CRMP4 can bundle F-actin filaments in B35 neuroblastoma cells 
(Rosslenbroich, Dai et al. 2005). The ability of CRMP4 to modulate the actin 
cytoskeleton raises the possibility that CRMP4 plays an additional role in regulating 
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actomyosin-based events during mitosis. Interestingly, we do observe localization of 
pT622 CRMP4 at the cortex during anaphase and telophase in areas that have been 
associated with actin structures, such as the cleavage furrow. However, the role of 
CRMP4 in modulating these actin-based events during mitosis remains to be investigated.  
2.6.3 The role of CRMP4 phosphorylation during mitosis 
The ability of L-CRMP4-WT-V5 but not L-CRMP4-AAA-V5 to rescue the 
chromosomal misalignment phenotype and the altered spindle morphology phenotype 
resulting from CRMP4 loss of function indicates that the function of CRMP4 in mitosis 
is highly dependent on its phosphorylation status. Transient 
phosphorylation/dephosphorylation of proteins is often critical for the recruitment and 
release of binding partners. This raises the possibility that CRMP4 may also regulate the 
complement of proteins associated with the microtubule machinery over the course of the 
mitotic cycle. CRMP4 binds to RhoA in a phospho-dependent fashion and this interaction 
is disrupted by CRMP4 phosphorylation by GSK3β (Alabed, Pool et al. 2007; Alabed, 
Pool et al. 2010). An interesting possibility is that CRMP4 may recruit RhoA to the 
microtubule machinery and that CRMP4 phosphorylation may result in the local release 
of RhoA for binding to the microtubule machinery during the mitotic cycle. Further, the 
ability of CRMP4 to bundle F-actin and its localization to the cleavage furrow suggests 
that the role of CRMP4 during mitosis may not be limited to regulating spindle 
microtubules.  
2.6.4 GSK3 as a regulator of chromosomal alignment and mitotic progression 
Previous studies have reported that GSK3 inhibition results in a delay in mitotic 
exit, and this phenotype has been largely attributed to chromosomal alignment defects 
(Wakefield, Stephens et al. 2003; Tighe, Ray-Sinha et al. 2007). Our finding that CRMP4 
loss of function results in a delay in mitotic progression is consistent with our hypothesis 
that GSK3 regulates chromosomal alignment through CRMP4. However, the more severe 
effects observed with GSK3 inhibition on mitotic progression and spindle morphology 
suggests that, in addition to CRMP4, there are other downstream effectors of GSK3 that 
are involved with these processes.  
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Several other MAPs identified as GSK3 substrates are candidates for regulating 
additional aspects of microtubule dynamics during mitosis. GSK3 can phosphorylate Tau, 
MAP1B and MAP2C, all of which result in a decreased ability to stabilize microtubules 
(Lovestone, Hartley et al. 1996; Wang, Wu et al. 1998; Goold, Owen et al. 1999). Both 
CLIP-associated protein (CLASP) 2 and Adenomatous Polposis Coli (APC) are 
phosphorylated by GSK3, which alters their ability to bind and stabilize the distal end of 
microtubules (Akhmanova, Hoogenraad et al. 2001; Kaplan, Burds et al. 2001; 
Watanabe, Noritake et al. 2009). Further, mutations that eliminate the microtubule-
binding domain of APC result in defective chromosomal segregation (Kaplan, Burds et 
al. 2001).  
GSK3 can also target substrates other than MAPs that likely contribute to GSK3-
dependent effects on mitotic progression. There is evidence that GSK3 positively 
regulates protein levels of Aurora A, a mitotic kinase that has been implicated in the 
centrosome cycle, spindle assembly, chromosomal segregation and mitotic progression 
(Meraldi, Honda et al. 2004; Marumoto, Zhang et al. 2005; Fumoto, Lee et al. 2008). 
Further, GSK3 can phosphorylate cyclin dependent kinases (Cdks), which control cell 
cycle progression in response to mitogenic signals (Diehl, Cheng et al. 1998; Massagué 
2004; Pizarro, Folch et al. 2008). Therefore, the delay in mitotic progression seen with 
GSK3 inhibition may not be fully attributed to defects in chromosomal alignment but 
rather the dysregulation of mitotic complexes that control cell cycle progression. 
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Chapter 2 - Figure 1. CRMP4 localizes with spindle microtubules during mitosis. 
Immunofluorescence detection of CRMP4, α-tubulin, and DNA in mitotic HeLa cells. 
HeLa cells were permeabilized with a cytosolic extraction buffer prior to fixation with 
4% PFA. CRMP4 associates with microtubules throughout mitosis. Immunofluorescence 
detection of CRMP4 was markedly reduced in HeLa cells transfected with CRMP4 
siRNA. Bar, 10 um. 
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 Chapter 2 - Figure 2. siRNA-mediated knockdown of CRMP4 leads to 
chromosomal misalignment. 
(A) HeLa cells transfected with CRMP4 siRNA, control siRNA or treated with SB-
216763 (10 uM) were immunoblotted with a CRMP4 antibody. CRMP4 siRNA 
transfection results in a reduction of CRMP4 protein expression. (B) Synchronized HeLa 
cells were stained with Hoechst 33342 to visualize DNA. HeLa cells with misaligned 
chromosomes (arrows) were scored as abnormal metaphase. Only cells in metaphase 
were scored. Representative images of HeLa cells with normal and abnormal metaphase 
plates are shown. Bar, 10 um. (C) HeLa cells were transfected with either CRMP4 siRNA 
or control siRNA and were synchronized by double thymidine block. HeLa cells were 
released into thymidine-free culture medium and fixed 9 hours later, when a large 
proportion of cells were in metaphase. siRNA-mediated knockdown of CRMP4 resulted 
in an increase in the percentage of cells with abnormal metaphase (n=3, **p<0.01 
Student’s t test compared to control siRNA). Co-transfection of HeLa cells with CRMP4 
siRNA and a CRMP4 siRNA-resistant wild type rat L-CRMP4 construct (L-CRMP4-
WT-V5) rescued the abnormal metaphase phenotype (n=3, **p<0.01, Student’s t test 
compared to CRMP4 siRNA; n=3, ns = non significant p>0.05, Student’s t test compared 
to control siRNA). For experiments with the GSK3 inhibitor, SB-216763 (10 uM) was 
added 7.5 hours following release into thymidine-free media and fixed 90 minutes later. 
Inhibition of GSK3 with SB-216763 resulted in an increase in the percentage of abnormal 
metaphase cells (n=3, **p<0.01, Student’s t test compared to DMSO). n=3 refers to 3 
independent experiments where at least 100 cells were scored per experiment. 
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Chapter 2 - Figure 3. siRNA-mediated knockdown of CRMP4 leads to a delay in 
mitotic progression. 
HeLa cells transfected with a fluorescently tagged mcherry Histone H3 plasmid and 
either control or CRMP4 siRNA were analyzed by time-lapse microscopy. (A) Images 
from a time-lapse movie showing a control cell that undergoes normal mitosis. (B) 
Images from a time-lapse movie showing a CRMP4 siRNA treated cell that delays 
anaphase onset until the misaligned chromosome (arrow) aligns to the metaphasic plate. 
Time intervals are indicated in hours and minutes (0:00), where 0:00 corresponds to 
nuclear envelope breakdown (NEB). Bar, 10 um. (C) Scatter dot plot measuring the time 
interval from NEB to anaphase onset in control and CRMP4 siRNA treated groups for 71 
cells and 157 cells, respectively. CRMP4 siRNA treated cells delayed anaphase onset 
until all their chromosomes were aligned to the metaphasic plate (***p<0.0001, Student’s 
t test compared to control siRNA).   
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Chapter 2 - Figure 4. CRMP4 depletion yields monopolar syntelic attachments. 
HeLa cells transfected with either control siRNA or CRMP4 siRNA for 48 hours, or 
treated with SB-216763 (10uM) for 90 minutes were immunostained for α-tubulin (red), 
BubR1 (green) and DNA. Boxes outline either normal microtubule-kinetochore 
attachment (top panel) or abnormal monopolar syntelic attachments (middle and bottom 
panels). Bar, 10 um.  
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Chapter 2 - Figure 5. CRMP4 depletion reduces cold stable microtubules. 
(A) HeLa cells transfected with either control siRNA or CRMP4 siRNA for 48 hours, or 
treated with SB-216763 (10uM) for 90 minutes, were immunostained for α-tubulin (red) 
and DNA (blue). Bar, 5 um. Quantification of average tubulin intensity at the mitotic 
spindle (n=3, ns = non significant p>0.05, one sample t test compared to control siRNA.) 
(B) HeLa cells transfected with either control siRNA or CRMP4 siRNA for 48 hours, or 
treated with SB-216763 (10uM) for 90 minutes, were incubated with ice cold media for 
10 minutes and immunostained for α-tubulin (red) and DNA (blue). Bar, 5 um. 
Quantification of average tubulin intensity at the mitotic spindle following incubation 
with ice cold media for 10 mins. Both CRMP4 depletion (n=3, **p<0.01, one sample t 
test compared to control siRNA) and incubation with SB-216763 (n=3, *p<0.05, one 
sample t test compared to control siRNA) resulted in a reduction in the average tubulin 
intensity at the mitotic spindle. n=3 refers to 3 independent experiments where at least 19 
cells were analyzed in each experiment.  
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Chapter 2 - Figure 6. GSK3-dependent phosphorylation of CRMP4 during mitosis. 
(A) HeLa cells were synchronized by double thymidine block, released into thymidine-
free media and collected at different time intervals (number indicates hours post-release). 
Lysates were immunoblotted for pCRMP4 and total CRMP4. CRMP4 is phosphorylated 
throughout mitotic progression and is dephosphorylated as the cells complete mitosis. We 
observed that the majority of synchronized HeLa cells were in metaphase between 9-10 
hours following release from the second thymidine block. By 12 hours, the majority of 
cells had completed mitosis. (B) HeLa cells were synchronized by double thymidine 
block, released into thymidine-free media for 7.5 hours, and were incubated with either 
SB-216763 (10 uM) or CT-99021 (2 uM) for 90 minutes. Immunoblot of lysates with a 
pCRMP4 or CRMP4 antibody showed that GSK3 inhibition with either SB-216763 or 
CT-99021 reduced the amount of pCRMP4 compared to DMSO treatment. (C) HeLa 
cells were synchronized with nocodazole (1 uM) for 14.5 hours after which either SB-
216763 (10 uM) or CT-99021 (2 uM) was added for 90 minutes. Immunoblot of lysates 
with a pCRMP4 or CRMP4 antibody show that GSK3 inhibition with either SB-216763 
or CT-99021 reduced the amount of pCRMP4 compared to DMSO treatment. (D) HeLa 
cells were transfected with L-CRMP1-V5 and either blocked with nocodazole for 16 
hours or treated with calyculin for 30 mins. L-CRMP1-V5 was immunoprecipitated from 
lysates and immunoblotted with a pThreonine antibody. CRMP1 phospho-threonine 
levels did not increase following nocodazole treatment, while calyculin treatment did 
increase phospho-threonine levels. (E) HeLa cells were transfected with S-CRMP2-V5 
and either blocked with nocodazole for 16 hours or treated with calyculin for 30 mins. S-
CRMP2-V5 was immunoprecipitated from lysates and immunoblotted with a pCRMP2 
(pThr509/514) antibody. Phospho-CRMP2 levels did not increase following nocodazole 
treatment, while calyculin treatment did increase phospho-CRMP2 levels. Input lysates 
were immunoblotted for pCRMP4 and CRMP4. (F) Lysates from HeLa cells 
synchronized by double thymidine block were immunoblotted for pCRMP4, CRMP4, 
pCRMP2 (pThr509/514) and GAPDH. Endogenous phospho-CRMP2 levels were 
unchanged throughout mitosis but increased with calyculin treatment. 
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Chapter 2 - Figure 7. Phosphorylated CRMP4 localizes with the mitotic apparatus. 
Immunofluorescence detection of pCRMP4, α-tubulin, and DNA in mitotic HeLa cells. 
Phosphorylated CRMP4 accumulates both at the cortex adjacent to the spindle poles and 
spindle microtubules during metaphase. Immunofluorescence detection of pCRMP4 is 
reduced in HeLa cells treated with the GSK3 inhibitor SB-216763 (10 uM) for 90 mins or 
transfected with CRMP4 siRNA. Bar, 10 um. 
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Chapter 2 - Figure 8. Chromosomal alignment during mitosis is phospho-CRMP4-
dependent. 
Overexpression of L-CRMP4-WT-V5 rescued the abnormal metaphase phenotype 
observed with CRMP4 knockdown (n=3, one way ANOVA, post-hoc Bonferroni test, 
***p<0.001 compared CRMP4 siRNA) while overexpression of the CRMP4 mutant L-
CRMP4-AAA-V5 fails to rescue the phenotype (n=3, one way ANOVA, post-hoc 
Bonferonni test, ns = non significant p>0.05 compared to CRMP4 siRNA). n=3 refers to 
3 independent experiments where at least 100 cells were scored per experiment.  
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Chapter 2 - Figure 9. CRMP4 localization to the mitotic spindle is phospho-
dependent. 
(A) HeLa cells were transfected with either L-CRMP4-WT-V5 or L-CRMP4-AAA-V5. 
Immunofluorescence was used to detect V5, α-tubulin, and DNA in HeLa cells in 
metaphase. HeLa cells were permeabilized with a cytosolic extraction buffer prior to 
fixation. L-CRMP4-WT-V5 localizes along the spindle microtubules while L-CRMP4-
AAA-V5 does not. Bar, 10 um. (B) HeLa cells were incubated with either 10 uM SB-
216763 or DMSO for 90 minutes prior to fixation and immunostaining for CRMP4. Bar, 
10 um. (C) Quantification of CRMP4 intensity at the mitotic spindle shows a decrease in 
CRMP4 intensity in SB-216763 treated HeLa cells (n=3, *p<0.05, Student’s t test 
compared to DMSO). n=3 refers to 3 independent experiments where at least 20 cells 
were analyzed per experiment. 
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Chapter 2 - Figure 10. siRNA-mediated knockdown of CRMP4 alters spindle 
morphology. 
(A) HeLa cells were transfected with either control or CRMP4 siRNA, and for rescue 
experiments were co-transfected with either L-CRMP4-WT-V5 or L-CRMP4-AAA-V5. 
In some experiments, HeLa cells were treated with SB-216763 (10 um) for 90 mins. 
HeLa cells were permeabilized with a cytosolic extraction buffer prior to fixation with 
4% PFA and immunofluorescence detection of α-tubulin and DNA. Bar, 10 um. (B) Bar 
graph plotting pole to pole distance. HeLa cells transfected with CRMP4 siRNA had a 
shorter pole to pole distance (n=3, **p=0.0059, Student’s t test compared to control 
siRNA). Co-transfection with a L-CRMP4-WT-V5 construct rescued the shorter pole to 
pole distance phenotype (n=3, **p=0.0069, Student’s t test compared to CRMP4 siRNA) 
while a L-CRMP4-AAA-V5 construct did not rescue (n=3, ns=non significant p>0.05, 
Student’s t test compared to CRMP4 siRNA). HeLa cells treated with SB-216763 (10 
uM) for 90 mins resulted in a shorter pole to pole distance (n=3, ***p<0.0001, Student’s 
t test compared to control siRNA; n=3, *p=0.0322, Student’s t test compared to CRMP4 
siRNA). (C) Bar graph plotting spindle width. HeLa cells transfected with either control 
siRNA, CRMP4 siRNA or treated with SB-216763 did not show any differences in 
spindle width (n=3, ns=non significant p>0.05, Student’s t test compared to control 
siRNA). n=3 refers to 3 independent experiments where at least 20 cells were analyzed 
per experiment.   
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Chapter 2 - Figure S 1. GSK3 inhibition delays mitotic exit. 
Flow cytometry graphs of double thymidine block synchronized HeLa cells transfected 
with CRMP4 siRNA or transfection reagent alone. HeLa cells were collected at different 
time intervals following release into thymidine-free media (upper and middle panels) or 
media containing SB-216763 (10 uM) (lower panels). Knockdown of CRMP4 protein 
expression did not delay mitotic entry or exit, while treatment with SB-216763 resulted in 
a delay in mitotic progression. M2= 2n peak, M4= 4n peak. 
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Chapter 2 - Figure S 2. Phosphorylation of L-CRMP4 during mitosis. 
(A) An increase in L-CRMP4 phosphorylation at the Thr622 residue was observed with 
pT622 CRMP4 antibody in nocodazole blocked HeLa cell lysates. The phospho doublet 
band was also detected with a CRMP4 antibody, however the upper band was faint 
compared to the lower band. Overexpression of L-CRMP4-V5 or S-CRMP4-V5 in HeLa 
cells reveals that the majority of endogenous CRMP4 is L-CRMP4. (B) Lysates from 
HeLa cells transfected with either control or CRMP4 siRNA, and synchronized with a 
double thymidine block, were probed with either pT622 CRMP4, CRMP4 or GAPDH. 
(C) HeLa cells were transfected with pcDNA V5, L-CRMP4 WT-V5, or L-CRMP4 
AAA-V5 and were blocked with nocodazole (1 uM) for 16 hours. V5 was 
immunoprecipitated from the lysates and immunoblotted with pCRMP4 or V5 antibodies. 
The pCRMP4 antibody did not recognize L-CRMP4 AAA-V5. 
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Chapter 2 - Figure S 3. Representative line scan of pole to pole distance 
measurements. 
For pole to pole distance measurements, tubulin fluorescence intensities were measured 
from one end of the cell to the other end along the spindle axis using ImageJ, and when 
plotted as a function of spindle position, the tubulin intensity gave two peaks 
corresponding to the spindle poles. 
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3 ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF C4RIP AS A 
THERAPEUTIC AGENT TO PROMOTE CNS REGENERATION 
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3.1  PREFACE 
 Following central nervous system (CNS) injury, myelin associated inhibitors 
(MAIs) and chondroitin sulfate proteoglycans (CSPGs) signal through receptor 
complexes located on damaged axons to activate the intracellular protein RhoA. RhoA 
activation results in neuronal cytoskeleton rearrangements that lead to the inhibition of 
nerve regeneration. The RhoA effector proteins that mediate these events are not well 
characterized. We have previously identified CRMP4 as a RhoA-interacting protein that 
mediates neurite outgrowth inhibition in response to myelin. Antagonizing RhoA-L-
CRMP4 interactions with a competitive antagonist C4RIP attenuates neurite outgrowth 
inhibition in dorsal root ganglion neurons in vitro. The aim of this study was to 
investigate the role of CRMP4 in CNS regeneration in an in vivo preclinical model of 
CNS injury. We evaluate the ability of adeno-associated virus-mediated expression of 
C4RIP to promote retinal ganglion cell neuronal survival and axon regeneration 
following an optic nerve injury in the adult rat.  
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3.2 ABSTRACT 
 MAIs and CSPGs signal through receptor complexes located on the neuronal 
plasma membrane to activate the intracellular protein RhoA. RhoA pathway antagonists 
promote neuronal survival and regeneration following CNS injury, however side effects 
may limit their therapeutic application because RhoA is ubiquitously expressed and 
regulates multiple cellular processes including cell division, cell migration and dendritic 
spine morphology (Riento and Ridley 2003). In an attempt to identify more specific 
therapeutic targets to promote CNS regeneration following injury, we have previously 
identified CRMP4 as a RhoA interacting protein that mediates neurite outgrowth 
inhibition in dorsal root ganglion neurons (DRGs) in vitro. Through a structure function 
analysis we identified a fragment of CRMP4, C4RIP (CRMP4b-RhoA Inhibitory 
Peptide) that antagonizes RhoA-L-CRMP4 interactions and promotes neurite outgrowth 
inhibition of DRGs on inhibitory substrates in vitro. Here, we evaluate the ability of 
adeno-associated virus (AAV)-mediated expression of C4RIP to promote retinal ganglion 
cell (RGC) neuronal survival and axon regeneration following an optic nerve injury in the 
adult rat. We demonstrate that CRMP4 is expressed in adult RGCs and AAV serotype 2 
directs selective C4RIP transgene expression in adult RGCs. However, AAV C4RIP does 
not promote RGC neuronal survival or axon regeneration following optic nerve injury 
even if RGCs are in an active growth state. Analysis of C4RIP retinal expression levels 
by immunoblot suggests that C4RIP expression is insufficient for it to act as a 
competitive antagonist to RhoA-L-CRMP4 interactions. We discuss strategies for future 
studies focusing on increasing C4RIP levels in RGCs to promote axon regeneration 
following optic nerve injury.   
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3.3 INTRODUCTION 
 CNS neurons fail to spontaneously regenerate following injury, in part due to the 
expression of inhibitory molecules including MAIs and CSPGs in the glial scar (Yiu and 
He 2006). MAIs and CSPGs signal through distinct receptor complexes but the inhibitory 
signals converge to activate the cytosolic protein RhoA and its downstream effector Rho-
associated kinase (ROCK) (Jin and Strittmatter 1997; Lehmann, Fournier et al. 1999; 
Borisoff, Chan et al. 2003; Fournier, Takizawa et al. 2003). Although RhoA antagonists 
promote neuronal survival and regeneration in vitro and in vivo (Lehmann, Fournier et al. 
1999; Dergham, Ellezam et al. 2002; Winton, Dubreuil et al. 2002; Dubreuil, Winton et al. 
2003; Fournier, Takizawa et al. 2003; Monnier, Sierra et al. 2003; Fischer, Petkova et al. 
2004; Bertrand, Winton et al. 2005; Bertrand, Di Polo et al. 2007; Lord-Fontaine, Yang et 
al. 2008), the widespread roles of RhoA in multiple cellular processes and cell types may 
limit its potential as a therapeutic target (Riento and Ridley 2003). In an attempt to 
discover more specific therapeutic targets to promote nerve regeneration, our lab 
previously identified the cytosolic phosphoprotein L-CRMP4 (Long-Collapsin Response 
Mediator Protein 4, previously referred to as CRMP4b) as a protein that physically and 
functionally interacts with RhoA to mediate neurite outgrowth inhibition (Alabed, Pool et 
al. 2007).  
 CRMPs are cytosolic phosphoproteins that are highly expressed in the nervous 
system during development and play widespread roles in migration and axonal growth 
(Goshima, Nakamura et al. 1995; Wang and Strittmatter 1996; Gaetano, Matsuo et al. 
1997; Byk, Ozon et al. 1998; Quinn, Gray et al. 1999; Quach, Duchemin et al. 2004). The 
CRMPs are homologs of UNC-33, a protein originally identified in Caenorhabditis 
elegans to be important for axon extension and guidance (Hedgecock, Culotti et al. 1985; 
Siddiqui and Culotti 1991). The CRMP family is composed of five family members 
(CRMP1-5) in vertebrates (Goshima, Nakamura et al. 1995; Minturn, Fryer et al. 1995; 
Byk, Dobransky et al. 1996; Gaetano, Matsuo et al. 1997; Wang and Strittmatter 1997; 
Inatome, Tsujimura et al. 2000; Quinn, Chen et al. 2003). Each CRMP allele produces 
two transcripts that differ in their amino terminal domains producing long (L-CRMP) and 
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short (S-CRMP) isoforms that have been alternatively referred to as ‘a’ and ‘b’ isoforms 
(Quinn, Chen et al. 2003; Yuasa-Kawada, Suzuki et al. 2003; Alabed, Pool et al. 2007; 
Pan, Chao et al. 2009; Alabed, Pool et al. 2010).  
 The role of CRMP4 in the nerve regeneration has not been extensively studied. In a 
rat hypoglossal nerve injury model CRMP4a mRNA levels are unchanged following 
axotomy (Suzuki, Nakagomi et al. 2003). CRMP4 mRNA and protein expression are 
increased in both adult sciatic motor neurons and DRG neurons that are regenerating 
following a sciatic nerve lesion (Minturn, Fryer et al. 1995; Jang, Shin et al. 2010). 
Furthermore, an increase in CRMP4 protein expression is observed in the peripheral axon 
following the injury (Jang, Shin et al. 2010). With respect to CRMP4 function in CNS 
inhibition, we have previously demonstrated that L-CRMP4 can physically and 
functionally interact with RhoA to mediate neurite outgrowth inhibition in vitro (Alabed, 
Pool et al. 2007; Alabed, Pool et al. 2010). CRMP4 depletion in DRGs promotes neurite 
outgrowth on inhibitory CNS myelin (Alabed, Pool et al. 2007). Further, blockade of the 
RhoA-L-CRMP4 interaction with a competitive peptide, C4RIP (CRMP4b-RhoA 
Inhibitory Peptide), attenuates neurite outgrowth inhibition on both CNS myelin and 
aggrecan (Fig. 1) (Alabed, Pool et al. 2007). These findings identify CRMP4 as a 
convergent regular of axon outgrowth inhibition. However, the biological function of 
CRMP4 in an in vivo model of regeneration has not been extensively studied. The 
objective of this study is to evaluate the therapeutic potential of C4RIP to promote CNS 
nerve regeneration in a preclinical adult rat optic nerve injury model. We have developed 
an adeno-associated virus (AAV) containing C4RIP as a potential therapeutic agent to 
promote axon regeneration following CNS injury.  
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3.4 MATERIALS AND METHODS 
3.4.1 Recombinant Adeno-Associated Virus Serotype 2 vector 
 C4RIP-V5 cDNA was amplified by PCR from pcDNA 3.1 C4RIP-V5 (Alabed, 
Pool et al. 2007) using the following primers: 5’ GCCAAGCTTGCTTGAACCATGG 
CTTCG 3’, and 5’ GCCAAGCTTTCAATGGT GATGGTGATGATG 3’. The 
amplified C4RIP-V5 PCR product was digested with HindIII and inserted into the 
HindIII site downstream of the hybrid chick β-actin/CMV enhancer promoter in the 
plasmid pXX-UF12, which is derived from pTR-UF5 (Zolotukhin, Potter et al. 1996). 
The plasmid pXX-UF12 contains AAV terminal repeats, a simian virus 40 
polyadenylation sequence and an internal ribosomal entry site (IRES) driven GFP. 
Vectors were packaged, concentrated and titered as previously described (Hauswirth, 
Lewin et al. 2000). 
3.4.2 Intraocular Injection of Viral Vectors 
 All animal procedures followed guidelines from the Canadian Council of Animal 
Care. Surgeries were performed on female Sprague-Dawley rats (180g-200g) under general 
gas anesthesia (2-3% isofluorane mixed in oxygen, 0.8 L/min). The conjunctiva was 
dissected away until the sclera was reached. A small puncture wound was made in the 
superior quadrant through the sclera just temporal to the episcleral vein using a 30-gauge 
needle. Intraocular injections of the viral vectors (5 µl) into the vitreous space of the left 
eye were performed using a fine glass tube attached to a 10 µl-Hamilton syringe. The tip 
of the needle was inserted through the small puncture wound in the sclera at a 45º angle, 
with the tip of the needle pointed towards the optic nerve head (Fig. 2A). This route of 
administration avoided injury to the lens and iris, which have been shown to promote 
RGC survival and regeneration (Leon, Yin et al. 2000). The injection was performed over 
1 minute, after which the needle was held in place for approximately 2 minutes before 
slowly removing the needle. The puncture wound was sealed with surgical glue (Indermill, 
Tyco Health Care, Montreal, Quebec). Further surgical procedures were performed 3-4 
week after the administration of viral vectors to allow AAV-mediated transgene 
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expression levels to plateau. It has been proposed that the delay in AAV-mediated 
transgene expression in vivo is due to the need to convert single-stranded viral DNA to a 
double-strand prior to active transcription (Ferrari, Samulski et al. 1996). 
3.4.3 Retrograde labeling and RGC survival 
 RGCs were retrogradely labeled through the application of 2% FluoroGold 
(Fluoro-chrome, Englewood, CO) in 0.9% NaCl containing 10% DMSO to both superior 
colliculi (Fig. 2B). Seven day following the application of FluoroGold, the left optic nerve 
was axotomized 0.5-1 mm from the back of the eye, with care to avoid injury to the 
ophthalmic artery. Fourteen days later, the rats were intracardially perfused with 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB, pH=7.2), and retinal flat 
mounts were prepared as described previously (Pernet, Hauswirth et al. 2005). 
FluoroGold-labeled neurons were counted in 12 standard retinal areas as described 
previously (Cheng, Sapieha et al. 2002; Pernet, Hauswirth et al. 2005; Bertrand, Di Polo 
et al. 2007). Data analysis was performed using Prism by using Student’s t test. 
3.4.4 Forcep Crush Injury, Lens Injury and Immnohistochemistry  
 The lacrymal glands and extra-ocular muscles were resected to expose the optic 
nerve. The epineurium was cut along the long axis of the optic nerve and the optic nerve 
was crushed approximately 2 mm from the back of the eye with an angled jeweler’s 
forcep (Dumont #5) for 10 seconds (Fig. 2C). For a microcrush lesion, a 10-0 pt suture 
was tied around the optic nerve approximately 2 mm from the back of the eye, kept in 
place for 1 minute and removed (Fig. 2C). Optic nerve injury was visualized by the 
clearance of the crush site and the retinal vascular integrity was evaluated by fundoscopic 
examination. Rats with impaired vascular integrity were excluded from the study. In some 
cases, we performed a lens injury by puncturing the sclera about 2 mm above the optic 
nerve head with a 30 gauge needle to intentionally damage to posterior surface of the lens 
(Fig. 2D). We immediately visualized the lens injury through the cornea and observed a 
cataract form within a week of the injury. Thirteen days later, an intraocular injection of 5 
µl of 1% cholera toxin beta-subunit (CTβ) (Sigma, Oakville, ON) in phosphate-buffered 
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saline (PBS) through the same puncture wound was performed to anterogradely label 
regenerating axons. 24 hours later, rats were intracardially perfused with 4% PFA 0.1 M 
PB and their left eye and optic nerve was removed. The anterior part of the eye and the 
lens were dissected away, and the eye cup and optic nerve were fixed for an additional 2 
hours at 4 ºC. The eye cup and optic nerve were cyroprotected in 30 % sucrose in PBS 
overnight at 4 ºC, and embedded in OCT (optimal cutting temperature) compound 
(Tissue-Tek, Miles Laboratories, Elkhart, IN) and frozen in 2-methylbutane on dry ice. 
Cryosections (14 µm for optic nerves and 16 µm for retinas) were collected on Superfrost 
slides (Fischer Scientific) and processed for immunohistochemistry. Sections were post-
fixed for 15 minutes in 4% PFA, followed by blocking in blocking solution (5% bovine 
serum albumin (BSA), 0.3% Triton-X100 (Sigma), in PBS) for 1 hour at room 
temperature. Primary antibodies were diluted in blocking solution and incubated overnight 
at 4ºC. The following primary antibodies were used: goat CTβ (List Biological 
Laboratories), mouse βIII tubulin (Covance), mouse V5 (Sigma), mouse PLP, rabbit 
CRMP4 and rabbit L-CRMP4 as previously described (Alabed, Pool et al. 2007). 
Secondary antibodies were diluted in blocking solution and incubated 1 hour at room 
temperature. Secondary antibodies used were: rabbit anti-goat biotin; anti-mouse-FITC, 
Alexa-568; anti-rabbit-FITC, Alexa-568 (Invitrogen). Streptavidin-FITC and Alexa-568 
(Invitrogen) were also used to amplify the biotin signal.  
3.4.5 Analysis of RGC axon regeneration 
 Axon regeneration was analyzed by counting the number of CTβ-positive axons 
that crossed a virtual line parallel to the lesion site divided by optic nerve width (Fig. 2E). 
The lesion site was identified by darkfield microscopy. CTβ-positive axons were counted 
at distances of 100 um, 250 um, 500 um, 750 um, and 1000 um from the lesion site in at 
least four sections per animal from at least 3 animals per condtion. Data analysis was 
performed using Prism by two-way ANOVA followed by Bonferroni post hoc test.  
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3.4.6 Immunoblot of Retinal lysates 
 Rats were given an overdose of 70% chloral hydrate in H2O, their retinas were 
quickly dissected away and manually homogenized using a pestle in lysis buffer (20 mM 
Tris, pH=8.0, 135 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 10% 
glycerol, and 1X protease inhibitors (Roche)) at 4 ºC. Retinal lysates were sonicated for 
20 seconds at 20% amplitude followed by a 10 minute centrifugation at 13,200 rpm at 4 
ºC. Supernatant lysate was collected and stored at -20 ºC. 100 µg protein samples were 
separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels (PAGE) and 
transferred to polyvinylidene fluoride membranes (PVDF). Membranes were blocked for 
1 hour with 5% milk in tris-buffered saline 0.1% Tween-20 (TBST). Primary antibodies 
were diluted in 5% milk TBST and incubated overnight at 4 ºC. Primary antibodies used 
were: rabbit CRMP4 and rabbit L-CRMP4. Secondary antibodies were diluted in 5% milk 
TBST and incubated 1 hour at room temperature. Secondary antibody used was anti-
rabbit antibody linked to horse radish peroxidase (HRP). Protein signal was detected used 
a chemiluminescence reagent (ECL, Amersham Biosciences).  
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3.5 RESULTS 
3.5.1 CRMP4 is expressed in the adult retina 
To determine if CRMP4 was expressed in the adult rat retina, retinal lysates were 
immunoblotted using two different CRMP4 antibodies: a CRMP4 antibody raised against 
the C-terminal domain common to L-CRMP4 and S-CRMP4, and a L-CRMP4 antibody 
raised against the unique N-terminus of L-CRMP4. Both L- and S-CRMP4 were 
expressed in the adult rat retina as detected with both CRMP4 and L-CRMP4 antibodies 
(Fig. 3A). To localize where CRMP4 was expressed in the retina, adult rat retinas were 
collected and immunostained with either a CRMP4 or a L-CRMP4 antibody, and a βIII 
tubulin antibody to visualize the RGCs. Immunostaining with the CRMP4 antibody 
revealed CRMP4 expression throughout the retina, with strong expression in the RGC 
and nerve fiber (NF) layers  (Fig. 3B, top row). Immunostaining with the L-CRMP4 
antibody revealed strong expression in the retinal layers that contained cell bodies: RGC 
layer, inner nuclear layer (INL), outer nuclear layer (ONL) (Fig. 3C middle row). L-
CRMP4 expression was also observed in the outer plexiform layer (OPL) and the outer 
segment (OS) of the retina. Lower expression level of L-CRMP4 was observed in the IPL 
and NFL. The differences in expression pattern between CRMP4 and L-CRMP4 raises 
the possibility that L-CRMP4 and S-CRMP4b are targeted to different compartments 
with the RGC, where L-CRMP4 preferentially localizes to the cell body and S-CRMP4 
preferentially localizes to dendrites and axons. However, L-CRMP4 is localized in RGC 
axons throughout the optic nerve (Fig. 3B, lower row). Interestingly, strong L-CRMP4 
expression was also observed in cell bodies that were in aligned in rows along the long 
axis of the optic nerve (Fig. 3C). Some of the L-CRMP4 was co-localized with 
proteolipid protein (PLP) staining, which demonstrates that L-CRMP is also expressed in 
oligodendocytes. Further, we performed co-localization studies in retinas from eyes that 
had their RGCs retrogradely labeled with FluoroGold applied to the superior colliculi. L-
CRMP4 immunoreactivity was observed in FluoroGold back-labeled RGCs (Fig. 3D, 
upper row). No immunoreactivity was seen when the L-CRMP4 antibody was pre-
incubated with a blocking peptide, which demonstrates the specificity of the antibody 
(Fig. 3D, lower row).      
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3.5.2 Adeno-associated virus serotype 2 directs selective C4RIP transgene 
expression in adult retinal ganglion cells 
 We used a recombinant AAV serotype 2 to selectively transduce RGCs with 
C4RIP-V5. AAV-C4RIP-V5 was delivered through a single intraocular injection into the 
vitreous space of the eye. Retinas and optic nerves were collected 4 weeks following the 
administration of AAV-C4RIP-V5, which is the time required for transgene expression to 
reach a plateau in adult rat RGCs (Bennett, Anand et al. 2000; Cheng, Sapieha et al. 
2002; Pernet, Hauswirth et al. 2005). Since C4RIP is the unique N-terminal domain of L-
CRMP4, we could not use the L-CRMP4 antibody to differentiate between C4RIP-V5 
and endogenous L-CRMP4 expression. Therefore, we used an antibody raised against the 
V5 epitope tag present only in C4RIP-V5 to evaluate AAV-mediated C4RIP-V5 
expression in RGCs. Immunohistochemistry was performed on retinas cut in cross 
section and flatmounted retinas. Strong C4RIP-V5 expression was detected in the RGC 
cell bodies in retinas from eyes that were injected with AAV C4RIP-V5 but not AAV 
GFP (Fig. 4A). Additionally, C4RIP-V5 expression was also observed in RGC dendrites 
extending into the IPL (Fig. 4A), and in RGC axons projecting through the optic nerve 
head and down the optic nerve (Fig. 4B). We performed immunohistochemistry on 
flatmount retinas from eyes that were injected with AAV C4RIP-V5 using the V5 
antibody to visualize C4RIP-V5 expression and a βIII tubulin antibody to identify RGCs 
and their processes (Fig. 4C). Qualitative assessment of these retinas revealed that the 
majority of RGCs were effectively infected with AAV C4RIP-V5. Consistent with our 
observations from immunohistochemistry performed on cross sections of these retinas, 
we localized C4RIP-V5 expression in RGC cell bodies, dendrites and axons (Fig. 4C).    
3.5.3 AAV C4RIP does not promote neuronal survival or regeneration in adult 
retinal ganglion cells 
Previous studies have demonstrated that RhoA activity plays an important role in 
the regulation of both neuronal survival and regeneration following CNS nerve injury 
(Fischer, Petkova et al. 2004; Bertrand, Di Polo et al. 2007). The administration of the 
RhoA antagonist C3 transferase to RGCs either through AAV-mediated gene transfer or 
through a cell-permeable protein promotes both neuronal survival and regeneration 
following optic nerve injury in the adult rat (Fischer, Petkova et al. 2004). Our previous 
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studies have identified L-CRMP4 as an important RhoA interacting protein that mediates 
neurite outgrowth inhibition on inhibitory substrates such as myelin and aggrecan 
(Alabed, Pool et al. 2007; Alabed, Pool et al. 2010). Expression of a RhoA-L-CRMP4 
competitive antagonist, C4RIP, is able to significantly attenuate neurite outgrowth 
inhibition in vitro (Alabed, Pool et al. 2007). These findings prompted us to assess the 
effectiveness of antagonizing RhoA-L-CRMP4 interaction with C4RIP to promote 
neuronal survival and nerve regeneration in vivo following optic nerve injury. Three weeks 
after a single intraocular injection of either AAV C4RIP-V5 or AAV GFP, RGCs were 
retrogradely labeled with FluoroGold applied to the superior colliculi, and one week later 
the optic nerve was axotomized. Retinas were collected two weeks following axotomy 
and were analyzed for neuronal survival by determining the neuronal densities in the four 
retinal quadrants (superior, nasal, temporal and inferior). AAV-mediated expression of 
C4RIP V5 did not promote neuronal survival following axotomy compared to AAV GFP 
(Fig. 5B).  
Four weeks following a single intraocular injection with either AAV C4RIP-V5 
or AAV GFP, a forcep crush injury was applied to the optic nerve to transect all RGC 
axons. Thirteen days following forcep crush injury, an intraocular injection of the 
anterograde tracer cholera toxin beta-subunit (CTβ) was performed to labeled 
regenerating axon fibers. Fourteen days following forcep crush injury, the optic nerves 
were collected and regeneration was assessed through immunohistochemistry with an 
anti-CTβ antibody. In optic nerves from rats injected with AAV C4RIP-V5, we observed 
many V5-positive axon fibers proximal to the lesion site indicating that C4RIP-V5 was 
transported down RGC axons (Fig. 5C). In optic nerves from rats injected with either 
AAV GFP or AAV C4RIP-V5, we observed many CTβ-positive axons proximal to the 
lesion site but we did not observed many distal to the lesion site (Fig. 5C). Further, AAV 
C4RIP-V5 did not promote RGC axon regeneration compared to AAV GFP (Fig. 5D).   
3.5.4 AAV C4RIP does not promote axon regeneration in adult retinal ganglion 
cells in an active growth state 
 It has been previously shown that in certain cases RGCs must be in an active 
growth state for regeneration to occur (Fischer, He et al. 2004). One method to activate 
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the growth state of RGCs is to perform a lens injury, which stimulates RGC survival and 
axon regeneration in the adult rat optic nerve (Fischer, Pavlidis et al. 2000; Leon, Yin et 
al. 2000; Fischer, He et al. 2004; Pernet and Di Polo 2006). The introduction of a 
dominant negative form of Nogo-66 receptor (DN-NgR1) alone does not enhance nerve 
regeneration following optic nerve injury in adult rats. However, when a lens injury is 
performed at the time of optic nerve injury, the introduction of DN-NgR1 enhances nerve 
regeneration compared to lens injury alone (Fischer, He et al. 2004). To assess the effect 
of AAV-mediated C4RIP expression in RGCs in an active growth state, we performed a 
lens injury immediately following forcep crush injury. We immediately visualized the 
lens injury and observed the opacification of the lens (cataract) within a week. We 
observed many more CTβ-positive axons proximal and distal to the lesion site, thereby 
validating our ability to promote axon regeneration through lens injury (Fig. 6A). We 
quantified axon regeneration by counting the number of CTβ-positive axons per optic 
nerve width at different distances from the lesion site (Fig. 6B). AAV-mediated C4RIP-
V5 expression did not promote axon regeneration in RGCs in an active growth state 
compared to AAV GFP (Fig. 6B).  
 Together, these findings indicate that AAV-mediated expression of C4RIP-V5 in 
adult RGCs does not promote neuronal survival or axon regeneration following optic 
nerve injury. However, during our in vitro characterization of C4RIP-V5, we observed 
that the ability of C4RIP-V5 to function as a competitive antagonist of RhoA-L-CRMP4 
interactions was dependent on the molar excess of C4RIP-V5 compared to endogenous 
L-CRMP4. Therefore, we assessed C4RIP-V5 expression levels by immunoblot with a L-
CRMP4 antibody in retinal lysates from eyes that were injected with AAV C4RIP-V5 
four weeks prior (Fig. 7). A single intraocular injection of AAV C4RIP-V5 resulted in the 
expression of C4RIP-V5, which was detected as a 20 kDa band at higher exposure times. 
On the same immunoblot we were able to visualize a 75 kDa band that corresponded to 
endogenous L-CRMP4 in the retinal lysates. The expression levels of C4RIP-V5 were 
robustly lower compared to endogenous L-CRMP4 expression levels. These findings 
suggest that perhaps the inability of AAV C4RIP-V5 to promote axon regeneration 
following optic nerve injury in the adult rat is attributed to insufficient C4RIP-V5 protein 
expression levels. This can be partially explained by the RGC-restricted expression of 
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AAV C4RIP-V5 but these findings also raise the distinct possibility that AAV C4RIP-V5 
fails to promote axon regeneration due to insufficient expression.  
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3.6 DISCUSSION 
 In this study, we localize CRMP4 protein expression throughout the adult rat 
retina and optic nerve. We use a recombinant AAV to investigate the ability of C4RIP, a 
RhoA-L-CRMP4 competitive antagonist, to promote neuronal survival and axon 
regeneration in adult rat RGCs following optic nerve injury. Recombinant AAV vectors 
have a number of important advantages over other gene delivery vectors such as their 
lack of significant pathogenicity and their ability to induce long-term transgene 
expression (Di Polo, Aigner et al. 1998; Dudus, Anand et al. 1999; Guy, Qi et al. 1999; 
Martin, Klein et al. 2002). The efficiency of transduction is dependent on a number of 
factors including the site of injection, the AAV serotype and titer, the amount of 
passenger DNA, and the specific gene promoters and enhancing elements used (Martin, 
Klein et al. 2002). Consistent with previous studies, our recombinant AAV serotype-2 
predominately transduces RGCs in the adult rat retina. Four weeks following a single 
intraocular injection of AAV C4RIP-V5 into the vitreous space, we observe C4RIP-V5 
protein expression in the majority of RGC cell bodies, dendrites and axons (Martin, Klein 
et al. 2002; Fischer, He et al. 2004; Fischer, Petkova et al. 2004; Pernet, Hauswirth et al. 
2005; Pernet and Di Polo 2006). However, our studies demonstrate that AAV-mediated 
expression of C4RIP-V5 does not promote neuronal survival or axon regeneration in 
RGCs following optic nerve injury, even if the RGCs are stimulated to an active growth 
state by lens injury.  
 There are a few possibilities to explain why AAV-mediated C4RIP-V5 expression 
failed to promote neuronal survival and axon regeneration in adult RGCs following optic 
nerve injury. Although RhoA antagonist promote neuronal survival and axon regeneration, 
our previous in vitro studies in DRGs only investigated the ability of C4RIP-V5 to 
attenuate neurite outgrowth inhibition in response to myelin and aggrecan (Alabed, Pool 
et al. 2007). While this data implicates the RhoA-L-CRMP4 interaction as an important 
mediator of axon regeneration inhibition, we have no in vitro data to suggest that L-
CRMP4 regulates neuronal survival.  
 One unlikely explanation of why C4RIP-V5 did not promote axon regeneration in 
adult RGCs may be attributed to differences in intracellular signaling mechanisms in 
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different cell types. Our in vitro experiments were performed with embryonic (E13) chick 
DRGs, while in this in vivo study adult RGCs were used. However, there is strong 
evidence to support a model where RGCs inhibitory signaling following axonal injury is 
similar to other neurons including DRGs. The administration of RhoA antagonists such as 
purified cell-permeable C3 or AAV-C3 enhance RGC regeneration following optic nerve 
injury (Fischer, Petkova et al. 2004; Bertrand, Di Polo et al. 2007). These studies 
demonstrate that RhoA is an important mediator of axon outgrowth inhibition in RGCs. 
Furthermore, counteracting Nogo receptor with a dominant negative version enhances 
RGC axon regeneration if they are in an active growth state (Fischer, He et al. 2004). 
Importantly, in this study we have determined that adult RGCs express CRMP4. 
Overall, these findings suggest that adult RGCs are likely to engage the same intracellular 
signaling cascades that other neurons use to inhibit axonal regeneration.  
 Therefore, if RhoA-L-CRMP4 interaction mediates RGC axon outgrowth 
inhibition in response to a CNS injury, then antagonizing this interaction with our 
competitive protein C4RIP-V5 should promote axon regeneration. Our in vitro data 
suggests that in order for C4RIP-V5 to act as a competitive antagonist, C4RIP-V5 levels 
must be in molar excess of endogenous L-CRMP4 levels. Our observation that 
endogenous L-CRMP4 levels in retinal lysates are robustly higher than those seen for 
C4RIP-V5 suggest that AAV-mediated expression of C4RIP-V5 does not result in 
adequate C4RIP-V5 levels to act as a competitive antagonist. However, as previously 
described, our localization of endogenous L-CRMP4 to many different retinal layers, 
while AAV selective transduces RGCs make these results difficult to interpret. We have 
attempted to increase AAV-mediated C4RIP-V5 expression by performing multiple 
injections of AAV C4RIP-V5 but failed to observe a significant increase in C4RIP-V5 
expression in retinal lysates.  
 We have also attempted to perform in vitro outgrowth experiments on inhibitory 
myelin with dissociated postnatal day 8 rat retinas. These experiments would allow us to 
validate C4RIP in RGCs and to compare the ability of C4RIP to attenuate neurite 
outgrowth inhibition on inhibitory myelin in DRGs and RGCs. However, while we were 
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successful at culturing non-infected dissociated mixed retinal neurons and having them 
respond to myelin, we were unable to do this after viral transduction of the RGCs with 
C4RIP or mRFP due to virus toxicity. In addition to the poor growth we observe from 
virus toxicity, our experimental conditions required us to trypsinize the cells off the 
culture dish following viral infection and reseeding them on a myelin substrate. Despite 
extensive troubleshooting, we were unsuccessful at achieving culture conditions that 
yielded consistently good growth.  
 To address some of the challenges we encountered with AAV-mediated delivery 
of C4RIP to RGC, in the next chapter, Chapter 4, we develop a cell permeable 
recombinant TAT C4RIP protein. These have certain advantages and disadvantages when 
compared to AAVs, which we will discuss in the next chapter.  
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Chapter 3 - Figure 1. Schematic representation of C4RIP  blockade of the RhoA-L-
CRMP4 interaction.  
MAIs, CSPGs and other inhibitory molecules signal through neuronal receptors to 
activate RhoA. RhoA signals through L-CRMP4 to mediate neurite outgrowth inhibition. 
The overexpression of the competitive peptide C4RIP disrupts the RhoA-L-CRMP4 
interaction and promotes neurite outgrowth on inhibitory substrates. Adapted from 
Essentials of Spinal Cord Injury: Targeting Rho inactivation to promote regeneration 
and treat spinal cord injury: Bench to bedside translational medicine (In press) by L. 
McKerracher, M. Fehlings, A.E. Fournier and S. Ong Tone, 2010, NY: Thieme Medical 
Publishers. 
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Chapter 3 - Figure 2. Schematic representation of surgical procedures. 
(A) AAV C4RIP-V5 and AAV GFP were administered through an intraocular injection 
into the vitreous space. (B) Retinal ganglion cells were backlabelled through the 
application of FluoroGold to the superior colliculi. (C) Optic nerve injury was achieved 
through a microcrush lesion with a 10-0 pt suture or through a forcep crush directly to the 
nerve. (D) Retinal ganglion cells were induced to an active growth state through a lens 
injury with a 30 ½ gauge needle. (E) Retinal ganglion cell regeneration was assessed 
through an intraocular injection of cholera toxin β and subsequent immunohistochemical 
analysis. 
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Chapter 3 - Figure 3. CRMP4 expression in the adult retina and optic nerve. 
(A) Immunoblot on retinal lysates from 3 separate rats probed with a CRMP4 antibody, 
which recognizes both L- and S- CRMP4, and a L-CRMP4 specific antibody. (B) 
Fluorescent micrographs on retinal sections stained for βIII tubulin, DNA and either 
CRMP4 (top panel) or L-CRMP4 (middle and lower panel). The bottom panel shows L-
CRMP4 expression at the optic nerve head and optic nerve. NF= nerve fiber layer, RGC= 
retinal ganglion cell layer, IPL= inner plexiform layer, INL= inner nuclear layer, OPL= 
outer plexiform layer, ONL= outer nuclear layer, OS= outer segment, ONH= optic nerve 
head, ON= optic nerve. Bar, 100 um. (C) Fluorescent micrograph of an optic nerve 
section stained for proteolioprotein (PLP), DNA and L-CRMP4. Strong L-CRMP4 
expression is observed in oligodendrocytes of the optic nerve (arrows). Bar, 100 µm. (D) 
Fluorescent micrograph of a FluoroGold backlabeled retinal section stained for L-
CRMP4. L-CRMP4 is strongly expressed in FluoroGold positive retinal ganglion cells 
(Top panel). The immunosignal is abolished with the pre-incubation of the L-CRMP4 
antibody with its blocking peptide (lower panel). Bar, 20 µm. 
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Chapter 3 - Figure 4. Adeno-associated virus (AAV)-mediated transgene expression 
of C4RIP-V5 in retinal ganglion cells. 
(A) Fluorescent micrographs on retinal sections that were stained with a V5 antibody four 
weeks following a single intraocular injection of AAV-C4RIP-V5 (top) or AAV-GFP 
(bottom). Bar, 100 µm. (B) C4RIP-V5 is expressed in retinal ganglion cell bodies, 
dendrites and axons projecting down through the optic nerve head and optic nerve. 
ONH=optic nerve head, ON=optic nerve. Bar, 100 µm. (C) Flatmount of an AAV-C4RIP 
infected retina stained for V5 and βIII tubulin. C4RIP-V5 expression is observed in the 
majority of retinal ganglion cells. Bar, 100 µm. 
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Chapter 3 - Figure 5. AAV-mediated transgene expression of C4RIP-V5 in retinal 
ganglion cells does not promote neuronal survival or axon regeneration. 
(A) AAV C4RIP-V5 does not increase the density of FluoroGold backlabeled RGCs two 
weeks following axotomy. Bar, 100 µm. (B) Quantitative analysis of RGCs survival 
following injection of AAV-GFP (black bar) or AAV-C4RIP (grey bar). RGC density is 
calculated by counting the number of RGCs per mm2 in 12 standard areas of the retina. 
RGC survival is represented as a percentage of RGC density from intact retinas (white 
bar). AAV-C4RIP V5 does not promote RGC survival compared to AAV GFP (n=6, 
Student’s t test, non-significant = p>0.05). (C) AAV C4RIP-V5 does not promote axon 
regeneration following optic nerve injury. Fluorescent micrographs on optic nerve 
sections stained for cholera toxin beta-subunit (CTβ) and V5 six week following a single 
intraocular injection of AAV C4RIP-V5 and two weeks following optic nerve injury. 
Regenerating fibers were anterogradely labeled with a single injection of CTβ one day 
before collection of the optic nerve. RGC axons positive for both CTβ and V5 are seen 
proximal (p) to the lesion site (*), but no regenerating fibers are observed distal to the 
lesion site (d). Bar, 100 µm. (D) Quantitative analysis of axon regeneration following 
intraocular injections of either AAV GFP (black bars) or AAV C4RIP-V5 (grey bars). 
CTβ-positive axons were counted at 100 µm and 500 µm from the lesion site. At least 
four optic nerve sections were counted per animal. AAV C4RIP-V5 did not promote axon 
regeneration in RGCs following optic nerve injury compared to AAV GFP (n=3, two-
way ANOVA, Bonferroni post hoc test, non-significant= p>0.05).  
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 Chapter 3 - Figure 6. AAV-mediated transgene expression of C4RIP-V5 in retinal 
ganglion cells stimulated to an active growth state does not promote axon 
regeneration. 
(A) AAV C4RIP-V5 does not promote axon regeneration in RGCs stimulated to an active 
growth state following optic nerve injury. Fluorescent micrographs on optic nerve 
sections stained for CTβ six week following a single intraocular injection of AAV 
C4RIP-V5 and two weeks following optic nerve injury. RGCs were stimulated to an 
active growth state through a lens injury performed immediately after the optic nerve 
injury. Regenerating fibers were anterogradely labeled with a single injection of CTβ one 
day before collection of the optic nerve. CTβ-positive RGC axons are seen proximal (p) 
and distal (d) to the lesion site (white line) in both AAV GFP and AAV C4RIP-V5 
groups. Bar, 100 µm. (B) Quantitative analysis of axon regeneration following lens injury 
and injection of AAV GFP (black bar) or AAV C4RIP-V5 (grey bar). CTβ-positive 
axons were counted at 100 µm, 250 µm, 500 µm, 750 µm and 1000 µm from the lesion 
site and were divided by the optic nerve width. At least four optic nerve sections were 
counted per animal. AAV C4RIP-V5 did not promote axon regeneration in RGCs 
stimulated to an active growth state compared to AAV GFP (n=4, two-way ANOVA, 
Bonferroni post hoc test, non-significant= p>0.05).  
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Chapter 3 - Figure 7. AAV-mediated transgene expression of C4RIP-V5 in retinal 
ganglion cells may not be expressed to sufficient levels to antagonize RhoA-L-
CRMP4 interactions. 
Immunoblot on retinal lysates from 3 separate rats four weeks following a single 
intraocular injection of AAV C4RIP-V5. C4RIP-V5 is detected only in immunoblots that 
undergo high exposures, while endogenous L-CRMP4 is detected under low exposures.       
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4 THE DEVELOPMENT OF TAT-C4RIP, A CELL PERMEABLE RhoA-L-
CRMP4 COMPETITIVE ANTAGONIST  
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4.1 PREFACE 
 In Chapter 3, we demonstrate that AAV-mediated expression of C4RIP does not 
promote retinal RGC neuronal survival or axon regeneration following optic nerve injury 
in the adult rat. However, C4RIP expression levels may not have been sufficient to 
antagonize the RhoA-L-CRMP4 interaction, thereby having no effect on axon 
regeneration. The aim of this study was to develop a recombinant cell permeable TAT 
C4RIP protein and to evaluate its ability to promote RGC axon regeneration following 
optic nerve injury in the adult rat.   
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4.2 ABSTRACT 
 The ability of the trans-acting activator of transcription (TAT) protein 
transduction domain (PTD) to transport macromolecules across biological membranes 
raises the possibility of developing it as a therapeutic delivery tool. Most studies have 
produced TAT PTD fusion protein in bacteria, which can result in problems such as 
protein solubility, the formation of inclusion bodies and the lack of eukaryotic post-
translational modifications. While some groups have investigated the production of TAT 
PTD fusion protein in mammalian cells, these strategies are focused on generating TAT 
PTD fusions that are targeted to the secretory pathway, where furin protease can cleave 
the TAT PTD. As an alternative to mutating the furin cleavage site in the TAT PTD, 
which can alter its transduction property, we have developed a novel method to generate 
cytosolic TAT PTD fusion proteins and purify them from cell lysates. Here, we use this 
method to generate TAT C4RIP, a cell permeable RhoA- L-CRMP4 competitive 
antagonist and validate its ability to transduce cells in vitro and in vivo. We demonstrate 
that this method generates TAT C4RIP that retains its functional ability to antagonizes 
RhoA-L-CRMP4 interactions and attenuate myelin inhibition in DRGs in vitro. However, 
the application of TAT C4RIP in vivo did not promote retinal ganglion cell axon 
regeneration following optic nerve injury possibly due to poor distribution of TAT 
C4RIP. In this study we have developed a novel purification strategy to generate and 
purify functional TAT PTD fusion proteins from mammalian cell lysates. Future studies 
should focus on optimizing the delivery and distribution of TAT PTD fusion proteins for 
therapeutic applications.   
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4.3 INTRODUCTION 
 The use of viruses as delivery vehicles for gene transfer has been shown to be a very 
efficient strategy to correct inherited diseases but its therapeutic use has been quite 
limited due to the risks of insertional mutagenesis and uncontrolled cellular proliferation 
(Hacein-Bey-Abina, von Kalle et al. 2003; Hacein-Bey-Abina, Von Kalle et al. 2003). The 
discovery that the trans-acting activator of transcription (TAT) protein of HIV-1 was 
able to cross cellular membranes and that chemically coupling TAT to proteins conferred 
transduction properties raised the possibility of utilizing TAT as a therapeutic delivery 
tool for macromolecules (Frankel and Pabo 1988; Green and Loewenstein 1988; Fawell, 
Seery et al. 1994). Furthermore, TAT is able to cross the blood-brain barrier in vivo, 
which would allow therapeutic proteins coupled or fused to TAT to target the brain 
(Schwarze, Ho et al. 1999). 
 The TAT protein transduction domain (PTD) allows proteins and peptides to cross 
biological membranes and enter the cytosolic compartment of a cell. The mechanism by 
which TAT fusion proteins cross cellular membranes was originally believed to occur in 
a receptor-, transporter- and endocytic-independent manner. This was largely due to the 
observation that TAT fusion proteins could still cross cellular membranes in a 
concentration-dependent manner at low temperatures, where all known mechanisms of 
entry are inhibited (Vivès, Brodin et al. 1997). However, these reports have been largely 
dismissed as artifactual and it is currently believed that transduction of TAT fusion 
proteins through cellular membranes occurs through macropinocytosis, a specialized 
form of endocytosis (Gump and Dowdy 2007).  
 The efficacy of various proteins fused to or linked to the TAT PTD produced in 
bacteria has been demonstrated in various cell types in vitro and in vivo (Nagahara, 
Vocero-Akbani et al. 1998; Schwarze, Ho et al. 1999). However, bacterial production of 
TAT fusion proteins results in several problems that may limit its translation into 
therapeutic agents such as protein insolubility, formation of inclusion bodies and the lack 
of eukaryotic post-translational modifications (Beerens, Al Hadithy et al. 2003; 
Flinterman, Farzaneh et al. 2009). Although many studies have investigated the 
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transduction properties of bacterially produced TAT PTD fusion proteins, only a few 
studies have investigated the ability to produce TAT fused proteins using mammalian 
expression vectors (Yang, Ma et al. 2002; Barka, Gresik et al. 2004; Flinterman, 
Farzaneh et al. 2009). This is largely because TAT PTD contains multiple arginine and 
lysine residues, which some endoproteases recognize as a target substrate. The TAT PTD 
contains the sequence R-Q-R-R, which is a furin cleavage site (R-X-R/K-R), and since 
furin is found largely in the trans-Golgi network, TAT fusion proteins directed to the 
secretory pathway are most likely cleaved by furin as they transition through the 
endoplasmic reticulum and Golgi apparatus (Beerens, Al Hadithy et al. 2003). One 
strategy to circumvent furin-mediated cleavage of TAT PTD has been to mutate the two 
furin cleavage sites found in the TAT PTD sequence (Flinterman, Farzaneh et al. 2009). 
This modified TAT sequence, TATκ, is no longer cleaved by furin and is highly secreted 
into the media (Flinterman, Farzaneh et al. 2009). This strategy is designed for the 
continuous in vivo secretion of TAT fusion proteins, since direct delivery of recombinant 
TAT fusion proteins may be quickly degraded by proteases and eliminated by renal 
filtration, thereby requiring multiple applications (Torchilin and Lukyanov 2003; 
Flinterman, Farzaneh et al. 2009). However, the need to transplant modified TAT fusion 
protein secreting cells into humans may limit its role as a therapeutic agent.  
 In this study, we describe a novel strategy to generate and purify TAT fusion 
proteins from mammalian cells for therapeutic application. To circumvent furin-mediated 
cleavage of TAT fusion proteins targeted to the secretory pathway, we target TAT fusion 
proteins to the cytosolic compartment of mammalian cells and purify it directly from cell 
lysates. As an example of our purification strategy, we focus on the biological property of 
C4RIP (CRMP4b-RhoA Inhibitory Peptide) to attenuate myelin-dependent neurite 
outgrowth inhibition in rat DRG neurons. We demonstrate that purified TAT C4RIP can 
transduce cells in vitro and in vivo. Importantly, our purified TAT C4RIP retains its 
ability to attenuate myelin inhibition in DRG neurons in vitro. We also evaluate the 
therapeutic potential of TAT C4RIP to promote CNS nerve regeneration in a preclinical 
adult rat optic nerve injury model. 
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4.4 MATERIALS AND METHODS 
4.4.1 Plasmids  
 Monomeric red fluorescent protein (mRFP) was PCR amplified from pHSV 
mRFP-actin using the primers: 5’GGGGGATCCGATGGCCTCCTCCGAGGA3’ and 
5’GGGAAGCTTGGCGCCGGTGGAGTG3’. C4RIP was PCR amplified from pcDNA 
C4RIP-V5 using the primers: 5’GGGGGGATCCGGCTTGAACCATGGCTTCGGGC3’ 
and 5’GGGGAAGCTTCTACTTGTCCTTGGGACC3’. mRFP or C4RIP were inserted 
into the BamHI and HindIII sites of the vector pET 28b TAT v2 (generously provided by 
Steve Dowdy, UCSD). TAT C4RIP and TAT mRFP were PCR amplified using the 
primers 5’GGGGACAAGTTTGTACAAAAAAGCAGGCTGGGGCAGGAAGAAGCG 
GAGA3’ and 5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTGGTGGTG 
GTGGTG3’ and were cloned into the vector pDONR221 by BP recombination, and then 
cloned into a modified pYD5 vector + cassette A compatible for Gateway cloning by LR 
recombination (Invitrogen). To generate cytosolic TAT fusion proteins, TAT mRFP and 
TAT C4RIP were PCR amplified from the modified pYD5 vector and inserted into the 
vector pTT5. 
4.4.2 Purification of cytosolic TAT proteins 
 pTT5-TAT mRFP or pTT5-TAT C4RIP were transfected with polyethylenimine 
in serum-free medium into suspension growing chinese hamster ovary (CHO) cells. 
Transfected CHO cells were lysed in lysis buffer (50mM HEPES pH-7.4, 150 mM NaCl). 
Lysates were sonicated and centrifuged for 20 minutes at 10, 000 rpm. Supernatants were 
collected at filtered with through a 0.45 µm filter unit. TAT fusion proteins were purified 
on a Fractogel cobalt column (EMD Bioscience). The Fractogel cobalt column was 
charged with 5 column volumes of 0.5 M NaCl, followed by 4 column volumes of 200 
mM cobalt chloride and 2 column volumes of 0.5 NaCl pH=5±0.2. The Fractogel cobalt 
column was equilibrated with 10 column volumes of phosphate-buffered saline (PBS). 
The TAT fusion protein supernatant was applied to the equilibrated column and allowed 
to flow through by gravity. The flow through was kept for future analysis of the 
purification efficiency. The Fractogel cobalt column was washed with 10 column 
volumes of wash buffer #1 (50 mM sodium phosphate pH=7, 300 mM NaCl), followed 
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by 10 column volumes of wash buffer #2 (50 mM sodium phosphate pH=7, 300 mM 
NaCl, 25 mM imidazole). TAT fusion protein was eluted in elution buffer (50 mM 
sodium phosphate pH=7, 300 mM NaCl, 300 mM imidazole). 1 ml elution fractions were 
collected and Bradford protein assay was performed of the fractions. Fractions that 
contained the TAT fusion protein were pooled and desalted using a desalting column 
(Bio-Rad). The desalting columns were first equilibrated in PBS-300 mM NaCl, after 
which the 3 ml pooled fraction containing the TAT fusion protein was applied to the 
column. The flow through was collected and an additional 4 mls of PBS-300 mM NaCl 
was applied to the desalting column and pooled with the flow through. Final protein 
concentrations were measured at 280 nm using Nanodrop (Thermo Scientific). TAT 
fusion proteins were aliquoted and kept at -80 °C.    
4.4.3 Immunoblot 
 Cell lysates were separated on an sodium dodecyl sulfate (SDS) – poly 
acrylamide gel (PAGE) gel and transferred to a polyvinylidene fluoride membrane and 
blocked in 5% milk in tris-buffered saline and 0.1% Tween-20 (TBST). Primary and 
secondary antibodies were diluted in 5% milk TBST. Secondary antibody used was anti-
rabbit antibody linked to horse radish peroxidase (HRP). Protein signal was detected used 
a chemiluminescence reagent (ECL, Amersham Biosciences). 
4.4.4 In vitro cell permeability assay 
 HeLa cells (ATCC; catalogue number CCL-2) were grown in DMEM (Invitrogen, 
Burlington, Ontario) supplemented with 10% FBS (HyClone, Logan, UT) and were 
maintained in 5% CO2 at 37 °C. HeLa cells were grown on 35 mm glass bottom dishes 
(MatTek Corp, Ashland, MA). TAT mRFP or TAT C4RIP were added to the culture 
medium to a final concentration of 100 µg/ml and incubated between 1 hour and 24 hours 
before processing for immunocytochemistry or live imaging. For immunocytochemistry, 
HeLa cells were washed with phosphate-buffered saline (PBS), followed by an acid wash 
(0.2 M acetic acid pH=2.8, 0.5 M NaCl) for 2 minutes, washed again with PBS, and fixed 
with 4% paraformaldehyde (PFA) in PBS, and stained for T7, filamentous (F) -actin and 
DNA. F-actin was visualized using phalloidin-488 (Invitrogen) while DNA was 
visualized using Hoechst 33342 (Invitrogen). In some cases, the mRFP signal was not 
 155 
amplified with an antibody. Cover slips were mounted using Fluoromount-G (Southern 
Biotech, Birmingham, AL). For live time-lapse microscopy, HeLa cells were washed 
with OptiMEM (Invitrogen) to remove any TAT mRFP in the media, and then incubated 
in OptiMEM. Microscopy was performed on Zeiss Axiovert 200 using a 100X objective 
equipped with an automated stage and an environmental control chamber, which 
maintained the cells at 37˚C and 5% CO2. 
4.4.5 Rat dorsal root ganglion neurite outgrowth assay 
 Dissociated postnatal day 5 (P5) rat DRG neurons were cultured in DRG medium 
(Neurobasal medium (Invitrogen), 2% B27, 1% penicillin/streptomycin, 1% L-glutamine, 
50 ng/ml NGF) in the presence of either PBS-300 mM NaCl, TAT mRFP or TAT C4RIP 
diluted in a 10X supplement stock (20% B27, 10% penicillin/streptomycin, 10% L-
glutamine, 500 ng/ml NGF) on 0.01% poly-L-lysine and 1µg/ml laminin-coated 
substrates. Rat DRG neurons were grown for approximately 16 hours, fixed in 4% PFA / 
20% sucrose in PBS, and stained with anti-βIII tubulin antibody (Covance). Neurite 
outgrowth length and the number of neurons were analyzed with the neurite outgrowth 
and multi-wavelength scoring modules of MetaXpress, respectively. Neurite outgrowth 
per neuron was calculated by dividing the total neurite outgrowth per condition by the 
total number of neurons. 
4.4.6 Intraocular Injection 
 All animal procedures followed guidelines from the Canadian Council of Animal 
Care. Surgeries were performed on female Sprague-Dawley rats (180g-200g) under general 
gas anesthesia (2-3% isofluorane mixed in oxygen, 0.8 L/min). The conjunctiva was 
dissected away until the sclera was reached. A small puncture wound was made in the 
superior temporal quadrant through the sclera just temporal to the episcleral vein using a 
30-gauge needle. In cases where a second intraocular injection was performed, a second 
small puncture wound was made in the superior nasal quadrant through the sclera just 
nasal to the episcleral vein using a 30-gauge needle. Intraocular injections of the TAT 
proteins (5 µl) into the vitreous space of the left eye were performed using a fine glass 
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tube attached to a 10 µl-Hamilton syringe. The tip of the needle was inserted through the 
small puncture wound in the sclera at a 45º angle, with the tip of the needle pointed 
towards the optic nerve head. This route of administration avoided injury to the lens and 
iris, which have been shown to promote RGC survival and regeneration (Leon, Yin et al. 
2000). The injection was performed over 1 minute, after which the needle was held in 
place for approximately 2 minutes before slowly removing the needle. The puncture 
wound was sealed with surgical glue (Indermill, Tyco Health Care, Montreal, Quebec). 
All subsequent intraocular injections were performed through these two initial injection 
sites.  
4.4.7 Forcep Crush Injury and Immnohistochemistry  
 The lacrymal glands and extra-ocular muscles were resected to expose the optic 
nerve. The epineurium was cut along the long axis of the optic nerve, and the optic nerve 
was crushed approximately 2 mm from the back of the eye with an angled jeweler’s 
forcep (Dumont #5) for 10 seconds. Optic nerve injury was visualized by the clearance of 
the crush site and the retinal vascular integrity was evaluated by fundoscopic examination. 
Rats with impaired vascular integrity were excluded from the study. In cases where a 
Gelfoam sponge (Pfizer) was used to deliver the TAT proteins, a small piece of Gelfoam 
measuring approximately 1mm X 1mm X 4mm was cut and soaked in 15 µg of TAT 
protein. Immediately after the optic nerve injury, the soaked Gelfoam sponge was applied 
directly to the lesion site, where it was wrapped entirely around the optic nerve and kept 
in place for the remaining two weeks. Thirteen days later, an intraocular injection of 5 µl 
of 1% cholera toxin beta-subunit (CTβ) (Sigma, Oakville, ON) in PBS through the same 
puncture wound was performed to anterogradely label regenerating axons. 24 hours later, 
rats were intracardially perfused with 4% PFA 0.1 M PB and their left eye and optic 
nerve was removed. The anterior part of the eye and the lens were dissected away, and 
the eye cup and optic nerve were fixed for an additional 2 hours at 4 ºC. The eye cup and 
optic nerve were cyroprotected in 30 % sucrose in PBS overnight at 4 ºC, and embedded 
in OCT (optimal cutting temperature) compound (Tissue-Tek, Miles Laboratories, 
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Elkhart, IN) and frozen in 2-methylbutane on dry ice. Cryosections (14 µm for optic 
nerves and 16 µm for retinas) were collected on Superfrost slides (Fischer Scientific) and 
processed for immunohistochemistry. Sections were post-fixed for 15 minutes in 4% 
PFA, followed by blocking in blocking solution (5% bovine serum albumin (BSA), 0.3% 
Triton-X100 (Sigma), in PBS) for 1 hour at room temperature. Primary antibodies were 
diluted in blocking solution and incubated overnight at 4ºC. The following primary 
antibodies were used: goat CTβ (List Biological Laboratories), mouse βIII tubulin 
(Covance), mouse T7 tag (Novagen). Secondary antibodies were diluted in blocking 
solution and incubated 1 hour at room temperature. Secondary antibodies used were: 
rabbit anti-goat biotin; anti-mouse-FITC, Alexa-568; anti-rabbit-FITC, Alexa-568 
(Invitrogen). Streptavidin-FITC and Alexa-568 (Invitrogen) were also used to amplify the 
biotin signal.  
4.4.8 Analysis of RGC axon regeneration 
 Axon regeneration was analyzed by counting the number of CTβ-positive axons 
that crossed a virtual line parallel to the lesion site. The lesion site was identified by 
differential interference contrast microscopy. CTβ-positive axons were counted at 
distances of 100 µm and 500 µm from the lesion site in at least four sections per animal 
from 3 animals per condition. Data analysis was performed using Prism by two-way 
ANOVA followed by Bonferroni post hoc test. 
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4.5 RESULTS 
4.5.1 Purification of cytosolic TAT fusion proteins from mammalian cell lysates 
 We initially generated bacterial pET 28b TAT v2 vectors expressing C4RIP or a 
control mRFP. These vectors contain an N-terminal TAT sequence (RKKRRQRRR) 
followed by a T7 epitope tag, our in-frame fusion protein (C4RIP or mRFP) and C-
terminal 6-histidine sequence. We collected and purified the secreted TAT fusion 
proteins from conditioned media and observed that this purification resulted in furin-
mediated cleavage within the TAT sequence. To circumvent furin-mediated cleavage of 
the TAT sequence, we generated a mammalian expression vector pTT5 that contained the 
cDNA for either TAT mRFP or TAT C4RIP. Importantly, this vector did not contain a 
signal sequence; thereby TAT fusion proteins were targeted to the cytosol and not to the 
secretory pathway. We transfected pTT5 TAT C4RIP or pTT5 mRFP into chinese 
hamster ovary (CHO) cells and collected the lysates two days post transfection. We 
purified TAT C4RIP and TAT mRFP over a Fractogel cobalt column and collected the 
purified protein. We analyzed fractions collected through out the purification by 
Coomassie stain and immunoblot with an anti-histidine (His) antibody (Fig. 1A,B). 
Purification of TAT C4RIP and TAT mRFP using this method resulted in an enrichment 
of full length TAT fusion proteins from CHO cell lysates. 
4.5.2 TAT mRFP crosses biological cell membrane 
 We investigated the ability of purified TAT mRFP to cross biological membranes 
by incubating HeLa cells with 100 µg/ml TAT mRFP for 24 hours. Before we fixed the 
cells, we performed a stringent acid wash to disrupt any non-specific or ionic interactions 
with the extracellular membrane. We labeled intracellular filamentous (F) -actin with a 
fluorescently tagged phalloidin. We observed a strong mRFP signal inside HeLa cells 
treated with TAT mRFP that gave a vesicular-like pattern, while no signal was seen in 
control PBS-300 mM NaCl treated HeLa cells (Fig. 2A). We also observed a strong 
nuclear localization of TAT mRFP that seemed to form large aggregates. This is 
consistent with previous studies that demonstrate a change in localization of TAT 
proteins following fixation (Richard, Melikov et al. 2003). This has been attributed to the 
affinity of the positively charged amino acids of TAT to negatively charged DNA. 
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Therefore, to investigate the localization pattern and to confirm the internalization of 
TAT mRFP in HeLa cells, we performed live time-lapse microscopy. TAT mRFP was 
seen diffusely distributed through out the cytoplasm but was strongly localized to vesicles 
within HeLa cells (Fig. 2B). In contrast to fixed HeLa cells, we did not observe the strong 
nuclear localization of TAT mRFP in live HeLa cells. We also observed TAT mRFP 
transduction into HeLa cells as early as 15 minutes following its application. To 
investigate the ability of purified TAT C4RIP to cross biological membranes, we 
incubated HeLa cells with 100 µg/ml TAT C4RIP for 3 hours, acid washed the cells and 
immunostained with a T7 antibody. Both TAT mRFP and TAT C4RIP contained a T7 
epitope. Similar to the pattern we observed with TAT mRFP, TAT C4RIP localized to 
vesicles and also formed large aggregates (Fig. 2C). Based on the differences in 
localization pattern of TAT mRFP in fixed and live HeLa cells, we believe this 
distribution pattern is due to fixation. However, the absence of a fluorescent tag in TAT 
C4RIP precluded us from confirming this. Together, these observations demonstrate that 
purified TAT mRFP and TAT C4RIP from HeLa cell lysates contain protein transduction 
properties in vitro.    
4.5.3 TAT C4RIP attenuates myelin inhibition 
 We have previously demonstrated that antagonizing RhoA-L-CRMP4 interactions 
through herpes simplex virus (HSV)-mediated C4RIP expression in DRGs attenuates 
myelin inhibition (Alabed, Pool et al. 2007). To determine if our purified TAT C4RIP 
retained the same functional property of attenuating myelin inhibition in DRG neurons, 
we performed a neurite outgrowth assay in rat DRG neurons. The application of 50 µg/ml 
TAT C4RIP, but not TAT mRFP, to DRG neurons resulted in the attenuation of myelin 
inhibition (Fig. 3A,B). These results confirm that our purified TAT C4RIP promotes 
neurite outgrowth on myelin in vitro. 
4.5.4 TAT mRFP and TAT C4RIP transduce retinal ganglion cells in vivo 
 To investigate if TAT mRFP and TAT C4RIP were capable of transducing cells 
in vivo, we performed an single intraocular injection of either protein into the adult rat 
vitreous space and collected the retinas either 3 hours or 24 hours post-injection. To 
visualize where the TAT proteins localized within the retina, we immunostained retinal 
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sections with the T7 antibody and βIII tubulin to label neurons (Fig. 3). Both TAT mRFP 
and TAT C4RIP strongly localized within RGCs at 3 hours and 24 hours post-injection 
(Fig. 3). TAT mRFP and TAT C4RIP localization was also observed with the inner 
plexiform layer and the inner nuclear layer. Together, these observations demonstrate that 
purified TAT mRFP and TAT C4RIP contain protein transduction properties in vivo. 
 We assessed the distribution of TAT mRFP in the retina 24 hours post-injection 
through T7 and βIII tubulin immunostained retina flatmounts (Fig. 4A). A single 
intraocular injection of TAT mRFP performed in the superior temporal quadrant of the 
retina resulted in a limited distribution of TAT mRFP to that quadrant (Fig. 4A, top 
panel). Furthermore, two separate intraocular injections of TAT mRFP performed in the 
superior temporal and superior nasal quadrants resulted in a greater distribution of TAT 
mRFP but still did not transduce all RGCs in the retina (Fig. 4B, bottom panel). 
 We attempted to deliver TAT mRFP directly to the injured RGC axons by 
soaking a Gelfoam sponge with TAT mRFP and applying it at the optic nerve lesion site. 
Gelfoam delivery of C3-transferase, a potent RhoA inhibitor, at the optic nerve lesion site 
has been shown to be an effective strategy to deliver and promote RGC axon regeneration 
following optic nerve injury (Lehmann, Fournier et al. 1999). 24 hours after application, 
we assessed TAT mRFP penetration through immunohistochemistry on optic nerve 
sections cut along the long axis. We observed that TAT mRFP localized mainly to the 
periphery of the optic nerve and penetrated very poorly into the central region (Fig. 4B).  
4.5.5 TAT C4RIP does not promote axon regeneration in retinal ganglion cells 
following optic nerve injury 
 Based on the distribution patterns previously described, we investigated the 
ability of intraocular injected TAT C4RIP to promote RGC axon regeneration following 
optic nerve injury. We performed two separate intraocular injections of TAT C4RIP in 
the superior temporal and superior nasal quadrants immediately following optic nerve 
injury and five days post-optic nerve injury. This delivery strategy was based on a 
previous study that demonstrated enhanced RGC survival and regeneration following the 
repeated delivery of cell-permeable C3-like Rho antagonists (Bertrand, Di Polo et al. 
2007). We assessed RGC axon regeneration through a single intraocular injection of 
cholera toxin beta-subunit (CTβ), which gets transported anterogradely down RGC 
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axons, followed by immunohistochemistry analysis of CTβ localization in optic nerve 
sections. Many CTβ-positive axons were observed proximal to the lesion site in TAT 
mRFP and TAT C4RIP injected animals (Fig. 6A). While a few CTβ-axons were seen 
distal to the lesion site, TAT C4RIP did not promote RGC axon regeneration compared to 
TAT mRFP (Fig. 6A, B). 
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4.6 DISCUSSION 
 Here we described a novel method to generate and purify TAT fusion proteins 
targeted to the cytosolic compartment of mammalian cells. These TAT fusion proteins do 
not enter the secretory pathway where they are cleaved by furin proteases. Mammalian 
expression allows for the production of TAT fusion proteins that possess relevant post-
translational modifications. We demonstrate that TAT fusion proteins generated using 
this novel method are capable of transducing cells in vitro and in vivo. We validate this 
method of generating cytosolic TAT fusion proteins with TAT C4RIP, a competitive 
RhoA-L-CRMP4 antagonist, and a control TAT mRFP protein. Our data indicates that 
TAT C4RIP and TAT mRFP transduce HeLa cells in vitro and adult RGCs in vivo. 
Importantly, we demonstrate that TAT C4RIP retains its functional ability to attenuate 
myelin inhibition in rat DRG neurons in vitro. We propose that the large-scale production 
of TAT fusion proteins using this novel method results in functional proteins that can be 
potentially used for various therapeutic applications.  
4.6.1 TAT C4RIP attenuates myelin inhibition in vitro but not in vivo 
 We confirmed that our purified TAT C4RIP retained its biological properties by 
demonstrating that TAT C4RIP attenuates myelin inhibition in DRGs in vitro as 
previously described with HSV-mediated expression of C4RIP (Alabed, Pool et al. 2007). 
However, the intraocular injection of TAT C4RIP did not promote RGC axon 
regeneration following optic nerve injury in vivo. The inability of TAT C4RIP to promote 
regeneration in this injury model can be attributed to various reasons. Our in vitro data 
suggests that in order for TAT C4RIP to act as a competitive antagonist, TAT C4RIP 
levels must be in molar excess of endogenous L-CRMP4 levels. Although we have 
attempted to increase TAT C4RIP levels through four separate intraocular injections, we 
have not confirmed if the TAT C4RIP levels reached in RGCs are sufficient to antagonize 
the RhoA-L-CRMP4 interaction. Indeed, the restricted distribution of TAT mRFP to 
areas surrounding the injection sites suggests that TAT mRFP is not well distributed 
throughout the retina.  
 We have also attempted in vitro outgrowth experiments with dissociated postnatal  
day 8 retinal culture but have encounter some difficulties achieving reproducible growth 
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with either TAT mRFP or TAT C4RIP on myelin. We are currently troubleshooting 
these experiments.   
4.6.2 TAT PTD fusion proteins as therapeutic agents 
 The ability of TAT PTD, and other CPPs, to ferry macromolecules through 
biological membranes has led to many studies investigating its application to treat various 
diseases such as cancer, ischemic stroke and neurodegenerative diseases. One strategy 
has been to use a TAT PTD fused to a single double-stranded RNA binding domain to 
mask the negative charge of nucleic acids (such as small interfering RNA) and transport 
them across the cellular membrane (Meade and Dowdy 2007; Meade and Dowdy 2009). 
Other strategies use TAT PTD fused to full length proteins or TAT PTD conjugated to 
peptides to treat diseases. For example, the use of TAT-survivin in adjuvant therapy for 
glioma is currently being investigated in preclinical animal models (Kim, Woo et al. 
2007). The TAT PTD conjugated to a selective activator peptide of ε-protein kinase C 
(PKC) confers sustained cardioprotection against ischemia-reperfusion in mice hearts 
(Inagaki, Begley et al. 2005), while TAT PTD conjugated to a specific inhibitor of δ-
PKC improves microvasculature and cerebral blood flow following acute focal ischemia 
in rats (Bright, Steinberg et al. 2007). Overall, these studies demonstrate that strategies 
utilizing TAT PTD as a delivery vehicle for therapeutic agents are effective. However, 
there are still some issues that need to be addressed before translating these therapies into 
humans. Most of these preclinical studies have been performed using TAT PTD fusion 
proteins produced in large quantities in bacteria. While adequate purification techniques 
can eliminate significant endotoxin levels in the final preparation, proteins produced in 
bacteria lack the post-translational modifications that they normally undergo in 
mammalian cells. This may result in different biological properties associated with each 
form of the protein. For example, in one study, they observed that the application of 
TAT- green fluorescent protein (GFP) produced in bacteria resulted in a cytosolic 
distribution when incubated with mammalian cells in vitro, whereas mammalian-
expressed TAT-GFP localized mainly to the nucleus (Yang, Ma et al. 2002). These 
differences in localization patterns demonstrate that TAT fusion protein produced in 
bacteria or in mammalian cells are not equivalent. While some mammalian expression 
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vectors have been used for the production of TAT PTD fusion proteins, these have all 
directed the TAT fusion proteins to the secretory pathway where they are likely cleaved 
by furin proteases (Beerens, Al Hadithy et al. 2003; Flinterman, Farzaneh et al. 2009). 
Modification of the furin cleavage site located in the TAT PTD circumvents this furin-
mediated cleavage event but can alter its transduction property. Here, we propose an 
alternative approach to circumvent furin-mediated cleavage of TAT PTD fusion proteins 
in the secretory pathway that does not require the mutation of the TAT PTD but still 
allows eukaryotic post-translational modifications to occur. Furthermore, this strategy 
allows for proteins that localize to the cytosol access to other modifying proteins that it 
would normally interact with in that compartment. In contrast, TAT PTD fusion 
proteins targeted for the secretory pathway may not have access to these interacting 
proteins. In this study, we purify TAT C4RIP, a RhoA-L-CRMP4 competitive 
antagonist using this novel method. Both RhoA and L-CRMP4 are normally found in the 
cytosol, therefore targeting TAT C4RIP to the cytosolic compartment allows for relevant 
post-translational modifications to occur.  
4.6.3 Potential limitations of TAT PTD fusion proteins 
 While there is certainly a lot of promise for TAT PTD fusion proteins as 
therapeutic agents, there are also some potential limitations. The highly charged nature of 
the TAT PTD and its high affinity for glycosaminoglycans might result in the 
extracellular matrix, which is rich in glycosaminoglycans, binding and sequestering all of 
the TAT PTD fusion protein (Beerens, Al Hadithy et al. 2003). Indeed, in our study we 
observe the limited distribution of TAT mRFP within the retina following either a single 
or double intraocular injection. Future studies should investigate strategies to circumvent 
this limitation. Further, TAT PTD fusion may also be rapidly degrade by extracellular 
proteases depending on the amino acid sequence of the fusion protein. This would result 
in the need for multiple applications of the TAT PTD fusion protein, although the 
implantation of irradiated mammalian cells that continuously secrete the TAT PTD 
fusion protein has been proposed as an alternative (Flinterman, Farzaneh et al. 2009). 
Finally, the major obstacle to overcome in the development of TAT PTD as therapeutic 
agents is the same property that makes it so attractive: lack of specificity. The presence of 
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glycosaminoglycans on all cell surfaces results in the non-specific transduction of all 
cells with the TAT PTD fusion protein, whether they are diseased or healthy. This may 
lead to unwanted side effects depending on the biological property of the fusion protein. 
Overall we believe that there are many advantages to using TAT PTD fusion proteins as 
therapeutic agents but that certain issues exists that must be addressed before translating 
them into humans. We believe that purification of cytosolic TAT PTD fusion proteins 
from mammalian cell lysates addresses one of these issues.  
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Chapter 4 - Figure 1. Purification of cytosolic TAT C4RIP and TAT mRFP from 
CHO cell lysates. 
pTT5-TAT C4RIP (A) or pTT5-TAT mRFP (B) were transfected into CHO cells and cell 
lysates were collected two days post-transfection. TAT fusion proteins were purified on a 
Fractogel cobalt column and the flow through was kept for analysis. The Fractogel cobalt 
column was washed with 10 column volumes of wash buffer #1 (50 mM sodium 
phosphate pH=7, 300 mM NaCl), followed by 10 column volumes of wash buffer #2 (50 
mM sodium phosphate pH=7, 300 mM NaCl, 25 mM imidazole). TAT fusion protein 
was eluted in elution buffer (50 mM sodium phosphate pH=7, 300 mM NaCl, 300 mM 
imidazole) and fractions that contained the TAT fusion protein were pooled and desalted 
using a desalting column. Collected fractions were run on a SDS-polyacrylamide gel and 
Coomassie stained or immunoblotted with an anti-histidine antibody.  
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Chapter 4 - Figure 2. Intracellular generated TAT mRFP crosses biological cell 
membranes. 
(A) HeLa cells were incubated with 100 µg/ml TAT mRFP (top panels) or equivalent 
volume of PBS-300 mM NaCl (bottom panels) for 24 hours before acid wash to remove 
proteins that were non-specifically bound to the extracellular plasma membrane, and 
subsequent fixation and staining with phalloidin-Alexa 488. Bar, 10 µm. (B) Fluorescent 
micrographs from time-lapse microscopy performed on HeLa cells incubated with 100 
µg/ml TAT mRFP for 3 hours, washed three times with media, and incubated in 
OptiMEM. TAT mRFP localizes to small vesicles, which are seen moving through out 
the cell (arrow). There is also a more diffuse cytosolic distribution of TAT mRFP 
observed through out the cell. t= time, s=seconds. Bar, 10 µm. (C) Fluorescent 
micrographs of HeLa cells incubated with either PBS-300 mM NaCl (top panel), 100 
µg/ml TAT mRFP (middle panel) or 100 µg/ml TAT C4RIP (bottom panel) for 3 hours, 
acid washed and stained for T7 and DNA. mRFP signal was visualized without any 
amplification of the fluorescent signal.  
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Chapter 4 - Figure 3. TAT C4RIP attenuates myelin inhibition. 
(A) Representative fluorescent micrographs of βIII tubulin stained dissociated rat dorsal 
ganglion neurons treated with either PBS-300 mM NaCl, TAT mRFP (50 µg/mL), or 
TAT C4RIP (50 µg/mL), and plated on a control substrate or myelin. Bar, 100 µm. (B) 
TAT C4RIP attenuates myelin inhibition. Outgrowth per neuron was determined by 
measuring the total outgrowth per well divided by the total number of neurons per well. 
For each experiment, values from duplicate wells were averaged and normalized to 
outgrowth on 0 µg of myelin (n=3, two-way ANOVA, ***p<0.001).  
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Chapter 4 - Figure 4. Intracellular generated TAT proteins transduce adult rat 
retinal ganglion cells in vivo. 
Fluorescent micrographs from retinal sections injected with 4 µg of either TAT mRFP or 
TAT C4RIP. Retinal sections were stained for T7, βIII tubulin and DNA. Both TAT 
mRFP and TAT C4RIP proteins can transduce into retinal ganglion cells as early as 3 
hours post-injection, and is detected 24 hours post-injection. No T7 signal is observed in 
the non-injected control retina (top panel). NF= nerve fiber layer, RGC= retinal ganglion 
cell layer, IPL= inner plexiform layer, INL= inner nuclear layer, OPL= outer plexiform 
layer, ONL= outer nuclear layer, OS= outer segment. Bar, 100 µm. 
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Chapter 4 - Figure 5. Optimizing the delivery method of TAT proteins to promote 
retinal ganglion cell axon regeneration. 
(A) Fluorescent micrographs of retinal flatmounts stained for T7 and βIII tubulin 24 
hours following either a single temporal injection of 4 µg of TAT mRFP (top panel) or 
single injections performed at two different locations in the sclera (nasal and temporal) of 
4 µg of TAT mRFP (bottom panel). Two injections result in a greater distribution of TAT 
mRFP within the retina. Bar, 1000 µm. (B) Fluorescent micrographs of optic nerve 
sections stained for T7 and βIII tubulin 24 hours following the sustained delivery of TAT 
mRFP directly to the lesion site with Gelfoam. Gelfoam delivery of TAT mRFP results is 
very poor distribution of TAT mRFP through out the lesion site. The strongest TAT 
mRFP signal is seen at the periphery of the optic nerve (arrow). Bar, 100 µm.  
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Chapter 4 - Figure 6. TAT C4RIP does not promote axon regeneration in retinal 
ganglion cells following optic nerve injury. 
(A) Fluorescent micrographs from optic nerve sections stained for CTβ two weeks 
following optic nerve injury and intraocular injections with 4 µg of either TAT mRFP or 
TAT C4RIP. Single injections at two different locations in the sclera (nasal and temporal) 
of 4 µg of TAT mRFP (top panel) or TAT C4RIP (bottom panel) were performed at the 
time of optic nerve injury and 5 days post-injury. In both groups, CTβ-positive axons are 
seen in the optic nerve proximal (p) to the lesion site (*), while very few are seen distal 
(d) to the lesion site. Bar, 100 µm. (B) Quantitative analysis of axon regeneration 
following intraocular injections of either TAT mRFP (black bars) or TAT C4RIP (grey 
bars). CTβ-positive axons were counted at 100 µm and 500 µm from the lesion site. At 
least four optic nerve sections were counted per animal. TAT C4RIP did not promote 
axon regeneration in RGCs following optic nerve injury (n=3, two-way ANOVA, 
Bonferroni post hoc test, non-significant= p>0.05).  
 
 
 
 
 
 
 
 
 
 181 
FIGURE 6 
                     
 182 
CHAPTER 5 
 
 
 
 
 
 
 
5 GENERAL DISCUSSION 
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5.1 Summary 
 The major aim of this thesis was to study the role of Collapsin Response Mediator 
Protein 4 during mitosis and CNS regeneration. The first part of this thesis identifies 
CRMP4 as a novel regulator of mitosis. The second part of this thesis describes two 
different in vivo strategies we undertook to develop a RhoA-L-CRMP4 antagonist as a 
therapeutic agent to promote CNS nerve regeneration following trauma. 
 In Chapter 2, we identify CRMP4 as a novel regulator of mitotic chromosomal 
alignment in HeLa cells. We observe that CRMP4 depletion results in chromosomal 
misalignment and delays mitotic progression, possibly through its altered spindle 
morphology. We also demonstrate that CRMP4 undergoes GSK3-dependent 
phosphorylation through out mitosis and that CRMP4 phosphorylation at its GSK3 sites 
is important for its mitotic function.  
 In Chapters 3 and 4, we investigate the role of CRMP4 in CNS regeneration 
through the introduction of a RhoA-L-CRMP4 competitive antagonist C4RIP. While we 
have previously characterized C4RIP and its ability to attenuate myelin inhibition in 
vitro, whether these finding translate into an in vivo model of CNS injury was the aim of 
these chapters. In Chapter 3, we demonstrate that CRMP4 is expressed in the different 
layers of the adult rat retina including the RGCs and their processes. We show that AAV-
mediated transgene expression of C4RIP in RGCs does not promote RGC neuronal 
survival and axon regeneration following optic nerve injury even if the RGCs are in an 
active growth state. However, we also identify insufficient AAV-mediated C4RIP protein 
expression in RGCs as a potential reason why we do not observe any increase in axon 
regeneration following optic nerve injury. In Chapter 4, as an alternative strategy to 
deliver C4RIP, we develop a recombinant cell permeable TAT C4RIP protein. We 
describe a novel method to generate and purify TAT PTD fusion proteins from 
mammalian cell lysates. Previous strategies used to generate TAT PTD fusion proteins in 
mammalian cells target them to the secretory pathway, where they are most likely 
cleaved by furin proteases (Beerens, Al Hadithy et al. 2003; Flinterman, Farzaneh et al. 
2009). As an alternative to mutating the furin cleavage site located in the TAT PTD 
which can change its transduction properties, we target TAT PTD fusion proteins, TAT 
C4RIP and TAT mRFP, to the cytosol where they are not cleaved by furin proteases and 
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also undergo normal post-translational modifications. We were able to successfully 
purify cytosolic TAT C4RIP and TAT mRFP from mammalian cell lysates and 
demonstrate that these TAT PTD fusion proteins transduce cells in vitro and in vivo. 
Importantly, we confirm that purified TAT C4RIP retains its functional ability to 
attenuate neurite outgrowth inhibition in DRGs in vitro. Although, the in vivo application 
of TAT C4RIP did not promote RGC axon regeneration following optic nerve injury, this 
may be attributed to the poor distribution of TAT C4RIP throughout the retina and optic 
nerve or to a lack of RGC survival. Overall, we believe that this novel strategy to produce 
TAT PTD fusion proteins is a significant step forward in the development of TAT PTD 
fusion proteins as therapeutic delivery vehicles. This method allows for the generation 
and purification of mammalian expressed TAT PTD fusion proteins without the need to 
mutate the TAT PTD sequence. 
5.2 The importance of CRMP4 during mitosis 
 The effects we observed following CRMP4 depletion in HeLa cells indicate that 
CRMP4 plays a role during mitosis. However, if CRMP4 was an essential mitotic protein 
we would expect it to be expressed in all proliferating cells. Studies characterizing CRMP 
expression patterns in vivo indicate that CRMP4 is not ubiquitously expressed, rather its 
expression pattern is mostly localized to cells within the nervous system, the developing 
heart and muscles, and to certain cancers (Wang and Strittmatter 1996; Quinn, Gray et al. 
1999; Shih, Yang et al. 2001; Shih, Lee et al. 2003). Therefore, we believe that while 
CRMP4 depletion results in mitotic defects in HeLa cells, that in other cell types that lack 
CRMP4 expression, other proteins compensate in its absence. Interestingly, CRMP4 
expression in adult nervous tissue is highest in areas where ongoing neurogenesis occurs: 
the subventricular zone, the dentate granular layer of the hippocampus, the olfactory 
bulbs and the rostral migratory stream (Nacher, Rosell et al. 2000; Liu, Yang et al. 2003; 
Liu and Martin 2003). Based on this expression pattern, we can speculate that CRMP4 
may be an important mitotic regulator during neurogenesis.      
 We also demonstrate that phosphorylated CRMP4 at its GSK3 sites is important 
for chromosomal alignment and spindle morphology. While we have not fully elucidated 
the mechanisms through which CRMP4 mediates these effects during mitosis, our 
previous studies in neurons may provide some insight. In neurons, GSK3-dependent 
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phosphorylation of CRMP4 in response to myelin inhibitors regulates its interaction with 
RhoA, whereby phosphorylation drives this interaction apart (Alabed, Pool et al. 2010). 
While the significance of GSK3-dependent phosphorylation of CRMP4 on its interaction 
with RhoA during mitosis remains to be elucidated, there is some evidence in the 
literature to support a model in which RhoA mediates its mitotic effects through CRMP4. 
Neutralization of Lfc, a Rho GEF, with a function-blocking antibody or Lfc depletion 
with RNA interference results in a decrease in spindle length, increase in chromosome 
missegregation and an increase in the cells arrested in prophase/prometaphase (Benais-
Pont, Punn et al. 2003; Bakal, Finan et al. 2005). This phenotype is similar to the one we 
observe with CRMP4 depletion, although we do not observe the mitotic arrest. This 
difference may be attributed to the presence of other physiological substrates that RhoA 
can signal through, such as mDia. The identification of CRMP4 binding proteins during 
mitosis should provide more insight into how CRMP4 regulates this process.   
5.3 Limitations of C4RIP as a therapeutic agent to promote CNS regeneration 
 We have previously demonstrated that C4RIP expression in DRGs promotes 
neurite outgrowth on inhibitory myelin and aggrecan substrates in vitro (Alabed, Pool et 
al. 2007). We have biochemical evidence showing that overexpression of C4RIP 
selectively disrupts the interaction between RhoA and L-CRMP4 but not between RhoA 
and S-CRMP4 (Alabed, Pool et al. 2007). Based on these findings, we speculate that 
C4RIP antagonizes the interaction between RhoA and L-CRMP4 through steric 
hindrance. One possibility is that C4RIP is competing with endogenous L-CRMP4 for 
binding sites located with the RhoA protein. However, the inability of C4RIP to bind 
directly to RhoA suggests that C4RIP may be acting as a dominant negative form of L-
CRMP4 that can bind and sequester endogenous L-CRMP4 from its partners (Alabed, 
Pool et al. 2010). Therefore, the ability of C4RIP to act as a dominant negative form of 
endogenous L-CRMP4 relies heavily on the ratio of C4RIP to endogenous L-CRMP4, 
where a molar excess of C4RIP is required. Additionally, C4RIP has to be localized to 
the same subcellular compartments as endogenous L-CRMP4. In our experiments, we 
observed AAV-mediated C4RIP expression in RGC cell bodies and their axons but we 
were unable to confirm if the expression levels we achieved were sufficient to antagonize 
endogenous L-CRMP4 function. We attempted to increase AAV-mediated C4RIP 
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expression by performing multiple injections of AAV-C4RIP but were unsuccessful at 
achieving higher C4RIP protein levels. The difficulties we encountered using AAV as 
delivery vector highlights the major limitation of developing a competitive antagonist / 
dominant negative molecule for therapeutic applications: achieving adequate expression 
levels to competitively antagonize endogenous levels. While C4RIP expression was 
driven from a chick beta actin promoter, the levels we attained were most likely 
insufficient to act as a dominant negative to endogenous L-CRMP4. 
 As an alternative to AAV-mediated expression of C4RIP, we developed a cell 
permeable form of C4RIP, TAT C4RIP. While the use of a recombinant protein gave us 
the opportunity to repeatedly deliver large protein quantities to the intraocular space and 
directly to the lesion site, we lost the advantage of specificity when using AAV serotype 
2 vectors since TAT PTD transduces cells non-specifically. Although we were able to 
confirm TAT C4RIP protein transduction into the RGC cell bodies, we encountered 
difficulties in transducing all the RGCs within the retina. It is reasonable to speculate that 
this can be attributed to the high concentration of heparan sulfate preotoglycans within 
the retina, which bind and sequester the TAT proteins around the injection site.  
5.4 The importance of neuroprotection in promoting axon regeneration 
 In addition to its role as part of the NgR1 signaling complex that mediates 
outgrowth inhibition in response to myelin associated inhibitors, p75NTR signaling can 
also induce apoptosis (Barker 2004). Following spinal cord injury (SCI), injured neurons 
and glial cells upregulate the expression of p75NTR and these apoptotic cells have high 
levels of active RhoA (Dubreuil, Winton et al. 2003; Madura, Yamashita et al. 2004). 
Application of the RhoA inhibitor, C3-05, following injury blocks the increase in p75NTR 
expression and reduces the number of apoptotic cells. These results provide evidence that 
blocking RhoA protects cells from p75NTR–dependent apoptosis. Additional studies using 
either C3-07 or AAV-C3 transferase demonstrate that RhoA inhibition is also 
neuroprotective to RGCs following optic nerve injury (Fischer, Petkova et al. 2004; 
Bertrand, Winton et al. 2005; Bertrand, Di Polo et al. 2007). Therefore, the inactivation 
of RhoA as a strategy to promote both neuronal survival and axonal regeneration seems 
very promising.  
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Importantly, the beneficial effects on survival and regeneration observed with 
RhoA inhibition translate into improvements in neurological function in different types of 
SCI models. The most common method of assessing behavioral recovery following SCI 
is the Basso, Beattie, Bresnahan (BBB) locomotor rating scale, which evaluates open 
field locomotion (Basso, Beattie et al. 1995). The application C3 in a fibrin gel directly to 
the lesion site following an over-hemisection lesion results in an improvement in 
behavioral recovery by 24 hours post-injury (Dergham, Ellezam et al. 2002). These 
functional improvements are unlikely due to long distance regeneration but are more 
likely the result of the neuroprotective effects seen with RhoA inhibition. This finding 
highlights how neuroprotection can translate into significant functional improvements 
following SCI.  
While we have previously demonstrated that the overexpression of C4RIP in rat 
DRGs attenuates neurite outgrowth inhibition in response to myelin in vitro, we were 
unable to translate these findings to an in vivo model of CNS regeneration. Our data 
demonstrates that AAV-mediated C4RIP expression in adult rat RGCs has no effect on 
increasing neuronal survival 2 weeks following optic nerve injury compared to AAV-
mediated GFP expression. Under these conditions, approximately 15% of RGCs survive 
two weeks following injury. Therefore, it is possible that the effects of C4RIP on axonal 
regeneration may only be observed in the context of increased neuronal survival. Our 
studies combining AAV-mediated C4RIP expression and lens injury did not show an 
increase in regeneration compared to AAV-mediated GFP expression and lens injury. 
However, since it has been shown that lens injury alone can stimulate both neuronal 
survival and nerve regeneration (Pernet and Di Polo 2006), it is possible that these pro-
regenerative effects associated with lens injury alone is masking the ability of C4RIP to 
promote regeneration. Therefore, the combination of C4RIP with a therapeutic compound 
that exclusively increases neuronal survival, and not regeneration, may yield synergistic 
results. The exogenous administration of brain-derived neurotrophic factor (BDNF) to 
injured adult RGC results in an increase in neuronal survival but no effect on axonal 
regeneration (Pernet and Di Polo 2006). The neuroprotective effect of BDNF is mediated 
through activation of extracellular signal-regulated kinases 1/2 (Erk1/2) and 
phosphatidylinositol 3 kinase (PI3K) (Cheng, Sapieha et al. 2002; Pernet, Hauswirth et al. 
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2005). However, it is important to note that while the combination of BDNF and lens 
injury act synergistically to enhance RGC neuronal survival, the combination leads to 
regeneration failure following optic nerve injury (Pernet and Di Polo 2006). It has been 
proposed that either the downstream signaling pathways of BDNF overcome those 
activated by lens injury or that BDNF sends a stop signal to the RGC growth cone of the 
injured axon to inhibit regeneration (Pernet and Di Polo 2006). The combination of 
BDNF and lens injury leads to the formation of large, hypertrophic axonal swellings in 
the proximal injured optic nerve suggesting abnormal structural integrity of growth cones 
(Pernet and Di Polo 2006). Intriguingly, we have demonstrated that GSK3β, a 
downstream molecule in the PI3K pathway, is inactivated by myelin associated 
inhibitors, consequently regulating the phosphorylation status of L-CRMP4 and its 
interaction with RhoA (Alabed, Pool et al. 2010). Thus, in addition to its neuroprotective 
effects mediated through activated Erk1/2, BDNF-activated PI3K intracellular signaling 
may also result in the inactivation of GSK3β, an increase the L-CRMP4-RhoA 
interaction and the inhibition of axonal regeneration. In this context, we hypothesize that 
the introduction of C4RIP would disrupt the L-CRMP4-RhoA interaction but still allow 
for other neuroprotective PI3K signaling to occur, resulting in both neuroprotection and 
nerve regeneration. Future studies combining C4RIP expression, either with AAV-C4RIP 
or TAT C4RIP, and BDNF may result in an increase in neuronal survival and axon 
regeneration following optic nerve injury.  
5.5 The role of CRMP4 in CNS regeneration: future studies 
5.5.1 C4RIP 
 Through the work we have presented in this thesis, specifically in chapters 3 and 
4, we have attempted to elucidate the role of L-CRMP4 in CNS regeneration through the 
introduction of the competitive antagonist C4RIP. While these in vivo studies have 
yielded largely negative results, its is difficult to conclude that CRMP4 does not 
participate in CNS regeneration due to the many limitations we have encountered with 
both AAV-C4RIP and TAT C4RIP. Further, we have also demonstrated that siRNA-
mediated CRMP4 depletion in rat DRGs attenuates neurite outgrowth inhibition in 
response to myelin (Alabed, Pool et al. 2007). Similarly, we have also found that the 
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introduction of C4RIP, either through Herpes Simplex Virus-mediated expression or 
through a cell permeable recombinant protein, attenuates myelin inhibition in rat DRGs 
(Alabed, Pool et al. 2007). While our in vivo studies in adult rat retinal ganglion cells 
have yielded largely negative results, it is possible that the in vivo application of C4RIP 
to adult DRGs following dorsal column injury could promote nerve regeneration.    
5.5.2 CRMP4 knockdown  
 To further elucidate the role of CRMP4 in CNS regeneration ongoing studies not 
included in this thesis are investigating two different in vivo strategies aimed at depleting 
endogenous CRMP4 protein: (1) the generation of a conventional CRMP4 knockout 
mouse and (2) the selective depletion of CRMP4 in adult rat RGCs through an AAV 
vector encoding a CRMP4 shRNA.  
 We searched the Texas A&M Institute for Genomic Medicine C57BL/6N mouse 
gene trap library for Dpysl3 gene trapped embryonic stem (ES) cell clones. These ES cell 
clones have been shown to contribute to the germline and produce knockout mice 
(Hansen, Markesich et al. 2008). We selected 3 ES cell clones trapped at different 
locations within the Dpysl3 gene for the generation of chimeras (IST10930D2, 3rd intron; 
IST12341A8, 3rd intron; and IST14728H3, 1st intron). We anticipate that these ES cell 
clones will generate mice depleted of both L-CRMP4 and S-CRMP4. We are currently 
breeding the chimeric mice with wild type C57BL/6N mice to generate heterozygotes. 
Once we have generated and validated our CRMP4 knockout mice, we will investigate 
the role of CRMP4 in various CNS and PNS lesion models. 
 To further investigate the role of CRMP4 in vivo, we have generated an AAV-2 
expressing green fluorescent protein (GFP) from a chick beta actin promoter and, from a 
U6 promoter, a CRMP4 shRNA or a control scramble shRNA. AAV-CRMP4shRNA 
injection into the adult rat vitreous space should result in the selective viral transduction 
of RGCs, high levels of CRMP4 shRNA expression and depletion of endogenous 
CRMP4 protein. This strategy for in vivo protein knockdown has been effective in 
demonstrating that Mammalian sterile 20-like kinase-3b (Mst3b) regulates axon 
regeneration in the mature CNS (Lorber, Howe et al. 2009). We have validated that 
expression of our CRMP4 shRNAs result in endogenous CRMP4 protein knockdown in 
rat DRGs and we are currently optimizing the in vivo conditions for CRMP4 protein 
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knockdown in adult rat RGCs. While Lorber and colleagues have used their AAV-Mst3b 
shRNA to selectively knockdown Mst3b in adult rat RGCs, Liu and colleagues have used 
a Cre-expressing AAV to delete Pten, a negative regulator of mTOR, in the sensorimotor 
cortex and corticospinal tract of homozygous conditional Pten mutant (PtenloxP/loxP) mice 
(Lorber, Howe et al. 2009; Liu, Lu et al. 2010). Our future studies could take advantage 
of the ability of AAV to infect cortical neurons in the sensorimotor cortex and we could 
assess the effect of CRMP4 knockdown on the regenerative ability of adult corticospinal 
neurons following corticospinal tract injury. These experiments would complement our 
regenerative studies in the conventional CRMP4 knockout mouse.    
5.6 General conclusion 
 In this thesis we investigate the diverse roles of CRMP4 during mitosis and nerve 
regeneration. We identify CRMP4 as a novel mitotic regulator and demonstrate that 
CRMP4 depletion increases chromosome misalignment, delays mitotic progression, 
yields monopolar syntelic attachments, reduces cold stable microtubules and alters 
mitotic spindle morphology. Furthermore, we identify CRMP4 as an important 
physiological substrate of the mitotic kinase GSK3 and show that CRMP4 
phosphorylation at its GSK3 sites is critical for its mitotic functions. These findings 
suggest that despite their low expression levels outside the developing nervous system, 
CRMPs may play a larger role in other biological processes, particularly in those that rely 
on cytoskeletal rearrangements.  
 While our in vivo studies using C4RIP as a therapeutic agent to promote CNS 
regeneration follow injury were unsuccessful, we were able to develop a novel method to 
generate and purify mammalian expressed recombinant TAT PTD proteins. We hope that 
this novel purification technique will facilitate the translation of other therapeutic agents, 
where access to the intracellular compartment of the cell is a priority, into clinically 
relevant therapies.   
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